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Abstract 
The purpose of this thesis was to increase understanding of enterococcal urinary tract 
infection (UTI), in particular, the response of Enterococcus to antibiotic prophylaxis in vitro 
and in vivo and enterococcal communication with the bladder. 
We studied the in vitro effects of trimethoprim-sulfamethoxazole (TMP/SMX) and 
nitrofurantoin, two of the most commonly used antibiotic treatments for the management of 
both UTI and recurrent UTI (RUTI), on Enterococcus faecalis attachment to urothelial cells. 
In doing so, we documented increases in bacterial attachment at growth inhibitory 
concentrations of nitrofurantoin, but not TMP/SMX. This increased virulence did not 
correlate with increased expression of virulence factors but was correlated with increased 
expression of three putative genes. 
We then explored whether this corresponded to alterations in bacterial communities 
throughout antibiotic prophylaxis for paediatric patients with RUTI. Bacterial culture results 
indicated uropathogens were present in the urine of children with and without a history of 
RUTI and that antibiotic prophylaxis induced a transient decrease in uropathogen load. 
Interestingly, none of our patients were experiencing symptomatic UTI at the time of urine 
sample collection, yet a significant proportion of midstream urine samples met the clinical 
threshold for UTI, indicating these patients had asymptomatic bacteriuria (ABU). Further, E. 
faecalis bacterial load was positively correlated with non-E. coli uropathogens, suggesting 
some patients may be pre-disposed to polymicrobial UTI. 
To elucidate mechanisms by which enterococci can mask the host’s perception of UTI, which 
may also contribute to the polymicrobial nature of E. faecalis UTI, we completed targeted 
metabolomics of neuroactive molecules in vitro under conditions mimicking the bladder 
environment. Our results suggest Enterococcus may produce tyramine in the bladder at 
concentrations that are likely to have a physiological effect on both urothelial cells and 
cohabiting bacteria. 
Our data raises questions about the application of nitrofurantoin to enterococcal UTI and the 
efficacy of antibiotic prophylaxis for RUTI. Further, our clinical and in vitro data suggest E. 
faecalis may contribute more to polymicrobial UTI than previously thought. Indeed, 
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enterococcal production of tyramine may explain the high incidence of enterococci in not 
only polymicrobial UTI but also other infections. 
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Enterococcus faecalis, urinary tract infection, recurrent urinary tract infection, antibiotic 
prophylaxis, paediatric urology. 
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Chapter 1 * 
1 General Introduction 
The urinary tract encompasses the kidneys, ureters, bladder and urethra. Functionally, 
the kidney plays a role in blood pressure homoeostasis, secretion and absorption of 
molecules and ions, and blood filtration, while the bladder is often simplified to the 
storage and voiding of urine. However, signalling to control and transition between these 
states is much more complex than traditionally acknowledged and incompletely 
understood. Indeed, there appears to be multiple levels of sensation and action within the 
urinary tract, and this has become a broadly studied area in recent decades. 
While bacterial interactions with these systems are better studied in the context of the 
enteric nervous system and brain, sparse research has gone into understanding the 
bacterial interface with the sensory and motor systems of the urinary tract. The recent 
discovery of bacterial communities native to urine, however, has opened such avenues 
of research. 
Herein we explore the role of the urinary microbiota in paediatric disease, the role of 
antibiotics in the progression of urinary tract infections (UTIs), and the potential for 
bacteria to interact with the signalling systems of the urinary bladder. 
1.1 Functional anatomy of the urinary tract 
Bacteria are suspected of modulating bladder and host behaviour through multiple 
modalities; comprehension of the extent and downstream effects of these interactions 
during states of health and disease requires a basic understanding of functional anatomy. 
The urinary tract is divided into the upper urinary tract, consisting of the kidneys and 
                                                
* Parts of this chapter have been previously published and are adapted from: 
Whiteside, S. A., Razvi, H., Dave, S., Reid, G., & Burton, J. P. The microbiome of the 
urinary tract – a role beyond infection. Nat Rev Urol 12, 81-90 (2015). 
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ureters, and lower urinary tract (LUT), comprising the urinary bladder and urethra. The 
urinary bladder is a hollow, smooth muscle organ that functions to store and release 
soluble waste from the kidney. Anatomically, the bladder is divided into the bladder 
body, the region above the ureteral orifices and the bladder base, which is inclusive of 
the trigone and bladder neck (Figure 1-1)1. This is important to note, as the tissue 
structure and innervation of the bladder varies between these two regions. 
1.1.1 The bladder wall 
The bladder wall is composed of three layers; the mucosa, detrusor, and the 
adventitia/serosa (Figure 1-1). The mucosal layer consists of the urothelium, which lines 
the bladder lumen, and the lamina propria. The detrusor muscle, incorporates three 
smooth muscle compartments, of which the smooth muscle cells of the inner and outer 
layer are oriented longitudinally and the middle circularly; the layers run longitudinally, 
transversely and obliquely1,2. The muscle layer is covered by the serosa on the superior 
and lateral surfaces, and the retroperitoneal surface is surrounded by adventitia. 
1.1.1.1 Mucosa 
1.1.1.1.1 Urothelium 
The lumenal lining of the bladder, the urothelium, creates an impermeable, non-adherent 
barrier that forms an interface between the urinary space and underlying connective, 
nervous, vasculature, and muscular tissues. Given the presence of bacteria in urine from 
functionally healthy and diseased bladders, this tissue is the site of direct bacterial 
influence, mediating interactions with the sensory, motor, and immune systems. The 
urothelium also lines the renal pelvis, ureter, upper urethra, and glandular ducts of the 
prostate in males; these different anatomical locations represent different cell lineages 
and therefore differ in functional and biochemical properties3. Notably, the renal pelvis 
and ureter are mesoderm-derived, while the bladder, bladder neck and urethra are 
endoderm-derived4,5.
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A transitional epithelium, the urothelium is subdivided into three general layers, the 
basal layer, which is attached to the basement membrane, an intermediate layer, and a 
superficial apical layer of umbrella cells (UC). Humans are thought to have multiple 
intermediate layers, while rodents have a minimum of three, resulting in a tissue 
thickness between three and seven cell layers6,7. 
Umbrella cells are large hexagonal cells that create the bladder’s physical barrier against 
infection and toxic substances found in urine3,6,8. Maintenance of this watertight barrier 
function is multifactorial, involving tight junctions between cells, and uroplakin (UP)-
plaques as well as a unique lipid layer on the apical surface8. Indeed, the apical surface 
of these cells is unusually rich in cholesterol, phosphatidylcholine, 
phosphatidylethanolamine, and cerebroside9. The cell surface is further covered by a 
glycosaminoglycan (GAG) layer, which has also been suggested to play a role in the 
bladder’s barrier function10,11; however, this is controversial1,12. Collectively, these 
properties create one of the most effective barriers of any biomembrane3,13. 
Umbrella cells are truly exceptional cells in that they maintain their barrier properties 
while undergoing dramatic changes in shape. For instance, in the empty bladder UCs 
form globular rectangles, yet when the bladder is full, they take on a flattened, flagstone-
like shape. Such hypercompliance is conferred in part by UP-plaques and increased 
vesicular traffic during bladder filling, which physically adds membrane to the 
superficial surface8,13-15. This increased membrane traffic has also been linked to 
regulation of receptor and channel expression profiles of urothelial cells, including those 
of the apical and intermediate layers16. 
The formation of UP-plaques, which cover about 90% of the UC apical cell surface and 
form the asymmetric unit membrane, serves as a differentiation marker for UCs3. 
Indeed, UP proteins are highly expressed in the urothelium, yet expression in normal 
non-urothelial cells is uncommon17. Four UP proteins have been described, UPIa, UPIb, 
UPII, and UPIIIa3, each demonstrating a high degree of evolutionary conservation18,19. 
Differential expression is also noted within human urothelial layers, with the expression 
of UPIIIa, UPIa, and UPII occurring only in umbrella cells17,20. Expression of these 
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proteins is taken advantage of by uropathogens, such as uropathogenic Escherichia coli 
(UPEC) and Klebsiella pneumoniae, which bind UPs to initiate adhesion21. 
Concurrently, the interaction of UPEC FimH with UPIa induces UPIIIa phosphorylation 
followed by the elevation of intracellular calcium22,23, suggesting UPs modulate the 
early host response to infection. Unsurprisingly, UP deficiency contributes to a 
compromised urothelial permeability barrier and global urinary tract anomalies13,24-27. 
A number of factors modulate the urothelium’s barrier function, including tissue pH, 
mechanical or chemical trauma, hormonal changes and of relevance here, bacterial 
infection6,16. For example, bacterial contact with the UC apical surface induces 
exfoliation of UCs and loss of defined intercellular junctions at the apical surface, 
corresponding with a decrease in transepithelial electrical resistance (TER) relative to 
controls28,29. Of note, UTI, interstitial cystitis/bladder pain syndrome (IC/BPS), spinal 
cord injury (SCI), and senescence are associated with changes in the urothelium, which 
may explain some the associated bladder dysfunction28,30-34. 
In the healthy bladder, urothelial integrity is maintained through a complex process of 
migration, proliferation, and differentiation, yet some studies propose proliferation takes 
precedence over differentiation7,31. This was recently highlighted by a SCI model, 
wherein researchers noted signs of incomplete differentiation persisting at 28 days post-
injury7. Similar apical cell layer characteristics including; small cell size, lack of UC 
differentiation markers, and altered tight junction integrity, have been linked to 
increased apical surface stiffness, decreased TER, and increased permeability to both 
water and urea13,29,31,33. Interestingly, Scott Hultgren’s group has documented 
dysfunctional remodelling of the bladder mucosa in mice following experimentally 
induced chronic UTI28. The Hultgren model relies on two subsets of mice, those that 
spontaneously resolve chronic infection (resolved) and those that are unable to clear the 
infection and are subsequently treated with antibiotics (sensitised). At 8-weeks post-
infection, both resolved and sensitised mice display mucosal remodelling. However, 
when challenged with bacteria, resolved mice generally develop a mild infection that is 
rapidly cleared, while sensitised mice develop severe acute and chronic UTI. 
Furthermore, in sensitised mice the superficial cells remain up to 20-times smaller than 
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naïve UCs and express UPIIIa, but not Krt20, another marker of terminal UC 
differentiation. Acute infection studies suggest mucosal remodelling begins within 5 
hours of UPEC infection29. Notably, small superficial cells are also found in UPII and 
UPIIIa knockout (KO) mice, concomitantly with increased cell stiffness and 
permeability to both water and urea13,24-26. 
In humans, staining of UPIIIa from the urothelium of healthy individuals is uniform 
across the apical surface; however, in patients with recurrent UTI (RUTI) and 
vesicoureteral reflux (VUR) staining for UPIIIa is either inconsistent or absent34. 
Interestingly, UPIIIa KO mice are considered an appropriate model for human VUR, yet 
clinical studies have failed to link mutations in UPIIIa to primary VUR35,36. This 
suggests that the loss of UPIIIa expression along the apical surface in VUR patients may 
be secondary to infection-induced remodelling; particularly given the high incidence of 
UTI in this population. In general, study of the UP proteins in human disease is limited, 
the majority of research identifies UP proteins as effective markers of bladder cancer 
metastasis3. 
Thus, following urothelial damage, the barrier does not function optimally, even though 
the damage has been physically repaired. As one of the slowest cycling epithelia3,37, 
such damage may have long-lasting effects; predisposition to infection, as seen in the 
aforementioned mouse model, or interference with bladder sensation and detrusor 
contraction. Further, the similarities in mucosal remodelling associated with SCI and 
previous UTI may provide an explanation for the high rate of UTI in these populations. 
In addition to its function as a physical barrier, the urothelium is recognised as 
metabolically active and an active contributor to the sensory functions of the bladder. 
Notably, the urothelium responds to both chemical and mechanical stimuli and 
communicates with nerves, as well as smooth muscle, interstitial, and inflammatory 
cells6,38. Alterations in uroepithelial receptor expression and release of neurotransmitters, 
such as adenosine triphosphate (ATP) and acetylcholine (ACh), has been linked to 
bladder pathology16. 
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1.1.1.1.2 Lamina Propria 
Sometimes referred to as the suburothelium, the lamina propria (LP) lies between the 
basement membrane of the urothelium and the detrusor muscle (Figure 1-1). Within the 
LP, extracellular matrix (ECM) surrounds a variety of cell types including fibroblasts, 
adipocytes, interstitial cells (IC), afferent and efferent nerve fibres, as well as a rich 
vascular network, lymphatic channels, and smooth muscle fascicles (muscularis 
mucosae)6,39-42. The ECM acts a structural scaffold of proteins, proteoglycans, and 
glycosaminoglycans that provides support and signalling to bladder cells. Collagen I and 
III make up most of the protein mass within the ECM at a ratio of 3:140. When the 
bladder is empty, collagen III is distributed in a loose network of fibres without uniform 
orientation; however, during bladder filling these fibres rearrange to collectively reorient 
parallel to the urothelium40. 
While the functional role of the LP is undefined, researchers have suggested it may play 
a capacitance role, such that it determines bladder compliance and enables adaptive 
change to accommodate increasing bladder volume40. Cells of the LP have also been 
shown to accelerate the growth of urothelial and smooth muscle cells ex vivo in both a 
juxtacrine and paracrine manner43. The function and characterisation of many cells 
within the LP remains speculative, and in some cases controversial. 
The presence of muscularis mucosae was first described in the human bladder and 
confirmed in the guinea pig42,44,45; these muscle bundles, however, have not been found 
in the rat, rabbit, cat, or dog42. While not well defined, they are described as irregularly 
arranged muscle bundles containing small-diameter smooth muscle cells rich in 
nonspecific cholinesterase and glycogen. The smooth muscle cells are morphologically 
and histochemically distinct from detrusor muscle and innervated by 
acetylcholinesterase (AChE) positive nerve fibres42,46. 
Alternatively, bladder ICs are fairly well studied, although a lack of consensus on 
nomenclature hinders functional study comparison and contributes to the controversy 
surrounding these cells. In general, spindle-shaped bladder cells are categorised as ICs, 
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interstitial cells of Cajal (ICC), interstitial Cajal-like cells, myofibroblasts, and in some 
cases telocytes. Differences in IC response and immunoreactivity between species 
aggravate the controversy38. Throughout the literature, however, one facet has remained 
constant, the use of the gut as a model to study bladder ICs. 
In the gut, ICCs perpetuate signals between enteric nerves and smooth muscle cells 
(SMCs), serving as a pacemaker and mediator of neurotransmission47. Interstitial cells of 
Cajal are found in close proximity to enteric nerve fibres and are capable of generating 
and conducting electrical signals with one another and SMCs via gap junctions47. A 
similar function has been proposed for bladder ICs, yet this is a source of 
contention45,47,48. In the human bladder, ICs are identified in the lamina propria and 
detrusor based on immunoreactivity to vimentin, proto-oncogene c-Kit, and/or platelet-
derived growth factor receptor-α (PDGFRα), in addition to morphological properties, 
such as spindle or stellate morphology46,49-54. Notably, mast cells are also c-Kit+ and 
have been described in the human bladder, yet these cells exhibit a rounded shape46,55. 
Throughout the LP, ICs create a mesh-like network and are also found as elongated cells 
along the blood vessels and muscularis mucosae49. In addition to the LP, ICs are found 
within the detrusor, creating two populations of bladder IC that are morphologically and 
histochemically distinct46,54,56. Interstitial cells in the bladder demonstrate a number of 
electrical and structural characteristics that may allow them to act as an electrical 
network, including a resting membrane potential of -60mV, the presence of gap 
junctions, and co-localization with nerve fibres46,49,51,52,57. 
Similar to the gut, human bladder IC are in contact with nerve fibres, as characterised by 
antibody labelling for protein gene product 9.5 (PGP9.5)49, neuronal ubiquitin hydrolase 
that is often used as a general neuronal marker, and vesicular acetylcholine transporter 
(vAChT)46, which is cholinergic nerve specific. This property was also demonstrated in 
the detrusor, where ICs associate with vAChT-labelled nerve fibres46. Interestingly, 
other groups have documented expression of the muscarinic acetylcholine receptor 
(mAChR) subtypes M2 and M3 by ICs in the LP of human, rat, and guinea pig 
bladder50,58,59. Further, experiments in guinea pig ICs demonstrated the functional 
activity of these receptors and the ability of ICs to transfer the signal between adjacent 
21 
 
cells60. Thus, ICs are found in close contact with cholinergic nerve fibres and express 
functional receptors for the cholinergic effector, acetylcholine, which suggests ICs are 
capable of receiving and modulating cholinergic nerve input. 
Interstitial cells may also function as a regulator of detrusor excitability during bladder 
filling, as has been proposed in the mouse. Platelet-derived growth factor receptor-α 
immunoreactive cells are located throughout the LP and detrusor, creating a loose 
network where some, but not all cells, are in contact with PGP9.5+ nerve fibres57. These 
cells express small conductance calcium-activated potassium channels, which, when 
exposed to agonists, induced significant hyperpolarisation in isolated cells61. 
Administration of ATP to isolated PDGFRα+ cells also elicited hyperpolarisation via 
P2Y1, a purinergic G protein-coupled receptor (P2Y)62. In the gut, gap junctions are 
thought to mediate signal transduction between ICs and SMCs47,63. Co-localisation of 
the gap junction protein, connexin 43 with ICs in humans and mice52,64, supports a role 
for signal transduction between ICs and SMCs in the bladder. As such, gap junctions 
may facilitate hyperpolarisation of SMCs, potentially explaining the biphasic contractile 
response of SMCs to ATP, which is characterised as an initial contraction followed by 
sustained relaxation61,62. 
Many of the functions attributed to the LP are dependent on the rich nerve plexus found 
here. Indeed, afferent and efferent fibres have been identified in the LP of the human 
bladder by transmission electron microscopy and antibody-specific immunolabelling for 
PGP9.5, vAChT, AChE, calcitonin gene-related peptide (CGRP), Substance P (SP), 
neurokinin A (NKA), neuropeptide Y (NPY), neuronal nitric oxide synthase (nNOS), 
vasoactive intestinal peptide (VIP), ATP-gated P2X receptor cation channels (P2X), and 
transient receptor potential cation channel, subfamily V, member 1 (TRPV1), among 
other markers39,46,49,65-70. In the rat, CGRP+ nerves form an elaborate plexus just below 
the basement membrane71. A subset of these nerves were described as distinctly varicose 
and imaged running parallel to the basement membrane with branches extending into the 
urothelium, some of which penetrated almost the full urothelial thickness (Figure 1-1). 
In the mouse, almost 10% of bladder afferents are found in the urothelium72. An 
extensive suburothelial plexus is also well characterised in humans68,69. 
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Furthermore, intramural ganglion cells have been identified throughout the LP and 
embedded along smooth muscle bundles of the human bladder65,66. Further study using 
electron microscopy identified these as small in size, containing one to six neurons 
each66. Highlighting the complexity of bladder innervation, nerves positive for CGRP, 
SP, and NKA encircled the intramural ganglia and vasculature, while the VIP+ nerves 
were found within the suburothelial plexus and projected into detrusor muscle bundles67. 
1.1.1.2 Detrusor muscle 
The detrusor muscle provides the contractile power of the bladder through coordinated 
contraction and relaxation of SMCs. The detrusor is comprised of smooth muscle 
bundles of various sizes that contain staggered SMCs.  The smooth muscle cells are 
long, spindle-shaped cells with a central nucleus, which when fully relaxed are several 
hundred micrometres long and up to 6µm wide2, and are arranged such that the wide 
nuclear region of one cell is aligned with the tapered end of the adjacent cell73. Adjacent 
cells are attached at various points through gap junctions that allow ions to flow between 
cells, facilitating rapid spread of the electrical signal through the muscle2,74. These 
smooth muscle bundles interact with both ICs and nerves and are surrounded by 
connective tissue rich in collagen2. The ability of these cells to undergo drastic changes 
in shape is a key aspect of bladder compliance. 
In adults, bladder capacity ranges from 300-400mL1; this figure is different in children 
as bladder capacity increases throughout development and is estimated as75: capacity 
(mL) = [age (years) + 2] × 30. Using a spherical bladder model, a full, 400mL bladder 
has a circumference of approximately 30cm. If there is a residual volume of 10mL after 
voiding, the circumference will have been reduced to roughly 8cm1. Accommodating 
such a change is circumference requires a decrease in muscle length of almost 75% in a 
relatively short time, a unique property of smooth muscle. Notably, this also requires a 
drastic change in the surface area of the urothelium without loss of barrier function, as 
discussed above. 
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Detrusor contraction is initiated by an increase in intracellular Ca2+, which is primarily 
mediated through activation of the M3 muscarinic receptor and the P2X1 purinergic 
receptor. In the healthy human detrusor, M3 induced contraction predominates, yet this 
may change under pathological conditions2,76,77. The increase in cytoplasmic Ca2+ 
concentrations has been linked to long-lasting, voltage-dependent calcium (L-type Ca2+) 
channels and inositol triphosphate elicited release of Ca2+ from the sarcoplasmic 
reticulum. Intracellular Ca2+ complexes with calmodulin and this complex binds myosin 
light chain kinase (MLCK), activated MLCK phosphorylates the regulatory myosin light 
chains. This allows the interaction of myosin with actin and subsequent force 
generation78. 
In contrast, detrusor relaxation requires a decrease in intracellular Ca2+ and increase in 
myosin light-chain phosphatase (MLCP) activity, the enzyme responsible for 
dephosphorylation of the myosin regulatory chain. Detrusor relaxation in humans is 
mediated predominantly through the β3-adrenoceptors (β3-AR)2,79. Activation of β3-AR 
stimulates adenylyl cyclase, increasing cyclic adenosine monophosphate (cAMP) levels, 
which activates protein kinase A (PKA). Protein kinase A inhibits the formation of 
inositol triphosphate and has been linked to other contractile pathways, such as Ca2+-
independent and Rho/Rho-kinase mediated signalling. Furthermore, PKA reduces 
calcium influx through activation of K+-channels and downstream effectors of cAMP 
stimulate large conductance Ca2+-activated K+ channels, leading to hyperpolarisation80. 
1.1.1.3 Bladder Innervation 
The bladder cycles between two states, bladder filling and voiding. During bladder 
filling, the detrusor is relaxed and the urethra and bladder neck are contracted; however, 
the transition to voiding results in a comparatively fast detrusor contraction and 
relaxation of the urethra and bladder neck. Each of these states necessitates the 
coordinated action of detrusor, urethral, and sphincter muscle, requiring a high level of 
regulation. 
Three major nerves innervate the bladder, urethra, and sphincters each with afferent and 
efferent neurons located within the LUT. The sympathetic pathways of the hypogastric 
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nerve relax the bladder body while exciting the base and urethra. Parasympathetic 
pathways travel via the pelvic nerve; these neurons excite the bladder body and relax 
both the bladder neck and urethra. The pudendal nerves are associated with excitation of 
the external urethra through the somatic efferent pathway1. Application of axonally 
transported dyes highlights the cell bodies of these neurons in the lumbosacral dorsal 
root ganglion and terminations in the spinal cord. 
Post-ganglionic parasympathetic nerves predominantly terminate in the detrusor and 
release ACh, while sympathetic nerves primarily terminate in the lamina propria and 
urothelium where they release norepinephrine (NE)81. Indeed, most nerves running in 
the detrusor are positive for AChE and vAChT16,65,81. Cholinergic input is supported by 
electrical field stimulation studies, which identify ACh and ATP as providing the bulk of 
the excitatory input. Notably, these efferents also stain for VIP, NPY, and nitric oxide 
synthase (NOS)81, suggesting the release of multiple mediators. Nerves positive for 
tyrosine hydroxylase may also indicate the presence of adrenergic efferents16. 
Afferent nerve identification is traditionally made through morphological and molecular 
criteria; morphologically, two populations of afferent fibres are found in the bladder, 
thinly myelinated Aδ and small unmyelinated C-fibres. Each of these can be further 
characterised based on immunolabelling. For instance, CGRP+ afferents are abundant in 
the bladder wall, being found in the urothelium, LP, detrusor muscle and serosal blood 
vessels. Notably, these nerves are distinctly varicose, and these varicosities serve as 
release sites for stored neurotransmitters, indicating a role for afferents in “axon 
reflexes70,81,82.” Once activated, afferents convey information to the central nervous 
system and mediate localised responses through the release of molecules to proximal 
cells, such as SMCs, ICs, urothelial cells, and other neurons. In humans, CGRP+ fibres 
are rarely identified in the detrusor muscle, yet are frequently found within the LP where 
they integrate within the suburothelial plexus. Additionally, some synapse on intramural 
ganglia, providing a basis for local neural reflexes67-70. 
There is a differential distribution of afferents within the human bladder, wherein C-
fibres are present throughout the urothelium and lamina propria, while Aδ-fibres are 
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located in the detrusor layer53,82-84. Further, the suburothelial plexus is most dense within 
the bladder neck and initial part of the urethra yet becomes progressively less so towards 
the bladder dome. In contrast, afferent innervation of the detrusor is uniform throughout 
the bladder wall53. Interestingly, different peptide expression profiles exist in the 
neurons of detrusor and mucosa and are identified through co-localisation experiments. 
For example, nerves in the human bladder have been documented that are positive for 
CGRP and SP, NKA, or NPY67,68. 
At present, there is no consensus on a functional categorisation system for afferent 
neurons. Some groups categorise bladder afferents as distension sensitive 
mechanoreceptors, distension insensitive chemoreceptors, and silent afferents85; while 
other groups categorise by location in the bladder wall and normal function. For 
example, Yoshimura and Chancellor suggest Aδ-fibres of the smooth muscle sense 
bladder fullness (wall tension), while C-fibres of the mucosa respond to stretch (bladder 
volume), are nociceptive to over-distension, or silent afferents1. Silent C-fibres respond 
primarily to noxious stimuli, including chemical irritation and cooling76. Irrespective of 
the categorisation system, studies concede that nerves of the urinary bladder respond to a 
wide variety of stimuli. Furthermore, aberrant sensory feedback has been implicated in 
multiple disease states, including IC/BPS, overactive bladder (OAB), and idiopathic 
detrusor overactivity (IDO)2,77,81,86-88. 
1.1.2 Micturition 
As described above, an intricate neural signalling network is involved in the coordinated 
response of the urinary bladder and urethra in micturition2,76. Central control of the LUT 
is organised as a simple “on/off” switch that maintains a reciprocal relationship between 
the bladder and urethra. Importantly, as the bladder fills, gradual increases in bladder 
pressure activate sensory nerves, and this has been suggested to communicate fullness to 
the brain88. In humans, bladder fullness is sensed at an intravesical pressure of 5-15 
mmHg, triggering an increase in bladder afferent signalling. Urgency occurs at 20-25 
mmHg, and if not relieved, pain and/or discomfort are felt once the bladder exceeds 30 
mmHg89. However, sensations of fullness alone do not trigger the void reflex in healthy 
26 
 
adults or toilet-trained children rather micturition onset is voluntary and dependent on 
learned behaviour. 
During the storage phase, sympathetic nerves release NE, which acts on β3-AR in the 
detrusor and α-adrenoceptor (α-AR) in the urethra and bladder neck, while the pudendal 
nerve contracts the urethra. When the bladder wall tension exceeds the micturition 
threshold, increased afferent firing from tension receptors in the bladder reverses the 
efferent outflow, inducing parasympathetic release of ACh and ATP, and inhibiting 
sympathetic and somatic pathways. The expulsion phase is initiated by relaxation of the 
urethral sphincter via nitric oxide (NO) release and the removal of adrenergic and 
cholinergic input. Urethral relaxation is followed by bladder contraction, which 
increases bladder pressure and initiates urine flow. Furthermore, urine flow through the 
urethra activates afferent nerves that further induce bladder contraction, promoting 
complete bladder emptying76. 
Interestingly, the detrusor is not silent during filling; uncoordinated spontaneous activity 
has been documented in multiple species, including humans, and these are often referred 
to as non-voiding or transient contractions76,90,91. Although the function of non-voiding 
contractions is unknown, a number of research groups have supported their role as a 
sensory system47,90. Researchers argue transient contractions activate afferent nerves to 
send information to the brain regarding bladder fullness and the ability of the detrusor to 
maximally and efficiently contract, thus signalling the optimal time to void. An increase 
in amplitude and frequency of these contractions as the bladder fills supports this 
notion6,40. The generation and transduction of these contractions are also unclear, yet has 
been linked to ICs38,40,47,51. Notably, these transient contractions are also observed ex 
vivo in unstimulated whole bladder and isolated detrusor strips91-93. Increased incidence 
of micromotions has also been correlated with pathological conditions in humans and 
animals2,40,76,94. For instance, use of micromotion detection catheters has linked 
micromotions with urinary urgency and idiopathic chronic pelvic pain in women94,95. 
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1.2 Microbiome of the urinary tract 
The microbiota is defined as the microorganisms in a particular environment96,97. More 
specifically, the term refers to the microbial taxa that are associated with an environment 
and are revealed using molecular techniques such as 16S ribosomal ribonucleic acid 
(rRNA) sequencing. Conversely, the term microbiome is less firmly defined. Some 
groups limit the use of microbiome to the catalogue of microbes and their genes only97, 
whereas our group and others prefer to refer to this as the metagenome (all genetic 
material of a population including plasmids). The term microbiome is used as a 
reference to the habitat as a whole96, thus, incorporating the biotic and abiotic factors, 
encompassing host and microorganism genomes and environmental conditions 
(Figure 1-2). The populations are composed of bacteria, archaea, viruses and fungi, 
which are predominantly found in the gastrointestinal tract, but also in other exposed 
tissues, such as the skin, upper respiratory and urogenital tracts98-100. However, other 
tissues that were once considered sterile, such as the brain, breast, placenta and the 
urinary tract, also harbour unique bacterial communities101-104. 
The recent identification of a microbiota in the bladder has important implications for 
the urologist. Studies of other body systems suggest that the microbiota is critical in the 
maintenance of health and/or development of disease. For example in the 
gastrointestinal tract, links between gut dysbiosis, chronic Clostridium difficile infection 
and colorectal cancer have been reported105-107. For the urinary tract, researchers have 
only begun to assess the relationship between the urinary microbiota and urologic 
disease. 
Such studies suggest that the urinary tract harbours a unique urinary microbiota102,108-119, 
which is substantially different from the populations of the gut and vagina. These 
findings challenge the long-held doctrine of the urinary tract proximal of the urethra as a 
sterile environment and raise the question of why these bacteria had not been discovered 
previously. 
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1.2.1 Discovery of the urinary microbiota 
Traditionally, bacteriological culture of urine is used to isolate and identify pathogens 
involved in the development of UTIs; for example, aerobic, fast-growing organisms, 
such as E. coli and Enterococcus faecalis120. Conversely, slow-growing, anaerobic or 
fastidious organisms, such as Corynebacterium, Lactobacillus and Ureaplasma, are 
rarely isolated from the urinary tract, as routine culture techniques are not designed to 
support the growth of these genera108,121-123. However, using more advanced 
deoxyribonucleic acid (DNA) sequencing-based detection technologies, these bacteria 
have been identified as members of the urinary microbiota in multiple studies109-113. 
Similarly, owing to such advanced culture and molecular techniques, Lactobacillus iners 
replaced Lactobacillus acidophilus as the generally accepted dominant species in the 
microbiota of the healthy vagina124,125. Hence, improvements in polymerase chain 
reaction (PCR) and 16S rRNA sequencing technology have made it possible to ascertain 
the bacterial communities of the body126, leading to the discovery of the microbiota of 
the urinary tract. 
This revelation raises many questions. How can so many species, including some known 
to cause UTI, survive and multiply within the urinary tract without causing chronic 
infection? The required nutrients seem to be available, and presumably many organisms 
carry the necessary virulence factors for infection. Why would genera, such as 
Jonquetella, Parvimonas, Proteiniphilum and Saccharofermentans, previously 
unfamiliar to urologists, seemingly arbitrarily colonize the urinary tract of individuals 
aged >70 years and what are these organisms doing117?   
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Figure 1-2. Definition of microbiota, metagenome, and microbiome. 
Each image represents the same population; however, different approaches to define the 
population provide different information. Microbiota: 16S rRNA surveys are used to 
taxonomically identify the microorganisms in the environment (A). Metagenome: the 
genes and genomes of the microbiota, including plasmids, highlighting the genetic 
potential of the population (B). Microbiome: the genes and genomes of the microbiota, 
as well as the products of the microbiota and the host environment (C).   
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Stapleton127 has suggested that non-modifiable host factors have a role in colonisation 
by these organisms. If host factors indeed ‘select’ the species that become established, 
what are the receptors and the basis for selection in evolutionary terms for a given 
individual? Did bacteria and their hosts coevolve? This process might encompass human 
urinary tract adaptation to accommodate certain bacterial species, for example, through 
expression of specific receptors, as well as mutations in bacteria enabling adherence to 
the uroepithelium and survival in the variable urinary conditions. Clinically, it is known 
that children of women with a history of recurrent UTIs often also have recurrent 
infections128. Is this increased susceptibility to UTIs caused by genetic inheritance or the 
transfer of bacterial species throughout childhood or, more specifically, at birth?  
1.2.2 Alterations and disease 
Investigations of bacterial populations in the urinary tract of healthy volunteers and 
patients with different diseases have revealed an altered microbiota in individuals with 
IC/BPS, neurogenic bladder dysfunction (NBD), urgency urinary incontinence (UUI) 
and asymptomatic sexually transmitted infections (Table 1-1)109,113-116. In patients with 
NBD, the alterations to the microbiota seem to positively correlate with the duration of 
the condition and the type of catheter used in bladder emptying114. The latter is 
intriguing and supports the ‘receptivity’ concept, whereby the presence of a new surface 
‘attracts’ certain organisms, changing the dynamics of the microbiota. Urine from 
patients with IC/BPS had lower bacterial diversity than urine from healthy volunteers 
compounded by an increase in the relative abundance of the genus Lactobacillus (92% 
versus 57%)113. This finding raises two questions. First, is the loss of diversity a cause of 
or caused by the condition? Second, why is the increase specific for Lactobacillus, a 
genus that is considered beneficial in both the intestine and vagina, in a diseased 
state105,129,130? Interestingly, reduced bacterial diversity has also been correlated with 
other chronic inflammatory states, including obesity and inflammatory bowel 
disease131,132. Evidently, urinary microbiota studies are providing a whole range of novel 
ideas about urinary health and disease, yet still demonstrate that the microbiota of 
patients with symptomatic UTIs are dominated by organisms that have previously also 
been identified via traditional culture methods118. 
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1.2.3 Microbiota of different populations 
Although the numbers of studies are limited, some have found significant differences 
between the urinary microbiota of men and women114,117. This finding is not surprising 
given the differences in anatomical structure, hormones and local defences, but it is 
worthy of study in relation to disease susceptibility. For example, analysis of the 
EUROCARE-4 cancer survival data highlighted the disparity in bladder cancer survival 
between the sexes: the age-adjusted 5-year relative survival was 4.2% lower for women 
compared with men133. By contrast, when the data from various organs was combined, 
the report noted a significant survival advantage for women. As an example regarding 
non-cancerous urinary tract diseases, one study demonstrated that men have a higher 
incidence of renal calculi compared with women134. It is possible that differences in the 
urinary microbiota of men and women have a role in these disparities. 
To date, the variations in detected organisms between samples have been too high to 
indicate that comparable bacterial communities in individuals of the same age or gender 
exist112,115-117. However, Lewis et al.117 propose the presence of a ‘core’ bladder 
microbiota—a subset of bacteria that exist at variable abundances within the urinary 
tract regardless of age. This hypothesis needs to be confirmed by large studies 
accompanied by investigations to identify why these organisms have evolved with the 
human urinary tract. This evolution could encompass coevolution, but also changes in 
the urinary microbiota with an individual’s age: the microbiota of children are likely to 
differ from adults, and the microbiota of adults are likely to differ within age groups, for 
example, owing to changes in urinary metabolites, personal hygiene and voiding habits. 
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1.2.4 Maintenance of homeostasis 
Assuming a mutualistic relationship, in which the bacteria benefit from the host’s 
nutrient supply, pH, oxygen concentration and other survival factors, it remains unclear 
what advantage the microbiota provide to the host. The human microbiome is critical in 
the maintenance of health and development at different sites throughout the body, but 
whether the urinary microbiota have a role similar to that of bacterial communities at 
other mucosal sites requires further investigation (Figure 1-3). In addition, it is known 
that microbes are important in establishing the immune system after birth and 
maintaining its effectiveness throughout life148. The presence of dedicated immune cells 
within the urinary tract raises the question of whether the urinary microbiota has a 
similar role in priming the immune system. 
Bacteria are also able to interact with many environmental toxins, such as heavy metals, 
polycyclic aromatic hydrocarbons, pesticides, ochratoxins, plastic monomers, and 
organic compounds149-152. After certain toxins have been removed from the blood stream 
through renal filtration, their storage within the bladder provides ample time for the 
urinary microbiota to interact with and alter these compounds. This ‘metabolism’ can 
increase or decrease the risk of diseases, including cognitive dysfunction, renal 
pathologies and urinary cancers, that can be caused by these toxins153.
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Figure 1-3. Potential roles of the urinary microbiota in homeostasis. 
Bacteria might produce neurotransmitters that interact with the nervous system (1). 
Commensal bacteria might outcompete pathogens for common resources (2). Bacteria 
might have a role in the regulation and maintenance of epithelial junctions (3). 
Commensals might produce antimicrobial compounds that kill pathogens (4). Bacteria 
might prime epithelial defences, including immune defences (5). Commensal bacteria 
might degrade harmful compounds (6). Bacteria might be necessary for proper 
development of the urinary tract, including the uroepithelium, immune system, and 
peripheral nervous system within the bladder and surrounding tissues (7). Commensals 
might create a barrier, blocking pathogen access to the uroepithelium (8).   
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The gut microbiota has been linked to the development of both the enteric and central 
nervous system after birth154. However, little is known about bacterial interactions with 
the peripheral nervous system. The urinary microbiota might be required for correct 
development of and signalling within this system, potentially through the production of 
neurotransmitters or interactions with these systems. Loss of these functions might be the 
cause of diseases, such as OAB and IC/BPS. Indeed, studies on germ-free mice show that 
the absence of microbes correlates with a compromised immune system, leaky gut, as 
well as behavioural and neurological disorders155. Studies of urinary tract function in 
germ-free animals are rare, so it is currently unclear exactly how this system is influenced 
by the microbiota. Finally, the urinary microbiota might act as a barrier to uropathogens, 
for example, through competition for resources, similar to other body sites156. In the 
vagina, secretions can have inhibitory activity against E. coli, particularly in communities 
dominated by Lactobacillus crispatus157. 
One of the limitations of 16S rRNA sequencing is its inability to differentiate between 
live and dead bacteria or bacterial DNA fragments. Hilt et al.108 addressed this issue by 
expanding culture conditions beyond the ones that are used routinely to isolate bacteria 
from urine. Using these modified culture criteria, 80% of 65 samples, of which 92% were 
culture negative (<103 colony forming units (CFU)/mL) using traditional culture 
techniques, grew bacteria. Comparison of these findings to their high-throughput 
sequencing results suggested that a majority of the bacteria found within the urinary 
microbiota via 16s rRNA sequencing were indeed alive. 
1.2.5 Factors influencing the microbiota 
It is well known that dietary factors can influence the risk of urinary infections and 
calculi. Consistent high water intake is important, but it is perhaps a little simplistic to 
suggest that it can help cure UTIs. Indeed, urine from individuals with increased water 
intake significantly increased the initial deposition rates and numbers of adherent E. coli 
and E. faecalis to silicone rubber158. This finding is of particular importance in patients 
with catheter-associated UTI (CAUTI) and suggests that high water intake leads to the 
dilution of a urinary factor that inhibits microbial deposition, rendering it ineffective. 
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Notably, a proportion of UTI cases resolve without intervention for unexplained 
reasons159-161.  
These findings raise a number of questions. Does the urinary microbiota simply need 
time to reconstitute following an acute infection? If so, why do not all infections resolve 
without intervention? Are there other triggers of infection, for example, alterations in the 
gut microbiota? Many microbial metabolites are found in the urine, which can be used as 
an indicator of gut dysbiosis. For example, in rats, in which the microbiota was 
suppressed by antibiotic treatment, the urinary metabolite profiles between the treated 
and control rats were remarkably different162. Clearly, many waste products, including 
microbial metabolites, are excreted via the urinary tract, but whether these metabolites 
are harmful to the urinary microbiota and their role in the development of UTIs is 
unclear. Multiple groups have explored the use of nuclear magnetic resonance (NMR) 
spectroscopy to differentiate the metabolites in the urine from healthy patients and those 
with suspected UTI163, as well as to identify biomarkers of morbidity164. 
Consumption of cranberry juice has been proposed to reduce the incidence of recurrent 
UTIs; however, in 2012, a randomised controlled trial in women with a history of 
recurrent UTI found no protective effects165. Other studies have suggested that D-
mannose, a component of cranberry juice and other juices, especially pineapple juice, 
inhibits the attachment of bacterial type 1 fimbriae to cell surfaces, presumably reducing 
the pathogen’s ability to remain in the urinary tract and infect the host166. Although more 
studies are needed—which should also examine the effect on the total microbiota—
urinary components indeed seem likely to have an important role in determining which 
organisms inhabit the urinary tract. 
In addition, the virome is likely to be important in maintaining the urinary microbiota. 
The virome is defined as the set of viruses infecting eukaryotic, bacterial, and archaic 
microorganisms found within the host, as well as the virus-derived genetic elements that 
have integrated chromosomally167. Similar to the bacterial contingent of the microbiome, 
the virome can be found throughout the entire human body, including the urinary tract, 
and is not limited to the mucosal sites. To date, little is known about the influence of the 
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virome on the urinary microbiota and this topic is likely to receive much attention in the 
coming years. However, as viruses are either DNA or RNA encoded and owing to high 
genomic diversity, characterisation of the virome is complicated by the limitations of 
current technology and the lack of a universal phylogenetic marker, such as the 16S 
rRNA in bacteria168. 
Importantly, the ways in which antibiotics and antimicrobial agents prescribed to 
patients, as well as trace amounts found in drinking water and food, affect the human 
microbiome are only now being realized169. The fact that bacterial resistance to 
antibiotics is increasing is well known; however, the use of low-dose, empiric 
prophylactic antibiotics to prevent recurrent infection remains an accepted therapeutic 
option. These practices might be creating bacterial persister cells that are genetically 
homogenous to previous generations, but exhibit a greater fitness, enabling them to be 
more capable of invading the uroepithelium and acting as a source of sepsis and 
infection, but potentially also of becoming part of the urinary microbiota170. In children 
with anatomical anomalies that predispose to recurrent UTI, infection is often managed 
with low-dose antibiotic prophylaxis—the development of persister cells due to such 
medication might be contributing to the recurrent nature of UTI. 
Changes in bacterial diversity over the course of an individual’s life have been described 
for the intestinal microbiota and are also likely to occur to some extent in the urinary 
microbiota171, given the influence of the former on the latter. Hormonal changes 
associated with puberty and menopause172, as well as constipation and urinary 
incontinence, are known to influence the microbiome173. In women, such changes 
primarily affect the composition of lactobacilli populations in the vagina174. In addition, 
in women, sexual activity can alter the microbiota of both the urethra and the vagina99. 
Furthermore, in male adolescents (aged 14–17 years) who have engaged in vaginal sexual 
intercourse, bacteria commonly associated with bacterial vaginosis can colonize the 
coronal sulcus and distal urethra111. These genera were not found in sexually 
inexperienced individuals, suggesting that colonisation was related to sexual activity. The 
same study also found significant differences in the types of bacteria colonizing the 
coronal sulcus between circumcised and uncircumcised adolescents. After puberty, the 
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prostate has developed sufficiently to produce prostatic fluid that contains various 
antimicrobial substances175, which are capable of influencing the urinary microbiota. In 
addition, spermicidal agents might disrupt both the male and female urinary microbiota, 
similar to disruptions observed in the vagina176,177. Furthermore, anal and oral penetration 
during sexual intercourse exposes men to two atypical microbial environments. 
As has been proposed for the gut178, the balance between certain microbial groups or 
organisms that contribute to a conserved metagenome might be more important than the 
overall composition of the urinary microbiota. For example, two populations might 
contain completely different sets of bacterial species, yet perform the same function, as 
the genetic potential is present in both populations. This property adds an aspect of 
redundancy to the microbiome, acting as a safeguard in the maintenance of health and 
development of disease. It is important to note that the metagenome represents only the 
genetic potential of the microbiota, not the actual activity of the population. 
1.3 Infectious states of the urinary tract 
1.3.1 Urinary tract infections 
The ongoing characterisation of the urinary microbiota has urged some researchers to 
suggest the traditional definition of UTI requires an overhaul. The recent urinary 
microbiota findings have led to the conclusion that a subset of urinary conditions may 
need to be reclassified as dysbiosis, rather than invasion by a single pathogen179. Such a 
change in dogma would elicit significant changes in clinical strategies. 
The term “urinary tract infection” is widely used both within and without the clinical 
setting. However, the term itself is quite broad, encompassing an infection within any 
part of the urinary tract, such as an infection of the kidney (pyelonephritis), urethra, or 
ureter. The most common UTI is bacterial cystitis, a bacterial infection of the bladder; 
thus UTI and bacterial cystitis will be used interchangeably throughout this thesis.  
Urinary tract infections are commonly classified as either complicated or uncomplicated 
based on patient characteristics; such categorisation is used clinically to aid in treatment 
determination. In general, an acute uncomplicated UTI is the acute onset of symptoms in 
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a healthy, pre-menopausal, non-pregnant woman without known functional or anatomical 
abnormalities of the urinary tract180. Complicating factors include; pregnancy, immune 
suppression, renal failure or transplant, male gender, healthcare-associated infection, 
recent hospitalisation or antibiotic exposure, and infection with a multi-drug resistant 
bacterium181.  
The criteria involved in the diagnosis of UTI are consistently evolving, yet generally 
includes a combination of clinical features and the presence of bacteria in the urine. Of 
note, some researchers suggest UTIs can be reliably diagnosed based on symptoms alone 
and call for an end to laboratory culture for acute uncomplicated UTI180; unsurprisingly, 
these groups also argue for immediate empirical treatment. Meanwhile, other groups 
suggest the use of culture results is imperative and should be involved in the treatment 
decision-making process. Indeed, acute uncomplicated UTI in adult women is not life-
threatening, and the argument has been made to delay treatment in this population182. 
Arguments for the immediate treatment of cystitis often cite the risk for development of 
increasingly severe infections, such as pyelonephritis and bacteraemia. Although this 
progression is relatively rare, approximately 15% of nosocomial bacteraemia cases 
implicate the urinary tract as the portal of entry183. 
Diagnosis of acute uncomplicated UTI can be made for adult women with a high 
probability based on the sudden onset of dysuria, urgency, frequency, and suprapubic 
pain in the absence of vaginal discharge or irritation. The presence of fever and/or flank 
pain is highly suggestive of pyelonephritis184. Conversely, symptoms in early childhood 
are systemic rather than localised and often characterised by fever, lethargy, anorexia, 
and vomiting184-186. Laboratory diagnosis of UTI is based on the presence of significant 
bacteriuria, yet the cutoffs for this are widely disputed, have not been formally validated 
in children, and do not provide a measure of disease severity or renal involvement186. 
Throughout the scientific literature and clinical guidelines, the most commonly used 
definition of significant bacteriuria is greater than or equal to 105 CFU/mL186-188. In 
comparison, the European Association of Urology suggests a cutoff of 104 CFU/ml for 
men and Price et al. have taken it a step further, proposing each pathogen has a unique 
threshold for UTI diagnosis184,189. Additional urinary markers of UTI include the 
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presence of pyuria, nitrites, leukocyte esterase, protein, and blood184,186. Some research 
groups have also suggested urinary interleukin-6 (IL-6) and interleukin-8 (IL-8) have 
prognostic value for paediatric UTI and act as markers of disease severity190,191. Indeed, 
in vitro studies have demonstrated the production and release of cytokines by urothelial 
cells in response to whole bacteria and purified bacterial toxins, such as pyocyanin or 
lipopolysaccharide (LPS)192-194. 
It is important to note, that traditional bacterial culture strategies used for urine in the 
clinical lab are focused on the identification of “classic” uropathogens, which are aerobic, 
fast-growing bacteria. However, in recent years a number of bacteria have been 
associated with UTIs that are not cultured using these traditional techniques, including 
Prevotella and Porphyromonas195. Microbiota analysis also highlights the presence of 
anaerobic and fastidious bacteria throughout the urinary tract, which has led to the 
development of expanded quantitative urine culture (EQUC)108,189. In brief, EQUC builds 
on standard microbiological urine culture practices, which involve aerobic incubation at 
35°C for 24-hrs, to include incubation under high CO2 and anaerobic atmospheres at 
30°C and 35°C for 48-hrs. 
Urinary tract infections are the second most common cause of community and hospital-
acquired infection in both children and adults183,196,197, costing the American economy 
approximately 2.5 billion dollars annually198,199. In children, reports suggest up to 8% of 
children will experience a UTI before the age of 7186,200,201. While most of these studies 
are older, a retrospective analysis of data from a cohort of almost 75,000 children 
between 2001 to 2006 by Conway et al.200, supports these estimates, with a 4.2% 
cumulative incidence of UTI in children up to 6 years of age. The same study 
documented an increased risk for UTI in children aged 3 to 5, which had previously been 
suggested by a group in the Netherlands202. The authors suggest this age discrepancy 
could be due to dysfunctional elimination, a known risk factor for UTI186. In adults, 50-
60% of women will experience at least one UTI over the course of their life203. Incidence 
is estimated to be particularly high in sexually active women aged 18-24, wherein one of 
five will report an uncomplicated UTI annually in the US204. 
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In all populations, UTI is causative of a decreased quality of life, associated with 
psychological distress, and loss of “functional” hours205. In adult women, UTI has also 
been correlated with dyspareunia, vulvodynia and lower urinary tract symptoms (LUTS), 
having a significant impact on sexual activity206. Economic loss is also notable during 
UTI, with women experiencing an average of 6.1 days of symptoms, 2.4 days of 
decreased activity, and 0.4 days of bed rest per symptomatic episode198. 
It is understandable then that researchers would attempt to identify risk factors of UTI in 
hopes of preventing disease and/or limiting severity. Gender appears to play the largest 
role in UTI risk; after all, females are significantly more likely to develop a UTI than 
males. Infection history is also a key factor in determination of UTI risk, notably women 
with a history of RUTI and those with a first UTI before 15 years of age have increased 
risk28. Most other key risk factors are directly associated with manipulation of the 
genitourinary tract including; sexual activity, which induces retrograde force up the 
urethra, the use of contraceptive devices and spermicides that alter the vaginal and 
periurethral bacterial communities, urological surgery, and indwelling or intermittent 
catheterisation22. The duration of catheterisation is the most important risk factor for the 
development of CAUTI; in fact, the incidence of bacteriuria associated with an 
indwelling catheter is 3-8% per day207. Similarly, risk of UTI is increased by anatomical 
or functional defects that compromise normal urination, such as urinary obstruction, 
neurogenic bladder, urinary incontinence, labial adhesions, and VUR184,186,208. Diabetes 
mellitus, immunosuppression, chronic constipation, obesity, renal insufficiency, bacterial 
vaginosis, lupus erythematosus, and rheumatoid arthritis also predispose a person to UTI 
and RUTI184,209. Although not completely understood, genetics and advanced age have 
been correlated with increased risk of UTI21. 
Further, increasing voiding frequency and water intake are strategies associated with 
RUTI treatment, which is interesting as increased voiding frequency was associated with 
lower UTI incidence in an interventional study of clean room workers210. This could be 
due to a number of factors, including the correlative increase in fluid intake; however, it 
may also be a reflection of damage due to repeated and prolonged bladder 
distension211,212. 
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1.3.1.1 Aetiology 
Although the exact numbers vary, E. coli is consistently recognised as the most common 
cause of UTI and is associated with more than 80% of both community and hospital-
acquired infections204. After E. coli there is no true consensus on the most common 
etiological agent; however, Enterococcus sp., Klebsiella sp., Staphylococcus sp., Proteus 
sp., Enterobacter sp., Pseudomonas sp., Serratia sp., Group A and B streptococci, and 
Candida sp. are all recognised as major causes of disease21,184,196,200,213,214. With that said, 
case reports and clinical studies have begun to identify other agents of UTI; these 
commonly represent fastidious bacteria or those that are difficult to differentiate from 
“every day” uropathogens. 
As an example, Aerococcus urinae is reported most often in association with elderly 
patients, yet a series of recent case studies have also linked this bacterium to paediatric 
male patients215. Identification of this bacterium is complicated as it displays similar 
colony morphology to α-hemolytic streptococci, Gram staining properties with 
staphylococci and antimicrobial resistance patterns to enterococci; thus the clinical 
impact of A. urinae has likely been underestimated216. The introduction of 16S rRNA 
gene sequencing and matrix-assisted laser desorption ionisation time-of-flight mass 
spectrometry (MALDI-TOF MS) to clinical microbiology labs will likely correspond 
with an increase in the perceived prevalence of bacteria such as A. urinae as clinical 
pathogens. 
Interestingly, one published study has assessed the urinary microbiota in patients with 
acute UTI118, which was defined as a minimum of 103 CFU/mL and a white blood cell 
count of greater than 104 cells/mL from midstream urine. Unsurprisingly, E. coli was the 
most common bacterial isolate and concordantly the most abundant genus identified in 
microbiota analysis. However, 16S rRNA sequencing identified other bacterial genera in 
the E. coli-dominated UTI samples, which may also play a role in disease. Of note, 
Enterococcus sp., were present in low abundance in almost a third of the E. coli-
dominated samples. Enterococci do not appear to have been co-cultured with these 
samples, which may be due to low bacterial abundance or an indication of sample 
contamination, yet the potential exists for bacterial interplay between these two 
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uropathogens. This research also highlights the presence of anaerobic and fastidious 
bacteria at high abundance as determined via 16S rRNA sequencing in some active UTIs, 
which are not isolated using routine methods, yet may also contribute to pathogenesis, 
highlighting the need for EQUC testing. Notably, the limited diversity in these samples 
suggests that every genus present may play a key role in regulating the transition between 
health and disease, or disease progression. 
1.3.2 Recurrent urinary tract infections 
Defined as three or more symptomatic UTIs in a 12-month period or two or more within 
six-months, RUTI is one of the greatest challenges associated with acute uncomplicated 
UTI. Recurrence rates are high in UTI patients, although reports vary on the exact 
incidence rate. In one study, 25% of women with acute UTI experienced recurrence 
within 6 months205; another suggests 25% recurred within 12-months and 22% went on 
develop RUTI217. A more conservative estimate suggests up to 5% of women 
experiencing their first UTI will go on develop three or more per year205. Global 
estimates suggest 1% of women will experience more than six UTIs per year218. In the 
United States, almost 11% of women over 18 will report at least one UTI over 12 months, 
with the majority of these cases in women with a history of RUTI219. Aetiology and risk 
factors are similar to those of UTI, with increased weight placed on a previous history of 
UTI, index infection at an early age, and maternal history of UTI184. 
In children, a retrospective study of almost 75,000 children demonstrated an incidence of 
recurrence of 12% per year in a primary care setting200. In contrast, studies on referral 
and emergency department populations estimate paediatric recurrence rates at 20-48% in 
the first 6-12 months185,220. Risk factors for paediatric RUTI include poor hygiene and 
voiding habits, as well as constipation and index infection before 12-months of age. In 
fact, recurrence rates in children with a UTI before one year are 75%, and this drops to 
40% in girls and 30% in boys at the one year mark186. 
Pathogenesis of RUTI is not well understood, although studies of E. coli RUTI suggest 
recurrent infections are often caused by the same strain. Recurrence may be a result of 
relapse, wherein infection occurs within 14 days of the previous and is related to 
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incomplete clearance; or may be due to reinfection from external sites, such as the 
gastrointestinal tract or vagina. Work by Scott Hultgren’s group has shown UPEC invade 
host tissues and form intracellular bacterial communities (IBCs) in the murine bladder, 
these communities are associated with latent infection, yet extrusion provides an 
additional explanation for RUTI221. Furthermore, exfoliated IBCs have been identified in 
urine samples from women with UTI, supporting the applicability of this theory to human 
RUTI222. Following this model of latent RUTI in mice, Gilbert et al., triggered E. coli 
emergence into the urine through transient exposure to Gardnerella vaginalis218. This led 
the researchers to propose a new paradigm for RUTI, covert pathogenesis. In brief, the 
classical view of UTI diagnosis and treatment is based on the pathogen present at the 
time of clinical pathogenesis, in this case, E. coli. Covert pathogenesis, conversely, 
suggests transient exposure to G. vaginalis triggered E. coli to cause disease, despite G. 
vaginalis being absent at the time of disease emergence. The theory suggests that long-
term exposure is not necessary, merely a transient one and that this is likely missed in the 
clinical setting as they occur before symptom onset, but may drive recurrence and disease 
severity caused by a recognised pathogen. If this holds true in humans, it may explain the 
link between RUTI and sexual activity and would not necessarily apply to only G. 
vaginalis and E. coli. Demonstration of covert pathogenesis in humans would also 
support the reclassification of UTI to dysbiosis. 
Recurrence may also be aided by pathogen instigated remodelling of the bladder mucosa 
as has been demonstrated by Scott Hultgren’s group (section 1.1.1.1.1)28. In this model a 
bimodal outcome is associated with chronic murine bladder infection; spontaneous 
resolution or antibiotic-induced sensitsation. Interestingly, this pattern mimics the 
spontaneous resolution of both symptoms and bacteriology noted in 25%-75% of women 
with UTI204,223. Sensitised mice exhibit altered bladder pathology, similar to the urothelial 
hyperplasia and defects in terminal differentiation noted in females with a history of 
UTI34,224. Further, on subsequent challenge, sensitised mice experience a significantly 
more severe UTI compared to naïve mice. Thus, UTI may induce lasting changes to the 
bladder’s barrier, which increases host sensitivity to infection, partially explaining 
previous infection as a risk factor for RUTI. 
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1.3.3 Asymptomatic bacteriuria 
At the other end of the spectrum is asymptomatic bacteriuria (ABU), which is classified 
as the presence of significant bacteriuria without the signs or symptoms of UTI188. 
Asymptomatic bacteriuria is a fairly common condition, occurring in 3-8% of 
premenopausal and 4-43% of postmenopausal women225. The aetiology of ABU is much 
the same as UTI and RUTI; E. coli is implicated most often, followed by Enterococcus 
sp., Pseudomonas sp., Proteus sp., Staphylococcus sp., and Klebsiella pneumoniae199. 
However, the bacterial cause of ABU is strongly influenced by gender, age, medical 
interventions (catheterisation), and comorbidities (pregnancy, diabetes, etc.). Incidence 
estimates suggest up to 10% of women will be diagnosed with ABU throughout their 
lifetime, with the state being more common in diabetics and the elderly199. Although not 
well understood, most studies suggest ABU is harmless in those without risk factors, such 
as pregnancy where ABU has been linked to preterm labour and delivery184,188. The 
presence of ABU does not lead to renal damage or impaired renal growth when left 
untreated185,226,227, and a 24-year follow-up study, demonstrated ABU was not associated 
with an increase in mortality or kidney disease compared to controls228. 
When ABU was first identified, clinicians believed it to be harmful and worthy of 
eradication; with further study, this belief changed to a benign observation requiring no 
therapeutic intervention, unless pregnant. Indeed, multiple studies have shown antibiotic 
treatment of ABU to increase the risk of symptomatic UTI226,229,230; thus ABU is now 
interpreted as a protective state in some populations231,232. Such a protective effect has 
been linked to bacterial interference, wherein the ABU strain outcompetes the pathogen 
for nutrients or produces toxic molecules190,233. 
1.3.4 Infection management strategies 
Antibiotic administration is the standard of care for both UTI and RUTI, in fact, 
uncomplicated UTI is one of the most common indications for antimicrobial prescription 
in otherwise healthy women234. Indeed, between 2007 and 2009, UTIs were the third 
most likely reason for adult antibiotic prescription in the ambulatory setting, accounting 
for 9% of antibiotic use, 70% of which were broad-spectrum235. At present, most primary 
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care guidelines recommend antibiotics for UTI treatment as this provides effective and 
fast symptom resolution. 
Current first-line antibiotics depend on the country and antibiotic resistance trends of a 
specific area. In the US, trimethoprim-sulfamethoxazole (TMP/SMX) is commonly used 
as a first line strategy234. Strong evidence also exists for the application of nitrofurantoin 
to the treatment of uncomplicated UTI, and indeed it is listed within the international 
clinical guidelines as a first-line therapy234. Interestingly, nitrofurantoin was initially 
approved in 1953 by the FDA for treatment of bacterial cystitis, yet fell out of style in the 
1970’s to TMP/SMX and the beta-lactams; however, increasing resistance to these 
antibiotics have led clinical guidelines to reposition nitrofurantoin as a first-line 
therapy236,237. In fact, resistance has been linked to relapse in 5-10% of women following 
completion of antimicrobial therapy225. 
Canadian guidelines are no exception to these; the Toronto Central Local Health 
Integration Network suggests empirical treatment for uncomplicated UTI in adults using 
5-days of oral nitrofurantoin as first-line followed by TMP/SMX and ciprofloxacin as 
second- and third-line, respectively. However, in complicated UTI TMP/SMX and 
ciprofloxacin make up first-line strategies238. In January 2017, the Canadian Paediatric 
Society (CPS) reaffirmed their guidelines for UTI in children239. In brief, CPS supports 
empirical treatment for UTI, using a two to four-day course of oral antibiotics, such as 
cefixime, TMP/SMX, amoxicillin, amoxicillin-clavulanic acid, or cephalexin. In children 
with febrile UTI, the course is extended to 7-10 days. 
1.3.4.1 Antibiotic prophylaxis for RUTI 
The standard of care for prevention of RUTI is also antibiotics; yet in this case, the 
recommendation is long-term low dose therapy. Less common prophylactic options 
include post-coital antibiotics in patients where RUTI is correlated with sexual 
intercourse and acute self-treatment in compliant patients with a clearly documented 
RUTI history184,240. Trimethoprim-sulfamethoxazole daily for six months is the most 
recommended strategy in adults and children186,240; however, other antibiotics are also 
commonly used including cephalexin, amoxicillin-clavulanic acid, cefadroxil, and 
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nitrofurantoin184. Given that the optimal duration of antibiotic prophylaxis is unknown, 
many clinical guidelines suggest continued evaluation of the patient over the course of 
prophylactic therapy with the potential to discontinue after 3-6 months. However, 50% of 
women will recur within three months of discontinuation, requiring the patient 
“reinstitute” antibiotic therapy225. 
The effectiveness of antibiotic prophylaxis for the prevention of RUTI is a contentious 
topic that many studies and meta-analyses have sought to address. In children, the 
impetus for antibiotics to treat RUTI is primarily to reduce the risk of pyelonephritis 
induced kidney damage185; yet, multiple studies have addressed this outcome, and none 
have identified a benefit to antimicrobials in the prevention of renal scarring186,220. Given 
the status of antibiotic prophylaxis as the standard of care, studies are lacking that have 
appropriately studied the effectiveness of prophylaxis, particularly in the paediatric 
population. 
The prevention of recurrent urinary tract infection in children with VUR and normal renal 
tracts (PRIVENT) study220, was designed to address this question. Study coordinators 
recruited over 500 children who had experienced at least one culture-proven UTI; 
patients were asymptomatic at recruitment and during the run-in period. In this double-
blind study, over 500 children who had experienced at least one culture-proven UTI were 
randomised to receive either placebo or TMP/SMX for 12 months. Patients were 
asymptomatic at recruitment and during the run-in period. Notably, and this was not 
touched on in their commentary, all patients received a 14-day course of TMP/SMX 
during the run-in period. Additionally, 15% of patients recruited in both groups had 
previous infections that were resistant to the antibiotic. The researchers found a small 
reduction in the absolute risk of UTI in predisposed children receiving probiotic (6 
percentage points), meaning 14 children need to be treated with TMP/SMX for 12-
months to prevent a single UTI. Half of the UTI events in the placebo group occurred in 
the first three months after randomisation, this is of particular interest, as this is within 
three months of antibiotic usage, suggesting they are not a true control group. 
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A potential explanation for the recurrence of infections in the placebo group lies within 
the treatment of ABU. As stated, none of these patients was experiencing a symptomatic 
UTI at recruitment, or during the run-in; however, the authors did not assess the patients 
for ABU. It is often noted in clinical practice that women with a history of RUTI present 
as symptom-free with “sterile” urine immediately after antibiotic treatment followed by 
ABU232. Thus, these children may have had ABU, which the run-in antibiotics would 
likely have disrupted. This is important to note, as antibiotic treatment of ABU is 
associated with poor outcomes217,226,227,229,230. In their study, Cai et al. noted UTI 
recurrence in patients treated for ABU with a history of UTI compared to those left 
untreated. By six months, the difference was statistically significant (7.6% vs 29.7%), yet 
was even more dramatic at 12 months, wherein 14.7% of the untreated patients 
experienced UTI compared to 73.1% of treated patients232. 
Another study, randomised intervention for children with VUR (RIVUR)241, focused on 
patients with VUR diagnosed after a first or second febrile UTI. The results from this 
randomised, double-blind, placebo-controlled trial of TMP/SMX suggest prophylaxis is 
beneficial for prevention of RUTI in patients with VUR. However, antibiotic resistance 
rates in uropathogens were significantly increased in the prophylaxis group (68%) 
compared to the placebo group (24%). A Cochrane review came to similar conclusions; 
antibiotic prophylaxis reduced the risk of significant bacteriuria relative to placebo and 
offered a slight benefit in preventing symptomatic UTI in children while increasing the 
likelihood of antibiotic resistance185. In contrast, another meta-analysis did not find a 
significant reduction in UTI incidence associated with prophylaxis, which was supported 
by subgroup analyses of participants with and without VUR242. Similarly, in a 
retrospective study of paediatric patients receiving TMP/SMX or, when culture history 
indicated resistance to this antibiotic, nitrofurantoin, every child in the study had a 
documented UTI during the 12 months of the review243. Furthermore, the rate of 
recurrent febrile UTI was also not reduced by prophylaxis in a recent Italian study244. 
1.3.4.2 Reconsidering antibiotics 
As discussed above, the applicability of antibiotic therapy for UTI and RUTI is 
debatable. Indeed, acute, uncomplicated UTI poses minimal risk of progression to tissue 
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invasion or sepsis; and spontaneous resolution of infection occurs in a large proportion of 
patients. A Belgium study noted over 30% of patients reporting either symptomatic 
improvement or cure within two days of starting placebo and this number was over 50% 
by seven days223, suggesting many patients are capable of clearing infection without the 
aid of antibiotics. Other groups have described clinical cure in the placebo group by day 7 
in over 25% of patients, reaching over 50% by the final 4-6 week follow-up159,213. 
Further, placebo-controlled trials of antibiotic treatment for uncomplicated UTI, noted no 
difference in time to symptom improvement between antibiotic and placebo, with 
bacteriologic cure rates only marginally better at 4-weeks post treatment205,245. 
This is not easily explained to patients though who are experiencing the uncomfortable, 
albeit temporary, symptoms associated with a UTI and physicians often acquiesce to a 
patient’s request for antimicrobial therapy. Such empirical therapy presumes the benefits 
of rapidly treating those with antibiotic-requiring UTI outweighs the risk of erroneously 
treating those without UTI or those within whom the infection will self-resolve. 
Empirical therapy is presumably less costly, as clinicians need not order bacterial culture 
unless complicating factors are present, and is associated with increased patient 
satisfaction. However, there are hidden costs associated with this strategy, and the 
medical field is beginning to question whether the benefits to the individual outweigh 
individual and societal risks205. 
At the individual level, antibiotic use is associated with multiple adverse events and has 
been implicated in damage to the human microbiome. Antibiotics are the most common 
cause of emergency department visits for adverse drug events in children under 18 and 
are responsible for up to 20% of all emergency department visits for adverse drug 
events246. Specifically, TMP/SMX is associated with Stevens-Johnson syndrome and 
toxic epidermal necrolysis requiring hospitalisation247. Nitrofurantoin has been linked to 
the development of erythema multiforme, as well as both acute and chronic pulmonary 
reactions247,248. Further, the fluoroquinolones are known to cause nausea, rash, and 
abnormal liver function tests205. With regards to microbiome effects, most research has 
focussed on changes to the gut and vaginal microbiomes following antibiotic therapy. Of 
note, a single antibiotic dose has been shown to decrease the bacterial diversity of the 
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gut249. Antibiotic induced-dysbiosis of these communities is associated with the 
overgrowth of certain pathogens and the development of disease, such as antibiotic-
associated diarrhoea, or vaginal and oral candidiasis. In fact, up to 22% of women that 
receive antibiotics for uncomplicated UTI will develop vaginal candidiasis205. 
In addition to these concerns, antibiotics often drop to below minimal inhibitory 
concentrations (MICs) in the host during treatment, particularly at the beginning and end 
of therapy, between doses, and throughout antibiotic prophylaxis. At sub-MIC 
concentrations bacteria adapt the regulation of cellular processes, leading to increases in 
fitness, virulence, and antibiotic resistance. This phenomena falls under the hormesis 
“umbrella”, or the concept that the response to a molecule is dependent on the molecule’s 
concentration. In a pioneering study from the Davies Lab, researchers noted the activity 
of up to 5% of Salmonella typhimurium promoters were modified in response to 
subinhibitory concentrations of erythromycin and rifampicin250. Other groups have taken 
a less global approach and focussed on specific markers of virulence. Specifically, studies 
have identified the up-regulation of Panton-Valentine leukocidin by oxacillin and 
haemolysins by β-lactams in Staphylococcus aureus251,252, exoproteins by clindamycin in 
Streptococcus pyogenes253, as well as type III secretion system protein PrgH and invasion 
protein by tetracycline in Salmonella typhimurium254; while downregulation has been 
shown for Panton-Valentine leukocidin by clindamycin and linezolid in S. aureus251, 
streptococcal pyrogenic exotoxin B by clindamycin and linezolid in S. pyogenes253, and 
flagellin by mupirocin in P. aeruginosa and P. mirabilis255. 
In terms of developing antibiotic resistance, selection by sub-MICs is often associated 
with low-fitness cost mutations, unlike selection at, or above, the MIC, which is 
associated with high-fitness costs and comparatively thrive under the selective pressure 
of high antibiotic concentrations. Subinhibitory concentrations also enrich for bacteria 
with a high mutation rate, coupled with increases in horizontal gene transfer and 
recombination; these strains accumulate mutations faster and therefore more rapidly 
adapt to the environment. Such growth-inhibitory conditions are also associated with an 
increased frequency of “persister” cells, wherein a subset of the susceptible population 
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arrests metabolic activity, converting to a slow/non-growing phenotype that is reversible 
upon removal of the selective pressure256. 
Given the empirical nature of antibiotic therapy for UTI, there is much concern 
surrounding the over use and inappropriate prescription of antibiotics to these patients. 
Notably, published guidelines exist outlining optimal antibiotic selection for UTI, yet the 
literature continues to demonstrate significant variation in the prescribing practices of 
physicians234. In fact, the Centre for Disease Control (CDC) estimates that up to 50% of 
all antibiotic prescriptions are unneeded or are not as optimally effective as possible246. 
Furthermore, empirical treatment increases the likelihood that some patients are treated 
with antibiotics lacking efficacy against the causative uropathogen234.  
One of the major concerns associated with inappropriate antibiotic use is the increasing 
prevalence of antibiotic resistance among bacteria, including uropathogens. Notably, 
many of the bacteria commonly associated with UTI, are on the CDC’s list of bacteria 
identified as antibiotic resistance threats and are either listed as urgent or serious, 
including E. coli, Enterococcus sp., Klebsiella sp., Pseudomonas aeruginosa, and S. 
aureus246. Less commonly linked to UTI, but still a known cause and included on the 
CDC’s list are; Acinetobacter sp., Campylobacter sp., Salmonella sp., Shigella sp., and 
Streptococcus pneumoniae. Inclusion of so many uropathogens on this list is concerning 
and suggests that antibiotic therapy for this disease is not being conducted effectively.  
Unsurprisingly, a retrospective analysis of over 600 children with first time UTI found no 
benefit in the use of antimicrobial prophylaxis to reduce the rate of RUTI; however, 
prophylaxis was associated with increased risk of resistant infections200. Furthermore, a 
prospective study comparing antibiotic prophylaxis with second-generation 
cephalosporins to TMP/SMX found the second generation cephalosporins increased 
resistance to both classes of antibiotics, while TMP/SMX increased resistance only to 
itself257. Predictably, TMP/SMX treatment in the previous 3-6 months is an independent 
risk factor of TMP/SMX resistance in UTI treatment234, and resistance to this antibiotic is 
increasing, in some areas uropathogen resistance is over 20%209. 
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Indeed antibiotic resistance is globally perceived as a looming public health crisis. In the 
US alone, 2 million people will acquire an infection with bacteria resistant to at least one 
antibiotic, and 23,000 will die each year as a direct result of these infections246. Globally 
antibiotic-resistant bacteria are estimated to kill 700,000 annually, a number that is 
predicted to rise to 10 million by 2050258. In addition to increased morbidity and 
mortality, antibiotic resistance can be directly related to increased expenditure. A 
retrospective Finnish study determined the cost of treating extended-spectrum beta-
lactamase (ESBL)-producing bacteria in children with UTI is roughly double the cost of 
treating a child with an ESBL-negative bacterium208. 
The antibiotic resistance dilemma is compounded by a number of factors; first and 
foremost is the development of resistant bacteria, which occurs for each new antibiotic 
and antibiotic class. Resistance development can be slowed down by antibiotic 
stewardship; however, bacterial evolution ensures it can never be completely stopped. 
Secondly, the drug development pipeline is inherently slow, taking up to 8 years to bring 
a drug from phase I clinical testing to product launch, not including the time spent on 
drug development259. Finally, there is limited investment in antibiotic discovery and 
development. Estimates vary on the cost of research and development for a new drug, 
ranging from $400 million to $1.5 billion258,259. For drugs used in chronic disease, the 
investment is worth it; however, antibiotics have a limited market, an effective antibiotic 
will be used for a few days or weeks, and then stopped. Additionally, use of newly 
developed drugs is often discouraged; they are maintained as drugs of last resort in an 
effort to curtail resistance development. Thus antibiotic development lacks economic 
incentives. 
A number of programs have been developed in the last few years to address some of 
these issues including the “New Drugs for Bad Bugs” programme and recent changes to 
European Medicines Agency policy that reduces clinical trial sizes260. However, it will 
take time for these policies to have affect clinical drug availability. In the interim, 
alternative treatment strategies should be considered for UTI. 
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1.3.4.3 Ibuprofen as an antibiotic alternative 
Multiple antibiotic alternatives for the treatment of UTI have been studied, including 
functional foods, mucosal vaccines, and bacterial interference strategies. Ours was one of 
the first groups to suggest bacterial interference may be effective in the prevention of 
UTIs after recognising a correlation between Lactobacillus sp. colonisation of the bladder 
and decreased risk of UTI261-263. Since then, multiple studies have assessed the use of 
probiotics in the prevention of UTI and have extended to the purposeful colonisation of 
bladders with ABU strains. 
An entirely different approach to UTI treatment is the concept of treating the symptoms, 
not the infection. This approach is based on the assumption that most UTIs are self-
resolving and that symptomology is the impetus for patient antibiotic requests. This 
approach also builds off the fact that many women do not immediately seek medical 
attention for UTI, rather they wait for the infection to clear on its own or try to treat with 
home remedies264. Indeed, a number of trials have studied the delay of antibiotic 
prescription for UTI, these reports comment on delayed symptom resolution and 
increased time to clearance, yet delay was not associated with serious complications265. 
Over the last decade, multiple studies have been published comparing the treatment of 
UTI symptoms to antibiotics237,264-268. Ibuprofen, a non-steroidal anti-inflammatory drug 
(NSAID), is often the drug of choice in these studies due to its analgesic, antipyretic, and 
anti-inflammatory properties. In a pilot study, Bleidorn et al., suggested the use of 
ibuprofen performed equivocally to ciprofloxacin for treatment of uncomplicated UTI 
with regards to symptom resolution and course of disease264. Secondary antibiotic 
treatment was required in 33% of the ibuprofen group compared to 18% in the 
ciprofloxacin, and this difference was not significant. Notably, 66% of patients recovered 
without the use of antibiotics. Building on this momentum, the same group conducted a 
double-blind, randomised, multicenter trial of almost 500 patients comparing ibuprofen to 
fosfomycin265,266. Again, 66% of patients receiving ibuprofen recovered without 
antibiotic treatment; however, non-antibiotic treatment correlated with a higher burden of 
symptoms. Concurrently, antibiotic prescription for symptom persistence or worsening 
occurred in 34% of ibuprofen patients compared to 14% of fosfomycin patients, and this 
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was a significant difference. Interestingly, between days 8 and 15 infection relapse was 
more common in the ibuprofen group, yet recurrence between days 15 and 28 was more 
common in the fosfomycin treated group. However, a follow-up of these patients 
identified no difference in self-reported recurrence between 28 days and six months 
between the two groups267. Further post-hoc analysis of this trial involved the 
development of a model for use in clinical decision making to determine which patients 
are likely to succeed using symptomatic therapy269, clinical validation of this method 
remains to be seen. 
Conference proceedings of a Swiss trial report similar findings between norfloxacin and 
diclofenac, wherein patients were more likely to seek reconsultation for UTI symptoms in 
the diclofenac group (19% vs 9%); however, over 60% of patients receiving diclofenac 
did not require antibiotics268. A further study was undertaken across four sites in Norway, 
Sweden and Denmark, comparing a higher dose of ibuprofen to mecillinam over the 
course of three days237. Although the study’s clinical trials registry lists it as completed, 
no data is presently available. 
Interestingly, the clinical cure rate of ibuprofen patients within each of these studies is 
generally higher than those reported in placebo studies. This is particularly interesting, as 
a number of groups have suggested ibuprofen has antimicrobial properties270,271. 
Recently, Obad et al. demonstrated ibuprofen mediated growth suppression of Gram-
positives including, Staphylococcus aureus, Staphylococcus epidermidis, Bacillus 
subtilis, and Micrococcus luteus; but not of Gram-negatives (E. coli, P. aeruginosa, or 
Salmonella typhimurium)271. The concentrations identified in these studies are 
physiologically relevant to human urine, suggesting ibuprofen may have inhibitory 
effects in the bladder. 
1.4 Enterococcus 
As discussed earlier, enterococci consistently rank within the top three uropathogens in 
regards to infection incidence, with most enterococcal UTIs being associated with E. 
faecalis.  Two species of Enterococcus, E. faecalis and E. faecium, account for the 
majority of clinical enterococcal infections including medical device-associated 
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infections, endocarditis, periodontitis, and UTI272. First observed as pathogens 100 years 
ago, Enterococcus sp. have since established themselves as a major threat to human 
health260. In addition to their pathogenic potential, enterococci are commensals of the 
gastrointestinal tract, with E. faecalis being the most ubiquitous among species of 
animals, birds, insects, mammals, and reptiles273. In humans, 98% of people are colonised 
by enterococci274. Commensal E. faecalis are also considered to offer a health benefit to 
the host; E. faecalis has been used as a commercial probiotic for over 50 years, and 
commensal E. faecalis produce a pheromone capable of killing multi-drug and 
vancomycin-resistant E. faecalis in addition to inhibiting both Gram-positive and 
negative pathogens272,275-277. 
A key step in the development of E. faecalis colonisation and infection is adherence to 
biotic or abiotic surfaces accompanied by biofilm development. In fact, most of the 
virulence factors that have been characterised from E. faecalis are biofilm and/or 
adhesion related. Examples of such factors are the endocarditis and biofilm-associated 
pili (Ebp), which plays a role in adherence to collagen and is necessary for adherence to 
fibrinogen278; adhesion to collagen of E. faecalis (Ace) which binds laminin as well as 
collagen types I and IV279; and aggregation substance (AS) which creates aggregates on 
the bacterial cell surface that are involved in conjugation and adherence to eukaryotic 
surfaces272. Other virulence factors include the E. faecalis endocarditis antigen (EfaA) 
and extracellular surface protein (Esp) along with the secreted enzymes; gelatinase 
(GelE), extracellular serine protease (SprE), and cytolysin (CylL). Regulation of 
virulence is mediated by multiple systems including, the global regulator of virulence 
(GrvRS, previously EtaRS), vancomycin resistance (vanSR), and fsr-quorum sensing 
systems (FsrABC). 
In addition to biofilm formation and virulence factor production, enterococci are 
notoriously antibiotic resistant272,280,281,	a	factor	of	both	inherent	and	acquired	
features.	The	CDC	included	vancomycin-resistant Enterococcus (VRE) as a serious 
domestic antibiotic resistance threat in their 2013 threat assessment246, and Enterococcus 
faecium was recently included in the World Health Organization’s (WHO) priority 
pathogens list for research and development of new antibiotics282. Across the genus, 
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Enterococcus resistance is relatively low, with approximately 10% of infections 
demonstrating antibiotic resistance, yet this figure is rising. This is unsurprising given 
almost 80% of all E. faecium isolates from health-care-associated infections are 
vancomycin-resistant in the US246. Enterococcal resistance to last-resort antibiotics, 
including daptomycin and linezolid, has also started to emerge260. 
Enterococci are one of the most common causes of sepsis in hospitalised patients283. 
Collectively, the CDC estimates there are 66,000 healthcare-associated Enterococcus 
infections each year in the states; of these 20,000 are vancomycin resistant, and 1,300 
deaths are directly attributable to this genus246. General properties that have contributed 
to the emergence of enterococci as nosocomial pathogens include; environmental 
persistence and associated resistance to clinical disinfection protocols, efficient host 
colonisation, and an intrinsic ability to withstand a broad-spectrum of antimicrobials. 
Genomic plasticity has likely also played a role as acquired mobile genetic elements can 
account for up to 25% of the genome for both E. faecalis and E. faecium280. Of all the 
species of Enterococcus, E. faecalis demonstrates the greatest resistance to desiccation, 
while E. faecium is the most tolerant of starvation273. 
1.4.1 Enterococci in the urinary tract 
Enterococcal pathogenesis in the bladder is severely understudied relative to other 
uropathogens. Most studies of UTI use E. coli as a model pathogen, which is 
understandable given it’s standing as the most prevalent uropathogen. Using E. coli as a 
guide, enterococcal adherence to and biofilm formation on urothelial cells has been well 
documented using mouse models of UTI and is thought to be primarily mediated through 
the Ebp pili, as well as the adhesins, Ace and Esp21,272,280. Unsurprisingly, attachment of 
Gram-negative uropathogens is much better characterised; both E. coli and Klebsiella sp. 
have been shown to bind UP proteins and E. coli binds α3β1 integrins to initiate 
adherence21. Enterococcal interactions with UP proteins has not been demonstrated; 
however, this has been proposed to be mediated through Esp284. Further, adherence to 
macrophages is mediated in part through AS-integrin interactions and enterococcal 
attachment to the gastrointestinal epithelium involves interactions with GAGs285,286, yet 
these interactions have not been demonstrated within the urinary tract. Similarly, invasion 
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of the bladder epithelium by E. faecalis was only recently reported via ex vivo imaging of 
shed human urothelial cells287. This invasive capability was then confirmed in vitro using 
a human bladder epithelial cell line. 
Unlike E. coli, the most common cause of UTI, E. faecalis, generally, does not induce 
severe symptoms of UTI.  On the contrary, many E. faecalis UTIs present as low-grade 
discomfort and urine counts below the classic standard threshold for UTI of 105 CFU/mL. 
However, it should be noted that groups have suggested this standard is too high for E. 
faecalis and that true enterococcal UTI may be caused by a lower bacterial count288. An 
alternative explanation is that most enterococci do not produce potent pro-inflammatory 
toxins and this is supported by research demonstrating minimal induction of bladder 
inflammation by E. faecalis in a murine cystitis model280,289. Unsurprisingly, enterococcal 
UTI is one of the least likely bacteria to meet standardised diagnostic criteria214. Further, 
Enterococcus is prevalent in polymicrobial UTI290; given that most polymicrobial isolates 
are dismissed as contamination, enterococcal UTI may be under-diagnosed. 
E. faecalis is also a common cause of ABU, with multiple studies identifying it as the 
second most prevalent organism199,232, despite the presence of a number of virulence 
factors291,292 . Interestingly, Cai et al. found E. faecalis in the majority of ABU patients 
who had a history of UTI but were recurrence free232. Of further interest is the finding 
that treatment of enterococcal ABU increases the incidence of symptomatic UTI in the 
post-treatment period291. Similar results have been found in children receiving antibiotic 
therapy for UTI; recurrence rates were higher for those with enterococcal UTIs compared 
to those with Gram-negative UTIs293. 
In the Wolfe et al.102 study of healthy adult female urine, no enterococci were detected, a 
trend further demonstrated by Siddiqui et al. in their study of healthy female urine112. 
However, a second study by this group positively identified Enterococcus in the urine of 
women with IC/BPS113. Further, neurogenic bladder patients tend to demonstrate a urine 
microbiota that is dominated by Enterococcus114, suggesting that a demonstrable 
abundance of these organisms are associated with a diseased, rather than a healthy 
urinary tract. 
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1.5 Bacterial interactions with the nervous system 
1.5.1 Sensory properties of the urothelium 
Over the last few decades, concepts surrounding urothelium function have vastly 
changed. Once considered to function purely as a barrier against urine, the understanding 
of urothelial functions has evolved to include metabolic activity and sensation of both 
chemical and mechanical stimuli6,87. Sensory input is communicated to nerves, 
interstitial, smooth muscle, vascular, and inflammatory cells through urothelial release of 
effector molecules38. In turn, the urothelium is responsive to signals from these systems; 
de-innervation of the bladder, for example, results in acute structural disruption of the 
urothelium and subsequent loss of barrier function31. This “sensory web” regulates 
urothelial permeability, contraction and relaxation of the detrusor, and host sensation of 
bladder fullness16.  
The neuron-like properties of the urothelium are accorded through a variety of receptors 
including those classically associated with the nervous or muscular systems, such as 
purinergic, adrenergic, and cholinergic receptors. In some cases, the density of these 
receptors is quite high, such as in pigs, where the mAChR population if 1.5 times greater 
in the urothelium than the detrusor294. Additionally, protease-activated ion channels, 
epithelium sodium channels, and members of the TRP family are found within this tissue 
layer8,16. Bladder epithelial cells are also able to respond to hormones, neuropeptides, and 
chemokines among other molecular signals38. Effector molecules released at either the 
apical or basolateral surface mediate the urothelial response. 
In a healthy bladder, bladder-filling increases pressure on the urothelium, which induces 
urothelial release of neuroactive effectors such as ATP, NO, ACh, adenosine, and 
prostaglandins (PGs)6,79. Although the exact mechanism has not yet been characterised, 
urothelial ATP is thought to activate P2X3 receptors on suburothelial sensory 
afferents8,77, communicating bladder fullness to the brain. The presence of P2X receptors 
on the serosal surface of urothelial cells suggests the ATP signal is propagated through 
the urothelial layer, which may play a dual role; relay of the signal to afferent nerves and 
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expansion of UC apical membrane surface area through stimulation of P2X receptor-
mediated vesicular traffic16. Further, the stimulus may be amplified through autocrine 
signalling or ICs acting as intermediaries between the urothelium and nerves or SMCs. 
Other response mechanisms include the release of NO following activation of urothelial 
TRPV1, α-AR or β-AR and release of an as-of-yet-unidentified inhibitory factor in 
response to autocrine or paracrine ACh15,76,79,87,295. 
Further support for the sensory functions of the urothelium can be found in pathological 
states, wherein alterations to urothelial structure or receptor expression patterns correlate 
with bladder pathology. Dysregulation of urothelial mAChRs has been linked to detrusor 
overactivity and increased release of ACh during bladder filling associated with 
OAB2,87,88. Alterations in urothelial expression of TRP family and purinergic receptors 
has been observed in IC/BPS, OAB, bladder outlet obstruction (BOO), and detrusor 
overactivity. Similarly, increased ATP release has been noted in response to stretch and 
electrical field stimulation in urothelial cells isolated from patients with functional 
bladder disorders. Correspondingly, urinary ATP is increased in patients with IC, OAB 
and other functional bladder disorders38. 
1.5.2 Potential for bacterial interactions 
Many bacteria have been documented to interact with the nervous system154,296-299. In 
most such cases this leads to the development of disease, for example, those caused by 
neurotoxins, such as botulinum (botulism) or the invasion of neural cells as is the case for 
Mycobacterium leprae. To date, neuronal interactions with bacteria have focused upon 
aggressive nervous system pathogens, though now we are beginning to understand that 
bacteria throughout the body may have other distinct but subtle effects on the nervous 
system. 
Bacteria have been documented to produce and interact with classical neurotransmitters 
for over 100 years, yet direct applications to host homeostasis were rarely considered, 
with the exception of infection, until relatively recently. Indeed, bacteria are known to 
produce γ-amino butyric acid (GABA), NE, ACh, tyramine, tryptamine, serotonin, and 
many other neuroactive substances300-304. Unfortunately, most studies assessing bacterial 
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production of these molecules are completed by food microbiologists and are thus 
primarily studied under food storage or production conditions. Strategies to reduce 
histamine associated scombroid poisoning or tyramine induced hypertensive crises in 
persons on monoamine oxidase inhibitors abound within the literature305-308. However, 
the potential for bacteria to produce these molecules in the human host and how this 
might alter the host response or progression of disease has been given minimal 
consideration. 
To date, most research has focussed on the microbiota-gut-brain axis, the theory that gut 
bacteria interact with the enteric nervous system (ENS), which in turn communicates 
with the brain to modulate host homeostasis or behaviour154,297,298. Given the gut is highly 
innervated and one of its primary functions is nutrient absorption, it stands to reason that 
metabolites produced by the gut microbiome would signal through the ENS. Notably, 
species of Lactobacillus and Enterococcus are capable of GABA production, and oral 
administration of Lactobacillus rhamnosus JB-1 reduces anxiety- and depression-related 
behaviour in mice through GABAergic signalling309-311. Abnormal behaviour has also 
been noted in germ-free mice296,312, which is likely due to a loss of microbial metabolites. 
In terms of the bladder, intravesical administration of chemical stimuli induces changes 
in bladder capacity and activity. Thus bacterial production of neuroactive substances in 
the bladder is likely to affect independent of damage to the bladder’s barrier. Intravesical 
instillation of vanilloids reduces symptoms of detrusor over activity and IC, PGE2 or ATP 
induces bladder hyperactivity, capsaicin reduces the desire to void and increased bladder 
capacity in patients with hypersensitivity, and nerve growth factor (NGF) sensitises the 
afferent nerves to subsequent mechanical stimuli6,16. While the exact mechanisms of 
action are unknown, urothelial sensory properties and innervation of the urothelium have 
been proposed. Groups have also demonstrated cytoplasmic projections that anchor the 
UCs to the basement membrane, which could provide a direct link to the suburothelial 
plexus or ICs. There is also reason to believe bacteria may indirectly produce neuroactive 
substances through natural response mechanisms, for example, the host response to 
bacteria involves inflammation and PGs are mediators of inflammation. However, PGs 
have also been shown to induce bladder contraction2. Interestingly, PGE2 is higher in the 
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urine of patients with acute UTI compared to healthy controls, and this correlates with 
symptom onset and duration313. 
Bacterial communication with the host through metabolite intermediates is certainly not 
something unique to the bladder or gut. Researchers at Johns Hopkins suggest 
microbially-derived short-chain fatty acids act as ligands for G-protein-coupled receptor 
41 and olfactory receptor 78 to modulate blood pressure control at the level of the 
kidney314. Bacteria have co-evolved with their mammalian hosts, and are constantly 
exposed to eukaryotic communication. Thus, the hypothesis that bacteria also use these 
systems as a means of communication intra-and inter-kingdom is not a leap. Indeed, 
GABA is a chemotactic agent for pseudomonads, increases the bacterial cytotoxicity of 
P. aeruginosa and induces lipopolysaccharide (LPS) rearrangement in P. 
fluorescens300,315. 
The catecholamines are also found throughout nature and elicit responses in many species 
of bacteria. Norepinephrine enhances the growth of P. aeruginosa in iron-limited 
minimal media by acting as a siderophore and represses production of virulence factors 
negatively regulated by iron316. The growth of E. coli O157:H7 and S. enterica is 
stimulated by NE, dopamine (DA), and epinephrine (EPI); while Yersinia enterocolitica 
only responded to NE and DA317.  Similarly, NE increased the growth, motility, and host 
cell invasion of Campylobacter jejuni under iron-limited conditions318. Yet, exposure of 
Salmonella enterica serovar typhimurium to EPI reduced the expression of an 
antimicrobial peptide resistance operon and concomitantly increased polymyxin B 
susceptibility319. Further, EHEC exposure to EPI and NE is associated with increased 
motility, biofilm formation, and attachment to porcine colonic mucosa and bovine 
illeum320-322. 
Alternatively, bacterial infection is known to alter the urothelium28, which has the 
potential to expose underlying, immature cell layers and/or tissues to direct interaction 
with bacterial metabolites. Such disorganisation may also extend to the ATP-mediated 
vesicular transport system, predisposing the host to urgency and frequency. 
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1.5.3 Linking bacteria to bladder dysfunction 
Symptoms associated with loss of micturition control or dysfunctional bladder sensations 
are associated with many urinary disorders, urgency and frequency are experienced by 
patients with OAB, and idiopathic pain is a hallmark of IC/BPS. However, these 
symptoms are also present during UTI. While inflammation is expected to play a role in 
these pathologies, our group proposes bacteria are capable of subterfuge – use of the host 
response to bacterial advantage. A good model of this is the difference between ABU and 
UTI. Patients with ABU meet the diagnostic cut-off for UTI, which is presumably caused 
by an equally virulent strain, yet experience no symptoms of UTI. Thus, the potential 
exists for the bacteria to either elicit a weaker immune response in this state or interfere 
with the regular signalling systems within the bladder, “dulling” the host sensation. 
Of note, patients with RUTI, OAB, IC/BPS, SCI, and BOO all experience LUTS and 
exhibit similar pathologies including an increase in urothelial apoptosis and decrease in 
urothelial E-cadherin expression, indicators of impaired urothelial differentiation30. 
Further to this point, UPII KO mice demonstrate voiding patterns typical of IDO, which 
could be a factor of increased urothelial permeability and/or dysfunctional smooth muscle 
tissue27,323. Observations have also been made in regards to reduced sensitivity of UPII 
and UPIIIa KO mice to carbachol-induced contractions of denuded bladder strips323. 
Given that the urothelial layer has been removed from these strips prior to contractile 
studies, it is unlikely that the UP proteins are actively contributing to the change in 
sensitivity. Thus, reduced sensitivity may be a result of mAChR and nicotinic 
acetylcholine receptor (nAChR) “overexposure” to urinary metabolites due to increased 
urothelial permeability, which also occurs during UTI. 
In contrast, the contractile response to carbachol was significantly higher in denuded 
detrusor strips from paediatric patients with a history of RUTI relative to age-matched 
controls, which was suggestive of infection-induced upregulation of cholinergic receptors 
or neurons324. Importantly, IDO has been correlated with increased CGRP and SP 
immunoreactivity in the bladder and OAB linked to increased urinary NGF and brain-
derived neurotrophic factor (BDNF)67,325. Inflammation is also associated with increased 
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expression of neuropeptides in the bladder and urine38,326. However, as most studies focus 
on acute inflammation, the length of time this persists for remains unknown, yet the links 
between UTI and subsequent bladder dysfunction seem to suggest that dysfunction is 
long-term in some patients. 
In particular, multiple studies have documented UTI episodes prior to the onset of 
IC/BPS and oversensitivity has been proposed as a mechanism for multiple chronic pain 
syndromes327. Similar trends have been found in the gastrointestinal tract; the density of 
SP and CGRP nerves was higher in H. pylori infected mice, remaining higher after H. 
pylori eradication328. These changes were coupled with a decrease in ACh release upon 
electrical field stimulation, suggesting H. pylori induced both morphological and 
functional changes to the nervous system. Furthermore, between 10 and 30% of patients 
with acute gastroenteritis will develop symptoms of irritable bowel syndrome329. The 
applicability of this to the bladder is supported by rat studies that demonstrate the 
relationship between early life inflammation and the persistence of SP upregulation into 
adulthood, which is associated with decreased bladder volume and a concomitant 
increase in micturition frequency330. In humans, a retrospective study comparing women 
with RUTI to those with stress urinary incontinence and no history of RUTI found that 
women with a history of bladder infection had a greater urinary frequency, lower average 
void volumes and a lower threshold of bladder sensitivity327. Thus, it is likely that 
bacteria either directly, through production of neuroactive substances, or indirectly, 
through host response to infection, modulate the sensitivity of the bladder to stimuli. 
1.6 Scope and purpose 
At the commencement of my doctoral studies, enterococcal invasion of the urothelium 
had not yet been demonstrated, the urinary microbiota not yet described, and microbial 
endocrinology was a fledgeling field of research. E. faecalis remains a major cause of 
UTI, and the rates of antibiotic resistance are increasing at a steady rate. Thus the purpose 
of this thesis was to increase understanding of enterococcal UTI, in particular, the 
response of Enterococcus to antibiotic prophylaxis in vitro and in vivo and enterococcal 
communication with the bladder. 
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The second chapter addresses the response of E. faecalis to nitrofurantoin and 
TMP/SMX, two of the most commonly prescribed antibiotics. Unexpectedly, 
nitrofurantoin induced a major increase in enterococcal attachment to urothelial cells. We 
further explored the transcriptional response of E. faecalis to nitrofurantoin. We also 
investigated IBU as a candidate antibiotic potentiator. 
The third chapter incorporates a clinical study we undertook in London, Ontario to study 
the effects of TMP/SMX and nitrofurantoin on bacteria in vivo. Our study was to be the 
first description of the urinary microbiota in the paediatric population, the first 
longitudinal assessment and the first to study changes in the urinary microbiota as a 
response to antibiotic prophylaxis. Our study demonstrated the presence of uropathogens 
in urine throughout the study period, regardless of antibiotic status and absence of UTI 
symptomology. 
In the fourth chapter, we discuss the neuromodulatory properties of E. faecalis. Our 
initial proposal involved the characterisation of GABA production by enterococci. 
However, as we moved forward with the experiments, we switched from a colourimetric 
assay to a mass spectrometry method. Through the use of targeted mass spectrometry, we 
were able to identify enterococcal production of neuroactive molecules in vitro under 
conditions mimicking the bladder environment. 
At the culmination of my thesis, Enterococcus remains a relatively understudied 
pathogen in the context of UTIs; however, this has started to change. Throughout this 
thesis, I have questioned the efficacy of antibiotic prophylaxis for RUTI, particularly in 
patients with a history of enterococcal UTI. Further, I demonstrate the potential for E. 
faecalis to interact with the sensory system of the bladder. It is my sincere hope that 
others use this thesis as a starting point for further hypothesis-driven investigations. 
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Chapter 2  
2 Nitrofurantoin increases bacterial attachment to urothelial 
cells 
2.1 Introduction 
Urinary tract infections (UTIs) can be associated with decreased quality of life, 
psychological distress, and loss of functional hours1. Females are significantly more 
likely than males to experience UTI, which has been attributed to the difference in 
urethral length2. Notably, women experience an average of 6.1 symptomatic days, 2.4 
days of decreased activity and 0.4 days of bed rest per symptomatic episode3, which is a 
huge economic loss when considering the high incidence of this disease. Further, 
recurrence rates are quite high; up to 25% of women with acute UTI will recur within 
12-months, and 22% will go on to develop recurrent UTI (RUTI)4, which is defined as 
three or more symptomatic UTIs in a 12-month period or two or more within six-
months. More conservative estimates suggest up to 5% of women experiencing their first 
UTI will develop RUTI1. In children, recurrence rates in primary care are approximately 
12% per year for both males and females5, while referral and emergency department 
data indicates 20-48% will recur within 12 months6,7. 
At present, antibiotic therapy is the standard of care for both UTI and RUTI8-10; 
however, such widespread use has become contentious. Antibiotic resistance has been 
linked to infection recurrence in 5-10% of women, and this figure rises to 50% following 
antibiotic prophylaxis11. In children, antibiotic prophylaxis is often used in RUTI as a 
strategy to reduce the risk of pyelonephritis, renal scarring and febrile UTI6; yet clinical 
studies do not demonstrate these benefits7,12,13. Rather, there is either a slight benefit in 
prevention of symptomatic UTI or no reduction6,14.  
Furthermore, sub-minimal inhibitory concentrations (MICs) of antibiotics are associated 
with bacterial adaptation of cellular processes, increasing bacterial fitness, virulence, and 
antibiotic resistance. Our lab has previously documented increased adherence to 
urothelial cells and bladder invasion by Staphylococcus saprophyticus and Escherichia 
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coli following exposure to sub-MIC ciprofloxacin15,16. Similar effects have been noted 
for a variety of antibiotic classes and bacteria17-20. Sub-inhibitory concentrations are 
often encountered throughout antibiotic prophylaxis, yet research into the effects of 
nitrofurantoin and trimethoprim-sulfamethoxazole (TMP/SMX), two of the most 
commonly prescribed prophylactic agents, is limited. 
Concerns with antibiotic usage, combined with the high rate of spontaneous cure 
associated with UTI, have paved the way for studies into alternative UTI therapeutics. 
The clinical intent for UTI is primarily cessation of symptoms; antibiotics quickly 
achieve this. However, ibuprofen (IBU) presents a viable alternative for symptom 
management, providing the relief patients desire, while the immune system clears the 
infection. As one of the most commonly used non-steroidal anti-inflammatory drugs 
(NSAIDs), IBU has a well-characterised safety profile and is known for its analgesic, 
antipyretic, and anti-inflammatory properties that are mediated through nonspecific 
inhibition of cyclooxygenases. In clinical studies, IBU compared equivocally to 
ciprofloxacin for the management of uncomplicated UTI21, yet did not perform as well 
when compared to fosfomycin22-24. In a murine model of acute UTI, NSAID 
administration reduced bacterial burden and prevented mucosal wounding25,26. The 
general belief is that IBU “masks” the symptomology, allowing the host’s immune 
system to clear the infection independent of antibiotics; however, clinical cure rates, 
defined as loss of symptoms, are generally higher in the IBU arm of UTI studies relative 
to the placebo arm of other studies22-24,27, indicating it may have antimicrobial 
properties. Indeed, multiple reports exist of Staphylococcus aureus, Staphylococcus 
epidermidis, Bacillus subtilis, and Micrococcus luteus growth suppression by IBU in 
vitro28,29. Ibuprofen is metabolised by cytochrome P450 (CYP) enzymes to two major 
metabolites, 2-carboxyibuprofen (CIBU) and 2-hydroxyibuprofen, and two minor 
metabolites 3-hydroxyibuprofen and 1-hydroxyibuprofen, which are ultimately excreted 
in the urine30,31. 
Given the high rate of antibiotic resistance among uropathogens and its relation to sub-
MIC antibiotics, the study of bacterial adaptation to antibiotics at these concentrations is 
a priority. Enterococcus faecalis, one of the most common uropathogens32-34, is well 
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known for innate and acquired antibiotic resistance properties, yet the bacterium’s 
response to sub-MIC antibiotics is understudied. Further, the effects of IBU on E. 
faecalis virulence are unknown. 
In this chapter, we assessed the role of nitrofurantoin, TMP/SMX, IBU and CIBU on 
enterococcus growth and adherence characteristics, as well as the potential for synergy 
between the antibiotics and IBU. We hypothesised that sub-MICs of nitrofurantoin and 
TMP/SMX would increase the attachment of E. faecalis to urothelial cells. We further 
hypothesised that addition of IBU or CIBU would reduce these effects, potentiating the 
antibacterial properties of nitrofurantoin and TMP/SMX. 
2.2 Materials and methods 
2.2.1 Bacterial strains, eukaryotic cell lines, media, and chemicals 
Bacterial strains used throughout these experiments are listed in Table 2-1. Strains were 
routinely cultured without aeration at 37°C, in brain-heart infusion broth (BHI; Difco 
Laboratories Inc., Franklin Lakes, NJ, USA) for E. faecalis and Luria-Bertani (LB) broth 
for E. coli. Growth experiments were conducted with Mclean’s Artificial Urine (AU)35. 
Minimal inhibitory concentration studies were completed using cation-adjusted Mueller 
Hinton broth (CAMHB; Difco) for both E. faecalis and E. coli. 
A human urinary bladder epithelial cell line, 5637’s (ATCC HTB-9), initially isolated 
from a 68-year-old male with grade II carcinoma, was acquired from the American Type 
Culture Collection (ATCC). Urothelial cells were maintained in T75 flasks, in a 5% CO2 
tissue culture incubator at 37°C in Roswell Park Memorial Institute medium 1640 
(RPMI; Gibco, Burlington, ON, CAN) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS; Gibco), 2 mM glutamine (Gibco) and penicillin-streptomycin 
(Gibco) at 100 U/mL and 100 µg/mL respectively. Supplemented-RPMI without the 
addition of antibiotics will herein be referred to as infection media. 
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Table 2-1. Strains used in this study. 
Strain Initial Isolation Source 
E. faecalis 
A256 Urine of patient with RUTI and urosepsis36 Our laboratory 
1131 Uropathogen37 Our laboratory 
1396 Female with UTI38 Our laboratory 
23241 Urine of patient with pyelonephritis39 ATCCa 
29212b Urine40 ATCCa 
OG1X Derivative of oral isolate 2SaR41 Our laboratory 
5024-8 Gastrointestinal Our laboratory 
19433b,c Documentation not available ATCCa 
33186b Documentation not available ATCCa 
E. coli 
UTI89 Patient with UTI42 Hultgren laboratory 
CFT073 Urine of patient with pyelonephritis43 ATCCa 
aAmerican Type Culture Collection. 
bStrain often used in quality control testing44. 
cType strain45. 
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Cells were routinely passed when confluency reached greater than 80%. To pass cells, 
the monolayer was gently washed with warm phosphate buffered saline (PBS) followed 
by trypsinization for 10 minutes at 37°C and 5% CO2 by addition of 0.25% trypsin-
ethylenediaminetetraacetic acid (EDTA; Gibco). Cells were dislodged with gentle 
tapping and trypsin inactivated by the addition of cell culture media. For cell 
maintenance, cell suspensions were reconstituted 10-fold in a new T75 flask with fresh 
supplemented-RPMI. For experiments, an aliquot of the cell suspension was mixed 1:1 
(v/v) with 0.4% trypan blue (Invitrogen, Carlsbad, CA, USA) and 10 µL of sample 
mixture added to the chamber port of a Countess Cell Counting Chamber Slide 
(Invitrogen) for use with a Countess Automated Cell Counter (Invitrogen). Only viable 
cell counts were considered. Cell suspensions then underwent centrifugation at 3,000 
rpm for 6 minutes, were reconstituted in infection media, and subsequently seeded to 24-
well tissue-culture treated plates (Sarstedt, Nümbrecht, Germany) at 1 x 105 cells/mL. 
Plates were incubated as above until the monolayer reached confluency, at 
approximately 48 hours. 
Solutions of both sulfamethoxazole and trimethoprim were prepared separately and 
combined prior to use at a ratio of 1:19 (TMP/SMX)46. Sulfamethoxazole (Sigma-
Aldrich, St. Louis, MO, USA) was solubilised in half the final volume of ddH2O with 
the addition of 2.5M NaOH until dissolved; additional ddH2O was added to a final 
concentration of 50 mg/mL. Similarly, trimethoprim (Sigma-Aldrich) was dissolved in 
0.05M HCl and water added to a final concentration of 20 mg/mL. Nitrofurantoin 
(Sigma-Aldrich) was prepared in dimethyl sulfoxide (DMSO; Sigma-Aldrich) at a stock 
concentration of 20 mg/mL. Gentamicin (Sigma-Aldrich) stock solutions were prepared 
in water to 50 mg/mL. Ibuprofen (Galenova, St-Hyacinthe, QC, CAN) was prepared at a 
stock concentration of 0.1M (20.6 mg/mL) in ethanol (Sigma-Aldrich) for bacterial 
growth and biofilm formation assays; and 100 mg/mL in methanol (Sigma-Aldrich) for 
co-culture experiments. Carboxyibuprofen (Toronto Research Chemicals, Toronto, ON, 
CAN) was prepared at a stock concentration of 2.5 mg/mL in DMSO (Sigma-Aldrich). 
All stock solutions were filter sterilised prior to storage at -20°C. 
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2.2.2 Minimal inhibitory concentration determination 
Minimal inhibitory concentrations (MIC) for TMP/SMX, nitrofurantoin, and IBU were 
determined according to CLSI standards44. In brief, isolated colonies were suspended in 
CAMHB and incubated overnight at 37°C without aeration. Stationary phase cultures 
were then diluted 1/100 in fresh CAMHB for incubation at 37°C until culture turbidity 
was equivalent to a 0.5 McFarland standard47. Turbid cultures were diluted 1/20 in fresh 
CAMHB and 10 µL of suspension added to pre-made antibiotic dilution plates. Based on 
the 0.5 McFarland standard, the final bacterial concentration was approximately 5×105 
CFU/mL. Inoculated plates were incubated at 37°C for 18-24 hours, at which point 
growth was assessed using an Eon microplate spectrophotometer (BioTek, Winooski, 
VT, USA). The MIC was determined as the lowest concentration to completely inhibit 
bacterial growth. The cutoff is less strict for TMP/SMX, as growth media may contain 
antagonists, thus the MIC was defined as the lowest concentration to reduce growth by 
greater than 80% compared to the growth control. 
Antibiotic dilution plates were prepared in advance and stored at -20°C until the day of 
the experiment. Plates were prepared as a series of 2 × antibiotic dilutions in CAMHB to 
a final volume of 100 µL/well. Antibiotic vehicle controls were included in the plates, as 
were both positive and negative growth controls. Antibiotics were regularly assessed 
against the quality control strains, E. faecalis ATCC 29212 and E. coli ATCC 25922, to 
ensure consistent results. 
2.2.3 Growth curves 
Growth inhibition by IBU and CIBU was assayed in 96-well plates that were prepared as 
serial dilutions of the compound of interest with stationary-phase bacteria added at a 
final dilution of 1/100. Plates were incubated for 24 hours at 37°C with optical density 
(OD) readings at 600 nm every 15 minutes using an Eon microplate spectrophotometer 
(BioTek). A range of both IBU and CIBU were assayed, between 200 and 0.02 µg/mL 
and 25 and 0.025 µg/mL respectively. These concentrations were selected based on 
solubility in the respective media and urinary availability reported in the literature30,48-50. 
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2.2.4 Bacterial adhesion and invasion of urothelial cells 
2.2.4.1 Co-culture of bacterial and urothelial cells 
Bacteria were prepared for co-infections as follows; overnight broth cultures (stationary 
phase) were reconstituted 100-fold to supplemented infection media (pre-treatment) and 
incubated to mid-exponential phase (4-hours) at 37°C and 5% CO2. Exponential phase 
cultures were then diluted to a final concentration equivalent to a multiplicity of 
infection (MOI) of 25:1 bacteria per host cell in appropriately supplemented infection 
media (co-culture). For IBU and CIBU only experiments, no supplements were added to 
pre-treatment media, and IBU and CIBU were added directly to the co-culture media. 
For experiments assessing bacterial attachment in the presence of antibiotic and IBU or 
CIBU, pre-treatment media was supplemented with the appropriate vehicle or antibiotic 
at the MIC, 1/2 MIC, 1/4 MIC, or 1/8 MIC. Following pre-treatment, bacterial cells were 
diluted in fresh infection media supplemented with the appropriate antibiotic or vehicle 
and either IBU, CIBU, or vehicle. Thus, bacteria were exposed to IBU and CIBU only 
when in the presence of urothelial cells, while exposure to the antibiotic occurred prior 
to and throughout urothelial co-culture. Ibuprofen was added to a final concentration of 
1000, 200, 100, or 10 µg/mL, while CIBU was added to a final concentration of 10 or 1 
µg/mL. Ibuprofen and CIBU concentrations are based on urinary values reported within 
the literature30,48-50. Higher concentrations of IBU caused the media to precipitate and 
the cost of CIBU was prohibitive towards replicates at higher concentrations. Pre-
treatment only experiments were completed with exponential phase cultures diluted in 
infection media without antibiotics. The MOI was calculated based on the urothelial cell 
count from a representative well. Cell counts were determined as described above. 
Confluent monolayers were washed three times with warm PBS, followed by the 
addition of 500 µL of the prepared bacterial suspension. Co-cultures were incubated at 
37°C and 5% CO2 for 4 hours. 
2.2.4.2 Determination of adhesion and invasion 
Internalisation counts were determined as follows; following a 4-hour incubation, the 
co-cultures were washed three times with 500 µL warm PBS followed by 500 µL 
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infection media supplemented with 200 µg/mL gentamicin, which we confirmed was 
lethal to non-internalized bacteria. The co-culture was incubated for an additional two-
hours to kill any non-internalised bacteria. Following the kill-incubation, the co-culture 
was washed three times with 500 µL warm PBS. The urothelial cells were then lysed by 
the addition of 500 µL 0.1% Triton X-100 (Sigma-Aldrich) in PBS at 37°C for 15 
minutes. Bacterial counts were acquired by serially diluting the cell lysate ten-fold in 
PBS, spot-plating 10 µL to agar plates, and counting the resulting colonies. 
For adherent cell counts, wells were washed three times with PBS after the 4-hour co-
incubation, then immediately lysed and plated as described for internalised cell counts. 
Total cell counts were acquired after the 4-hour co-incubation by the direct addition of 5 
µL 10% Triton X-100 in PBS, the remainder of the cell lysis and plating was as 
described. Thus for each condition three wells were required per replicate, one each of 
internalisation, adherence, and total bacterial counts; for experiments assessing 
attachment only, an internalisation well described above was not included.  
Internalised and adherent cell populations are represented as a percentage of the total 
cell population; the internalised population was considered negligible in the calculation 
of adherent populations. 
2.2.5 Distribution of target genes in E. faecalis  
2.2.5.1 Isolation of DNA 
Genomic DNA was isolated from strains of E. faecalis using InstaGene Matrix (Bio-Rad 
Laboratories, Mississauga, ON, CAN) according to the manufacturer’s instructions. 
Resultant DNA was stored in the matrix at -20°C and centrifuged at 10,000 rpm for two 
minutes prior to use. 
2.2.5.2 Primer design and PCR conditions 
Target genes were selected to characterise the genetic potential of E. faecalis isolates 
available within our collection and gene expression study based on major virulence 
factors and putative nitroreductases genes, as well as other genes that have been 
documented to be differentially regulated under antibiotic stress or by growth in pooled 
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human urine relative to laboratory growth medium51-54.  Primers were designed using 
Primer-Blast55, with primer-dimer detection by ThermoFisher Scientific’s Multiple 
Primer analyzer (Thermo Fisher Scientific, Waltham, MA, USA) and Beacon Designer 
(Premier Biosoft, Palo Alto, CA, USA) to assess for secondary structures. Prospective 
primers were only accepted with ΔG less than -6 and were synthesized by Invitrogen 
Life Technologies (Table 2-2). 
PCR reactions were performed in a total volume of 25 µL; 1 × PCR buffer (Invitrogen), 
20 µg/µL bovine serum albumin (Sigma-Aldrich), 10 µM deoxyribonucleoside 
triphosphates (Invitrogen), 10 µM forward and reverse primer, 50 nM MgCl2 
(Invitrogen), 1 U Taq-Polymerase (Invitrogen), 1 µL genomic template. PCR conditions 
were as follows; 94°C for 3 minutes, followed by 30 cycles of 30 seconds at 94°C, 30 
seconds at 60°C, 60 seconds at 72°C, and a final elongation of 5 minutes at 72°C. 
Products were visualised by ethidium bromide staining of 2% agarose gels. 
2.2.6 Bacterial gene expression 
2.2.6.1 RNA Extraction 
Following either a 1-hour or 4-hour incubation, 1 mL RNAprotect Bacteria Reagent 
(Qiagen, Toronto, ON, CA) was added to each well and incubated at room temperature 
for 10 minutes. The contents of the well were then transferred to a microcentrifuge tube 
and centrifuged at room temperature for 5 minutes at 5000 × g. The supernatant was 
discarded, and the pellet resuspended in 500 µL lysis buffer followed by incubation at 
37°C for 30 minutes and subsequent centrifugation at 4°C and 5000 × g for 5 minutes. 
The supernatant was discarded, and 500µL TRIzol reagent (Invitrogen) added to the 
microcentrifuge tube. Cell lysate was stored at -20°C until processed using the PureLink 
RNA MiniKit (Invitrogen) as per the manufacturer’s instructions. Lysis buffer was 
prepared fresh on the day of the experiment as follows, 20 mg/mL lysozyme (Sigma-
Aldrich) and 25 U/mL mutanolysin (Sigma-Aldrich) in Tris-EDTA buffer at pH 8.0. 
In brief, 200 µL chloroform (Sigma-Aldrich) was added to the microcentrifuge tube and 
shaken vigorously, followed by an additional 500 µL TRIzol reagent. The solution was 
incubated at room temperature for 3 minutes followed by centrifugation at 4°C and 
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12,000 × g for 15 minutes. The upper phase was transferred to a fresh microcentrifuge 
tube, followed by the addition of 100% ethanol (Sigma-Aldrich) at a 1:1 ratio. This 
mixture was then vortexed and transferred to a Spin Cartridge, which was centrifuged at 
room temperature and 12,000 × g for 15 seconds. The column was washed with Wash 
Buffer I, followed by PureLink On-Column DNAse treatment (Invitrogen) for 15 
minutes at room temperature. The product was washed twice with Wash Buffer II, and 
eluted in 30 µL RNase-free water. The resulting RNA was converted to complementary 
DNA (cDNA) using the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA, USA). Unused RNA was flash frozen and stored at -80°C. 
2.2.6.2 Quantitative PCR 
Quantitative PCR experiments were completed using Power SYBR Green PCR Master 
Mix (Applied Biosystems) on the QuantStudio 5 Real-Time PCR System (Applied 
Biosystems). Primer efficiency was determined against genomic DNA from E. faecalis 
1131; DNA was diluted five-fold and qPCR completed in triplicate. Primers that did not 
amplify, or those demonstrating an efficiency above 110% or below 90% were not used 
further (Table 2-2). Initial data analysis and quality control assessment was completed 
using the QuantStudio Design and Analysis Software v1.4.1 (Applied Biosystems). Data 
is presented as relative quantification according to the ΔΔCT method, wherein vehicle 
was used as the comparator with both 23S rRNA and recA as endogenous controls. 
2.2.7 Statistical analysis 
All experiments were completed in biological and technical triplicates. Results in the 
figures are presented as mean per group ± standard deviation. To test for significance in 
the final optical density of the growth curves and attachment/invasion we analysed the 
data using one-way analysis of variance (ANOVA) followed by post hoc Dunnett’s 
multiple comparisons tests. Bacterial relative gene expression analyses were completed 
using two-way ANOVA followed by post hoc Dunnett’s multiple comparisons tests. 
Pearson’s correlation coefficients were used to test for correlation within the data. Data 
analysis was completed using GraphPad Prism v7.0a for Mac OS X (GraphPad 
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Software, San Diego, CA, USA). Results were considered significant as follows; ****, P 
< 0.0001; ***, P< 0.001; **, P < 0.01; *, P < 0.05. 
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2.3 Results 
2.3.1 Effects of IBU and CIBU on E. faecalis growth 
The growth of E. faecalis 1396 and E. coli CFT073 was assessed in BHI broth in the 
presence of IBU at 200, 20, 0.2, or 0.02 µg/mL, and in AU with IBU at 20, 0.2, or 0.02 
µg/mL. We were unable to assess higher concentrations of IBU in AU given solubility 
issues. Representative growth curves are presented in Figure 2-1. There was a 
statistically significant decrease noted in the final optical density (OD) of E. faecalis 
exposed to IBU at 20 and 2 µg/mL (P = 0.0006, P = 0.002) in AU and E. coli at 200 
µg/mL IBU in BH (P = 0.001). Otherwise, growth patterns were indiscriminate with the 
exception of a disruption in the absorbance of E. coli exposed to 200 µg/mL IBU in BHI.  
The effect of CIBU exposure on the growth of E. faecalis 1396 was assessed in BH and 
LB for E. coli UTI89 (Figure 2-2). Growth patterns were not significantly altered by the 
addition of CIBU. However, the final OD of E. faecalis was significantly decreased by 
0.025 µg/mL CIBU (P = 0.03), while the OD of E. coli increased significantly by 25 and 
2.5 µg/mL CIBU (P = 0.0001, P = 0.005).  
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Figure 2-1. Growth of E. faecalis and E. coli in the presence of IBU. 
Growth curves are represented as the increase in absorbance over the course of 24 hours. 
E. faecalis 1396 (A) and E. coli CFT073 (B) were grown in BH (left) or AU (right) with 
vehicle (black) or IBU at 200 (blue), 20 (brown) 2 (green), 0.2 (red), or 0.02 
µg/mL(orange). Experiments were conducted as both technical and biological triplicates; 
data is representative of the average absorbance reading. Absorbance readings were 
completed every 15 minutes for 24 hours at 600 nm. Significance of the final optical 
density was determined using one-way ANOVA with Dunnett’s multiple comparisons 
test relative to the vehicle (***, P < 0.001; **, P < 0.01). 
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Figure 2-2. Growth of E. faecalis and E. coli in the presence of CIBU. 
Growth curves are represented as the increase in absorbance over the course of 24 hours. 
E. faecalis 1396 was grown in BH (A) and E. coli UTI89 in LB (B) with vehicle (black) 
or CIBU at 25 (brown) 2 (green), 0.25 (red), or 0.025µg/mL(orange). Experiments were 
conducted as both technical and biological triplicates; data is representative of the 
average absorbance reading. Absorbance readings were completed every 15 minutes for 
24 hours at 600 nm. Significance of the final optical density was determined using one-
way ANOVA with Dunnett’s multiple comparisons test relative to the vehicle (****, P < 
0.0001; **, P < 0.01; *, P < 0.05).  
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2.3.2 Bacterial attachment and invasion 
Prior to bacterial attachment and invasion experiments, the MIC of nitrofurantoin and 
TMP/SMX was determined for E. faecalis 1131 and E. coli UTI89 (Table 2-3). 
2.3.2.1 Bacterial attachment in the presence of sub-MIC antibiotics 
The attachment of E. faecalis 1131 and E. coli UTI89 to urothelial cells was determined 
in the presence of nitrofurantoin and TMP/SMX at the MIC and sub-MICs. There was a 
statistically significant increase in the attachment of both E. faecalis 1131 (P = 0.0001) 
and E. coli UTI89 (P = 0.005) to the 5637s in response to MIC nitrofurantoin, but not for 
TMP/SMX (Figure 2-3). There was also a dose-dependent correlation between 
nitrofurantoin concentration and E. faecalis 1131 attachment. 
To elucidate whether the increased attachment noted by E. faecalis 1131 was related to 
nitrofurantoin interactions with the urothelial cells, we repeated the experiments with E. 
faecalis under constant antibiotic pressure and pre-treatment only, assessing both 
attachment and internalisation (Figure 2-4). Enterococcal attachment was significantly 
increased by nitrofurantoin at the MIC in both the constant pressure (P= 0.001) and pre-
treatment only (P = 0.005) experiments relative to the vehicle control. Further, 
internalisation was increased by nitrofurantoin at the MIC in the constant antibiotic 
pressure group (P = 0.002), but not in the pre-treatment only group. 
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Table 2-3. Summary of strain MICs.  
Strain 
Minimal inhibitory concentration (µg/mL)* 
Nitrofurantoin TMP/SMX† IBU 
E. faecalis 1131 32 0.07/1.2 ≥ 200 
E. coli UTI89 8 0.07/1.2 ≥ 200 
*Susceptibility profile based on CLSI breakpoints44. 
†In vitro activity of TMP/SMX against E. faecalis is not an indication of clinical 
efficacy44. 
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Figure 2-3. Bacterial attachment to urothelial cells in the presence of antibiotics 
alone. 
Bacterial attachment to urothelial cells is presented as a percentage of the total viable 
population. E. faecalis 1131 or E. coli UTI89 were incubated in the presence of 
nitrofurantoin (A) or TMP/SMX (B) at the MIC, 1/2 MIC, 1/4 MIC, or 1/8 MIC then added 
to a urothelial monolayer in fresh antibiotic-supplemented infection media. Co-cultures 
were incubated for 4-hours, at which point the cultures were washed with PBS, lysed 
and bacterial counts acquired by serial dilutions to agar plates. Means from at least three 
different experiments are shown with significance. Significance was determined using 
one-way ANOVA with Dunnett’s multiple comparisons test (****, P < 0.0001; **, P < 
0.01). 
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Figure 2-4. Nitrofurantoin induced enterococcal attachment and internalisation. 
E. faecalis 1131 was exposed to nitrofurantoin at the MIC, 1/2 MIC, 1/4 MIC, or 1/8 MIC 
then co-cultured with urothelial cells with (constant antibiotic pressure; left) or without 
(pre-treatment only; right) nitrofurantoin. Percent attachment (A) and internalisation (B) 
is presented as a percentage of the total viable population. Gentamicin protection assays 
were used for internalisation determination, adherence counts were determined by serial 
dilutions of lysed urothelial cells following a 4-hour co-incubation Means from at least 
three different experiments are shown with significance. Significance was determined 
using one-way ANOVA with Dunnett’s multiple comparisons test (**, P < 0.01).  
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2.3.2.2 Bacterial attachment in the presence of IBU and CIBU 
We next tested bacterial attachment to urothelial cells in the presence of IBU at 1000, 
200, 100, or 10 µg/mL, or CIBU at 10 or 1 µg/mL (Figure 2-5). Vehicle controls, 
methanol for IBU and DMSO for CIBU, were included; however, as the vehicle did not 
alter bacterial attachment, the data is not shown. There were no significant differences in 
bacterial attachment to bladder cells at these concentrations. 
2.3.2.3 Bacterial attachment in the presence of antibiotics IBU or CIBU 
We then assessed the bacterial attachment to urothelial cells in the presence of IBU and 
either nitrofurantoin or TMP/SMX. Bacteria were pretreated with antibiotic, then 
brought into contact with urothelial cells with both the antibiotic and IBU. No 
differences were noted in the attachment of E. coli in the presence of IBU and 
TMP/SMX (Figure 2-6). However, there was a significant increase in E. faecalis 1131 
attachment at the MIC of TMP/SMX with 1000 µg/mL IBU (P = 0.02) and at 1/2 MIC 
with 200 µg/mL IBU (P = 0.02). In addition, a positive correlation is visible between 
IBU concentration and enterococcal attachment at the MIC of TMP/SMX, yet this did 
not meet statistical significance. IBU did not affect the attachment of E. faecalis or E. 
coli to urothelial cells in the presence of nitrofurantoin (Figure 2-7). 
Finally, we assayed the attachment of both E. faecalis 1131 and E. coli UTI89 to 
urothelial cells in the presence of nitrofurantoin and CIBU (Figure 2-8). Again, there 
were no significant differences in bacterial attachment related to CIBU exposure.  
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Figure 2-5. Effects of IBU and CIBU on bacterial attachment. 
The percent attachment of E. faecalis 1131 (A) and E. coli UTI89 (B) to urothelial cells 
was assessed in the presence of 1000, 200, 100, or 10 µg/mL IBU and 10 or 1 µg/mL 
CIBU. Co-cultures were incubated for 4-hours, at which point the cultures were washed 
with PBS, lysed and bacterial counts acquired by serial dilutions to agar plates. Means 
from at least three independent experiments are shown with significance. Lack of 
significance was confirmed using one-way ANOVA with Dunnett’s multiple 
comparisons test. 
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2.3.3 Distribution of target genes in E. faecalis 
Due to the major alterations in E. faecalis attachment during antibiotic exposure, isolates 
of urinary and non-urinary origin were screened for the presence or absence of 37 genes 
associated with virulence, adherence, host-colonisation, regulation and response to stress 
(Figure 2-9). Positive PCR reactions were noted for all gene targets against at least one 
strain except fabF-1 and cylLS. Most strains were positive for all classical virulence 
factors; however, asa1 was not present in E. faecalis 1131, OG1X or ATCC 19433; E. 
faecalis A256, 1131, OG1X and ATCC 29212 were esp-; and all but E. faecalis 5024-8, 
ATCC 29212 and 33186 were cylLL-. Five strains were negative for at least one of the fsr-
quorum sensing system genes, with E. faecalis 5024-8 being negative for all three. E. 
faecalis 5024-8 was also gelE- and emeA-. 
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Figure 2-9. Distribution of target genes in E. faecalis strains. 
Presence or absence of target genes was determined by PCR of E. faecalis isolates of 
both urinary and non-urinary origins. Products of the expected size were considered 
positive and are represented here by blue boxes, white boxes indicate a failure to amplify. 
  
A256 1131 1396 23241 29212 OG1X 5024-8 33186 19433
23S
recA
ace
asa1
ebpA
ebpB
ebpC
efaA
efbA
esp
fabF-1
fabI
fabZ-1
EF0404
EF0648
EF0655
EF1181
ahrC
fsrA
fsrB
fsrC
grvR
grvS
rnjB
slyA
cylL-L
cylL-S
gelE
salB
emeA
gls24
glsB
ohr
EF0420
EF0972
EF1370
EF1413
EF1732
EF1733
Urinary Non-urinary
Reference
Adhesion 
and 
colonisation 
Fatty acid 
biosynthesis 
Nitroreductases
Regulatory 
functions 
Secreted 
factors 
Stress and 
drug response 
121 
 
2.3.4 Bacterial gene expression 
Target gene expression was determined using RNA from E. faecalis 1131 co-incubated 
with urothelial cells for 1 or 4 hours in the presence of nitrofurantoin or vehicle. The PCR 
screen indicated primers for fabF-1, cylLS, asa1, esp, and cylLL would not amplify against 
E. faecalis 1131; thus these targets were not included in the qPCR reactions. Further, 
reactions for gelE, salB, slyA, and EF1413 were inconsistent; these targets were excluded 
from the data analysis. 
Among the classical E. faecalis virulence factors are those involved in adhesion and host 
colonization, such as ace, ebpABC, efaA, and efbA (Figure 2-10). Exposure to 
nitrofurantoin did not significantly alter expression of ace or efaA. However, ebpA 
expression was significantly decreased at the MIC (4 hours; P = 0.0001) and 1/2 MIC (1 
hour, P = 0.04; 4 hours, P = 0.001). Similarly, ebpB expression was decreased by 1 hour 
at both the MIC (P = 0.03), and 1/2 MIC (P = 0.03), and remained so at 4 hours (MIC, P = 
0.001; 1/2 MIC, P = 0.006). Expression of epbC and efbA was decreased only after 4 
hours by both 1/2 MIC (P = 0.01, P = 0.05) and MIC (P = 0.003, P = 0.005). 
In contrast, expression of the nitroreductases was generally increased in response to 
nitrofurantoin (Figure 2-11). Significant increases were observed by the MIC at locus 
EF0404 (1 hour, P = 0.003; 4 hours, P = 0.0001), EF0648 (4 hours, P = 0.01), and 
EF0655 (1 hour, P = 0.0001; 4 hours, P = 0.0001). Increased expression was also noted 
for EF0655 by 1/2 MIC (1 hour, P = 0.008), while EF1181 was not significantly 
differentially regulated. Increased relative expression was also noted for EF1732 and 
EF1733 of the multidrug-resistance (MDR) family proteins. EF1733 was significantly 
upregulated at both time points (1 hour, P = 0.03; 4 hours, P = 0.0001), while EF1732 
was significantly upregulated at 4 hours only (P = 0.003) (Figure 2-12).  
Of the genes involved in stress tolerance (Figure 2-13), EF0972 was differentially 
expressed in response to nitrofurantoin at the MIC (4 hours; P = 0.05) and 1/2 MIC (4 
hours; P = 0.02). The remaining stress tolerance genes were not significantly 
differentially regulated. 
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Regulatory genes trended towards decreased expression in response to nitrofurantoin 
(Figure 2-14). The MIC of nitrofurantoin led to down-regulation of ahrC expression (4 
hours, P = 0.01) and rnjB (1 hour, P = 0.02; 4 hours, P = 0.008). Significant decreases in 
expression were also noted at 1/2 MIC for ahrC (4 hours, P = 0.02) and rnjB (1 hour, P = 
0.02; 4 hours, P = 0.02). There were no significant differences in the expression of fsrA, 
fsrB, grvR, or grvS induced by nitrofurantoin exposure compared to the no treatment 
controls. Finally, we screened two genes involved in fatty acid biosynthesis, fabI and 
fabZ-1; however, differential expression was only noted for fabZ-1, which was down-
regulated by the MIC at 1 hour (P = 0.03; Figure 2-15).   
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Figure 2-10. Expression of adhesion and colonisation-associated factors in response 
to nitrofurantoin. 
Enterococcal gene expression of adhesion and colonisation-associated factors in response 
to nitrofurantoin challenge in the presence of urothelial cells is presented relative to 
vehicle controls. Expression was assessed after E. faecalis 1131- 5637 co-incubation for 
1 hour (black bars) or 4 hours (gray bars) with nitrofurantoin at the MIC (32 µg/mL), 1/2 
MIC (16 µg/mL), 1/4 MIC (8 µg/mL), or 1/8 MIC (4 µg/mL) of ace (A), ebpA (B), ebpC 
(C), ebpB (D), efaA (E), and efbA (F). Experiments and qPCR reactions were completed 
in triplicate. Means from at least three different experiments are shown with significance. 
Significance was determined against the no treatment control using two-way ANOVA 
with Dunnett’s multiple comparisons test (**, P < 0.01; *, P <0.05).  
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Figure 2-11. Upregulation of nitroreductase genes in response to nitrofurantoin. 
Enterococcal gene expression of the putative nitroreductases genes; EF0404 (A), EF0648 
(B), EF0655 (C), and EF1181 (D), in response to nitrofurantoin challenge is presented 
relative to vehicle controls. Expression was assessed after E. faecalis 1131- 5637 co-
incubation for 1 hour (black bars) or 4 hours (gray bars) with nitrofurantoin at the MIC 
(32 µg/mL), 1/2 MIC (16 µg/mL), 1/4 MIC (8 µg/mL), or 1/8 MIC (4 µg/mL). Experiments 
and qPCR reactions were completed in triplicate. Means from at least three different 
experiments are shown with significance. Significance was determined against the no 
treatment control using two-way ANOVA with Dunnett’s multiple comparisons test 
(****, P <0.0001; ***, P<0.001; **, P < 0.01; *, P <0.05). 
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Figure 2-12. Relative expression of MDR genes to nitrofurantoin exposure. 
Enterococcal gene expression of MDR genes in response to nitrofurantoin challenge is 
presented relative to vehicle controls. Expression of emeA (A), EF420 (B), EF1370 (C), 
EF1732 (D), and EF1733 (E) was assessed after E. faecalis 1131- 5637 co-incubation for 
1 hour (black bars) or 4 hours (gray bars) with nitrofurantoin at the MIC (32 µg/mL), 1/2 
MIC (16 µg/mL), 1/4 MIC (8 µg/mL), or 1/8 MIC (4 µg/mL). Experiments and qPCR 
reactions were completed in triplicate. Means from at least three different experiments 
are shown with significance. Significance was determined against the no treatment 
control using two-way ANOVA with Dunnett’s multiple comparisons test (****, P 
<0.0001; **, P < 0.01; *, P <0.05).  
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Figure 2-13. Relative expression of enterococcal stress response genes following 
nitrofurantoin exposure. 
Enterococcal gene expression following nitrofurantoin exposure of genes involved in the 
stress response is presented relative to vehicle. Expression of gls24 (A), glsB (B), ohr 
(C), and EF0972 (D) was assessed after E. faecalis 1131- 5637 co-incubation for 1 hour 
(black bars) or 4 hours (gray bars) with nitrofurantoin at the MIC (32 µg/mL), 1/2 MIC 
(16 µg/mL), 1/4 MIC (8 µg/mL), or 1/8 MIC (4 µg/mL). Experiments and qPCR reactions 
were completed in triplicate. Means from at least three different experiments are shown 
with significance. Significance was determined against the no treatment control using 
two-way ANOVA with Dunnett’s multiple comparisons test (*, P <0.05). 
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Figure 2-14. Expression of enterococcal regulatory genes in response to 
nitrofurantoin. 
Enterococcal gene expression of regulatory genes in response to nitrofurantoin challenge 
is presented relative to vehicle controls. Expression of ahrC (A), fsrA (B), fsrB (B), grvR 
(D), grvS (E), rnjB (F) was assessed after E. faecalis 1131-5637 co-incubation for 1 hour 
(black bars) or 4 hours (gray bars) with nitrofurantoin at the MIC (32 µg/mL), 1/2 MIC 
(16 µg/mL), 1/4 MIC (8 µg/mL), or 1/8 MIC (4 µg/mL) Experiments and qPCR reactions 
were completed in triplicate. Means from at least three different experiments are shown 
with significance. Significance was determined against the no treatment control using 
two-way ANOVA with Dunnett’s multiple comparisons test (**, P < 0.01; *, P <0.05).  
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Figure 2-15. Differential expression of fatty acid biosynthesis genes in response to 
nitrofurantoin. 
Enterococcal gene expression of the fatty acid biosynthesis genes, fabI (A) and fabZ-1 
(B) in response to nitrofurantoin challenge at the MIC (32 µg/mL), 1/2 MIC (16 µg/mL), 
1/4 MIC (8 µg/mL), or 1/8 MIC (4 µg/mL) in the presence of urothelial cells (black bars, 1 
hour; gray bars, 4 hours). Expression is presented as relative to the vehicle. Experiments 
and qPCR reactions were completed in triplicate. Means from at least three different 
experiments are shown with significance. Significance was determined against the no 
treatment control using two-way ANOVA with Dunnett’s multiple comparisons test (*, P 
<0.05). 
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2.4 Discussion 
In this chapter, we describe nitrofurantoin-induced attachment of E. faecalis and E. coli 
to urothelial cells, and characterisation of the enterococcal response to nitrofurantoin 
using qPCR. Additionally, we explored in vitro effects of IBU and its metabolite, CIBU, 
alone and with antibiotics for the reduction of bacterial attachment. 
Co-culture experiments were completed with 5637s and either E. faecalis 1131 or E. coli 
UTI89. Flow chamber experiments with E. faecalis 1131 demonstrated increased 
adherence to silicone in the presence of 1/8 MIC of vancomycin relative to control, but not 
1/4 MIC or sub-MICs of ampicillin59, suggesting this strain differentially responds to 
antibiotics at sub-MICs. E. coli UTI89 is a classically studied UPEC and served as a 
Gram-negative comparator. 
An unexpected finding of our co-culture experiments was the significant increase in 
attachment of both E. faecalis and E. coli to urothelial cells in response to nitrofurantoin 
at the MIC (Figure 2-3). This was contrary to the expected trend, namely increased 
attachment at sub-MICs, as has been noted for S. saprophyticus and E. coli in response to 
ciprofloxacin, ampicillin, and gentamicin15,16. The lack of response to various 
concentrations of TMP/SMX is also noteworthy; our data suggests, that, at least in the 
case of E. coli, TMP/SMX may be an effective prophylactic agent. Unfortunately, the 
same cannot be said for its action against E. faecalis, as TMP/SMX is not considered 
clinically active against this bacterium. However, our data does suggest administration of 
TMP/SMX for enterococcal UTI is not likely to cause harm through an inadvertent 
increase in enterococcal adherence and colonisation. 
To the best of our knowledge, this is the first time increased attachment has been 
documented for nitrofurantoin above sub-inhibitory concentrations. Previous reports have 
remarked on the variable effects of 1/4 MIC nitrofurantoin on the attachment of E. coli, 
wherein approximately half of strains increased and half decreased attachment in 
response to the antibiotic60. Notably, 1/4 and 1/2 MIC TMP/SMX also demonstrated 
variable effects on E. coli attachment, yet we did not observe this for E. coli UTI89 or E. 
faecalis 1131. 
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In addition to bacterial interactions, nitrofurantoin is cytotoxic to mammalian cells and 
has been implicated in oxidative stress, inducing single-strand DNA breaks61,62. Thus, we 
sought to identify if the increase in bacterial attachment was a result of the urothelial 
cell’s cytotoxic response. To do so, we repeated attachment experiments with two general 
groups, pre-treatment only and constant pressure (Figure 2-4). The increase in bacterial 
attachment remained significant in the pre-treatment only group, suggesting it was not 
due to urothelial cytotoxicity induced by nitrofurantoin. Further, internalisation was 
increased by nitrofurantoin at the MIC in the constant pressure group, but not the pre-
treatment only group. Thus, the nitrofurantoin appears to be inducing a selective pressure 
on the E. faecalis. 
Given this major increase in bacterial attachment, we chose to assess the transcriptional 
response of E. faecalis to nitrofurantoin. We developed a panel of target genes that are 
differentially regulated in human pooled urine or in response to antibiotic stress51-54. Our 
panel also included nitroreductases and known virulence factors (Table 2-2). 
We first assessed the prevalence of these genes in our E. faecalis collection through a 
conventional PCR screen. Many groups have studied the genetic distribution of virulence 
factors in clinical and environmental isolates of E. faecalis58,63-65; however, a large 
proportion of our strain collection is not widely available, nor do they have publicly 
deposited genomes. Additionally, E. faecalis ATCC 29212 and 33186 are primarily used 
as quality control strains in antibiotic susceptibility testing; thus genetic study of these 
strains is not commonplace. Until quite recently66, no research had been published on the 
presence or activity of nitroreductases in E. faecalis, although their presence has been 
assumed given sensitivity to nitrofurans. Our data demonstrating increased adherence in 
the presence of nitrofurantoin MICs suggest an understanding of nitroreductases in E. 
faecalis may present future antibiotic targets. 
Unsurprisingly, each of the four nitroreductases genes, EF0404, EF0648, EF0655, and 
EF1181, were conserved across the strains, as were genes involved in fatty acid 
biosynthesis and stress and drug responsive factors (Figure 2-9). Conservation was also 
noted for regulatory genes, except for the fsrABC locus. Five of our strains were negative 
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for at least one of the genes in the fsr-quorum sensing system. This correlates with the 
high incidence of fsrABC deletions in E. faecalis, which has been noted by multiple 
groups. In one study of uropathogenic E. faecalis, 79% of isolates negative for gelatinase 
activity had deletions in the fsrABC region, yet were gelE-sprE+67. Another noted 50% of 
urine isolates were gelatinase negative, and 44% of these were fsrABC-63. A screen of 
Greek clinical samples noted only 21% of isolates were fsrB+65. Most groups attribute the 
loss of fsrABC to the same 23.9-kbp deletion, which has been noted in almost 60% of 
fsrABC- clinical isolates68, and may explain the loss of fsrABC in E. faecalis 5024-8. Loss 
of the fsr-system is noteworthy as the system regulates virulence factor expression, 
including that of the ebp locus, gelE, extracellular serine protease (sprE), and efaA69-71. 
E. faecalis 5024-8 was the only strain to test negative for gelE and emeA. A plethora of 
information exists regarding the distribution and function of gelE in disease pathogenesis; 
however, minimal information is available on emeA. Indeed, since its initial discovery in 
200172, a total of six papers have been published on this gene33,72-76. Initially 
characterised as an MDR efflux pump of the major facilitator superfamily (MFS)72, 
EmeA, has since been linked to increased fluoroquinolone and ethidium bromide 
resistance33,72,75. Further studies of gene distribution suggest ciprofloxacin, gatifloxacin, 
and levofloxacin resistant E. faecalis are significantly more likely to be emeA+ than 
antibiotic sensitive strains33. In contrast, the general prevalence of emeA in E. faecalis 
varies depending on the report. A screen of E. faecalis from human, animal, and food 
sources noted 90% of isolates were emeA+74, yet analysis of Chinese clinical isolates 
indicated only 26% of E. faecalis are emeA+33. Most recently, 63% of E. faecalis from a 
swine meat line were positive73. Our data confirm E. faecalis 29212 as emeA+ and 
support a high prevalence of emeA in clinical isolates, particularly those associated with 
the urinary tract75. 
In agreement with larger-scale studies, efaA and ace were noted in all of our samples64,77. 
Findings with regards to asa1 (66%), gelE (89%), and esp (56%) were also comparable to 
clinical isolates from the University of Freiburg (80, 100, and 60% respectively)64. Other 
groups have reported esp in 40-70% of human isolates65,77. Asa1 is one of the best-
studied aggregation substance (AS) proteins, which are encoded on pheromone-inducible 
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conjugative plasmids78. Aggregation substance, and Asa1 in particular is involved in 
bacterial conjugation79, adherence to epithelial cells via interaction with the extracellular 
matrix80, and adherence to and survival within macrophages81. Similarly, Esp promotes 
primary attachment and biofilm formation by E. faecalis82, as well as colonisation and 
persistence within the lower urinary tract83. GelE, a secreted zinc metalloprotease is also 
involved in biofilm formation78. Expression of gelE is dependent on activation of the fsr-
quorum sensing system, and is responsible for cleavage of AltA, a peptidoglycan 
hydrolase key to daughter cell separation, and SprE, among other targets84,85. 
There were no positive reactions for generated for fabF-1or cylLS, although in silico 
analysis indicated a positive reaction for fabF-1 against the genome of E. faecalis 29212. 
There are a number of reasons these negative reactions may have occurred, including 
inappropriate reaction conditions, interference of secondary structures within the primers, 
or lack of binding sites on the template – indeed, these apply to all of our negative 
reactions. Given the wide selection of other targets, such as two additional fatty acid 
biosynthesis genes (fabF-1and fabZ-1) and the primarily negative response to cylLL, these 
targets were dismissed from further analysis. 
Given the high prevalence of our gene targets, we moved forward with measuring the 
relative expression of these genes in response to nitrofurantoin. The PCR screen indicated 
primers for fabF-1, cylLS, asa1, esp, and cylLL would not amplify against E. faecalis 
1131; thus these targets were not included in the qPCR reactions. Further, reactions for 
gelE, salB, slyA and EF1413 were inconsistent; these targets were not included in the data 
analysis. 
Expression of genes involved in adhesion and colonisation highlighted significant 
downregulation of ebpA, ebpB, ebpC and efbA (Figure 2-10). Expression of efaA trends 
towards decreased expression associated with nitrofurantoin concentration, yet this was 
not significant. These results were unexpected, as we noted an increase in bacterial 
attachment at the MIC, yet the expression of genes involved in the early stages of 
bacterial biofilm formation were down-regulated. Notably, the Ebp pilus is associated 
with primary adherence and biofilm formation71. Further, efbA and ebpABC mutants are 
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severely attenuated in both adherence and UTI pathogenesis86,87. Down-regulation was 
also noted for fabZ-1, yet this was only significant at the MIC and one hour. Expression 
of fabI also trends toward a concentration-dependent decrease in expression at one hour, 
yet this was not significant (Figure 2-15). Interestingly, fabI and fabZ-1 are up-regulated 
in urine, potentially as a contributor to cell membrane remodelling51, which was also 
somewhat expected in response to nitrofurantoin. 
Down-regulation was also noted for the regulatory genes, although this was only 
significant for ahrC and rnjB. There were no significant differences in the relative 
expression of fsrA, fsrB, grvR, or grvS; however, these did trend towards decreased 
expression. A transcription factor, AhrC, is involved in biofilm formation and is 
necessary for enterococcal endocarditis and UTI88. Similarly, RNase J2, the product of 
rnjB has a regulatory role. Knockout of rnjB correlated with decreased expression of 
ebpABC, gls24, glsB, gelE, fsrC, and fsrB in vitro, suggesting RNase J2 plays a role in 
regulating biological cues for fitness and virulence89. This is consistent with our data, as 
the enterococci appear to be responding to the nitrofurantoin through RNase J2, given 
that there was a significant decrease in the relative expression of ebpABC, and a trend in 
down-regulation of gls24, glsB, fsrB, and fsrC at 1 hour. 
The MDR efflux pumps encoded by the loci EF1732 and EF1733 were significantly up-
regulated, suggesting the enterococcal response to nitrofurantoin includes removal of the 
compound or its breakdown products from the cell. These loci are also upregulated by E. 
faecalis in response to chloramphenicol and erythromycin52,53.  
In line with these results, the nitroreductases EF0404, EF0648, and EF0655 were 
significantly up-regulated by nitrofurantoin at the MIC (Figure 2-12). Increased relative 
expression was also noted for EF1181, yet this did not meet statistical significance. This 
is particularly significant, as nitroreductases were only officially documented in E. 
faecalis last year66. Indeed, our work supports these findings and highlights that each is 
likely differentially regulated and responsive to nitrofurantoin. Further, transcriptomic 
studies of E. faecalis in human pooled urine showed an increase in the expression of 
EF0655 relative to culture media51. 
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Of the stress response genes assayed, increased relative expression was noted for locus 
EF0972 at 4 hours, while the expression of gls24, glsB, and ohr decreases slightly with 
increasing MIC, yet this lacked statistical significance. However, gls24, glsB, and ohr 
were significantly repressed in response to erythromycin and chloramphenicol and up-
regulated in human pooled urine51-53. The EF0972 locus encodes a putative DNA repair 
exonuclease, thus increased expression of this gene target is expected, given DNA 
damage is a mechanism of nitrofurantoin action. Further, an increase in expression of 
EF0972 was also noted in E. faecalis exposed to erythromycin53, suggesting EF0972 may 
be involved in the enterococcal response to multiple antibiotic classes. 
Given these major increases in bacterial attachment associated with antibiotics, we 
moved on to characterisation of the antimicrobial properties of IBU against E. faecalis 
and E. coli. Early clinical and animal studies suggested that NSAIDs, and in particular 
IBU, may have a place in the treatment of UTI, as an alternative to antibiotics. This is not 
yet widely accepted, given that antibiotics cure the infection and IBU is only regarded as 
symptom relief. Ibuprofen is widely available, relatively cheap, associated with minimal 
adverse reactions, and has an established safety profile90. With the global increases in 
antibiotic resistance, lack of financial incentive for antibiotic development and 
subsequent lack of new antibiotic classes in the development pipeline, many researchers 
have begun to explore the off-label use of approved drugs, including IBU. If IBU exhibits 
antimicrobial properties it may assist the patient’s immune system in clearing the 
infection. Further, Given the high spontaneous resolution rate associated with UTI, the 
option to reduce discomfort and thereby avoid antibiotic prescription, IBU represents a 
mechanism to reduce the burden of antibiotic side effects, resistance, and cost. 
Humans metabolise ibuprofen to two major metabolites, 2-hydroxyibuprofen and 2-
carboxyibuprofen (CIBU)30. Excretion of IBU, CIBU, and 2-hydroxyibuprofen occurs as 
both the free and glucuronic acid conjugated forms in the urine. Other metabolites are 
found at much lower concentrations in the urine, including 1-hydroxyibuprofen and 3-
hydroxyibuprofen91. Data on urinary excretion of IBU metabolites varies; patients 
receiving a long-term dose excreted 8% as 2-hydroxyibuprofen (free and conjugated 
forms) and 28% as CIBU (free and conjugated forms)92. While healthy males were found 
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to excrete 26% as 2-hydroxyibuprofen (free and conjugated forms), 42% as CIBU (free 
and conjugated forms), and 12% as conjugated IBU93. Other studies suggest 10-15% is 
excreted as unmodified IBU, 25-30% as 2-hydroxyibuprofen, and 30-40% as CIBU91. 
The classical view is that the hydroxy and carboxy metabolites are biologically inactive94; 
current literature fails to identify a link between these metabolites and pharmacological 
activity. 
We assessed the ability of IBU and its major metabolite, CIBU to alter the growth 
kinetics of E. faecalis and E. coli in rich bacterial culture media (BHI or LB) and AU. 
Under our experimental conditions, neither IBU nor CIBU were bactericidal (Figure 2-1 
and 2-2). There were significant decreases in the final OD of E. faecalis exposed to 20 
and 2 µg/mL IBU in AU and E. coli exposed to 200 µg/mL in BHI; however, whether 
these are physiologically relevant decreases is debatable. Indeed, we can likely attribute 
decrease in E. coli OD to bacterial clumping. In contrast, the effects of CIBU on the 
growth of E. faecalis and E. coli was variable and deserves further investigation, 
particularly in the context of human urine as the BHI and LB used for these experiments 
are not representative of the urinary environment. 
Accordingly, other groups have documented the MIC of IBU to be 5000 µM, or 1000 
µg/mL, for S. aureus, Bacillus subtilis, and Acinetobacter baylyi, yet the MIC for E. coli 
was out of the assay range95. In contrast, the same study identified significantly lower 
MICs for other NSAIDs, such vedaprofen, bromfenac, and carprofen, especially for the 
Gram-positives and this was linked to inhibition of DNA replication95. Other reports 
document MICs of 150 µg/mL IBU for S. aureus, and 50 µg/mL IBU for uropathogenic 
E. coli (UPEC) and Helicobacter pylori28,96,97. In a murine model of active tuberculosis, 
oral IBU reduced the bacillary load and increased animal survival, yet IBU is known to 
be ineffective against Mycobacterium tuberculosis, suggesting the antimicrobial effects 
may be anti-inflammatory mediated98. 
Ibuprofen is a non-selective inhibitor of COX enzymes, which are responsible for the 
conversion of arachidonic acid to prostaglandins. Both the constitutively expressed COX-
1 and the inducible COX-2 are expressed by urothelial cells99-101, leading to the urinary 
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release of prostanoids, such as prostaglandin E2 (PGE2)102. Prostaglandins are known 
primarily for their contribution to pain and inflammation; hence their production is an 
effective target for anti-inflammatories102,103. Given these downstream effects, it is not 
surprising that bacterial virulence factors, such as pyocyanin, lipopolysaccharide, and 
type I fimbriae increase PGE2 release in vitro100,101. Urinary PGE2 is also higher in 
patients with active UTI relative to healthy controls, and the concentration decreases 
significantly upon completion of antibiotic therapy104. Further, a murine study of UTI 
suggestsed that COX-2 inhibition significantly reduces bacterial titers and the incidence 
of chronic cystitis25. These findings, combined with the efficacy of COX-inhibitors in the 
prevention and treatment of UTI in vivo, suggests IBU may disrupt bacterial adherence to 
the urothelium. 
Adhesion studies were completed with IBU and CIBU at concentrations between 1000 
and 1 µg/mL to mimic the urinary environment; however, the literature lacks consensus 
on the concentration of IBU in human urine. For example, two hours after a 400 mg oral 
dose the urinary concentration of IBU was 153.5 µg/mL in one individual, this figure was 
98.3 µg/mL at four hours and 109.44 µg/mL at eight hours, the concentration then 
proceeded to drop to 16.51 µg/mL by 12 hours and 6.76 µg/mL by 1430. In another 
individual, five hours after oral administration of 600 mg, urinary concentration of IBU 
was 14.7 µg/mL49. Yet another group identified concentrations of 2.5 µg/mL two hours 
after a 200 mg dose and 1.74 µg/mL after three hours50. Finally, urine was collected up to 
36 hours after a 200 mg dose in ten participants; urinary recovery ranged from 18.2 to 
1,563 ng/mL of IBU and 181.2 to 4,176 ng/mL of CIBU48. Thus, while 200, 100, and 10 
µg/mL are likely to be encountered by bacteria in the bladder, 1000 µg/mL IBU is not 
and represents an extreme. 
Our attachment results did not indicate either an increase or decrease in the attachment of 
E. faecalis or E. coli to urothelial cells in response to IBU alone or in conjunction with 
TMP/SMX or nitrofurantoin (Figures 2-5, 2-6, 2-7). These experiments were completed 
with E. coli UTI89 and E. faecalis 1131; a uropathogenic strain that our lab had 
previously indicated was capable of adhering to both hydrophobic and hydrophilic 
surfaces in vitro37,105. There are two notable exceptions to this trend; attachment was 
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significantly increased by E. faecalis at the MIC of TMP/SMX and 1000 µg/mL IBU and 
at 1/2 MIC with 200 µg/mL IBU. The data also appear to trend towards a positive 
correlation between IBU concentration and enterococcal attachment, when exposed to 
TMP/SMX at the MIC. This did not meet statistical significance, yet could represent an 
adaptive stress response. 
Similarly, CIBU did not affect bacterial attachment, regardless of whether the bacteria 
were pre-treated with nitrofurantoin or not; we did not assess TMP/SMX due to material 
costs (Figures 2-5 and 2-8). In addition, 10 µg/mL CIBU appeared to be up-regulating 
attachment, yet this was not statistically significant and may present an experimental 
artefact. Future experiments should assess interactions of co-cultures with higher 
concentrations of CIBU; however, its low solubility is a complicating factor. Further, our 
data questions the status-quo that CIBU is biologically inactive91. 
In contrast to our findings, other groups have identified ibuprofen as an antimicrobial 
potentiator, wherein co-administration of IBU with an antimicrobial increased the 
microbe’s sensitivity to the antimicrobial106. In general, antibiotic potentiators restore or 
enhance the clinical utility of antibiotics, extending the spectrum of activity and 
increasing safety as lower concentrations become effective107. Using both an in vitro and 
murine model of Candida albicans infection, IBU was found to potentiate the activity of 
fluconazole and was synergistic in the treatment of murine sepsis with Pep19-2.5, an 
antimicrobial peptide108,109. Similarly, celecoxib, a COX-2 specific inhibitor, increased 
the sensitivity of MDR S. aureus and Mycobacterium smegmatis to ampicillin, 
kanamycin, ciprofloxacin, and chloramphenicol through inhibition of an MDR efflux 
pump110. This widespread effect against fungi and bacteria further supports the 
potentiator concept. 
While intriguing, our attachment data comes with a number of limitations. First of all, the 
large increase in uropathogen attachment could be a factor of the final concentration of 
bacteria. The number of bacteria added to the co-incubation was the same for all 
antibiotic concentrations, yet the MIC inhibited enterococcal growth, while growth 
continued, albeit at different rates, at 1/2, 1/4, and 1/8 MIC. Therefore, the same number of 
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bacteria may be attaching to the urothelial cells in each condition, yet as we represent the 
data as a fraction of the total, the percent attachment may be artificially increased. 
However, increased attachment was also significant within our pre-treatment group 
(Figure 2-4), suggesting that inhibition of bacterial growth may exaggerate the observed 
effect, but is not an indication of experimental artefact. To clarify this, experiments 
should be repeated with the use of microscopy.  
The four-hour time point may have been too early to catch the impact of IBU. In murine 
studies, COX-2 is barely detectable in the bladders of uninfected mice, or at 6-hours after 
UPEC infection; however, by 24-hours post-infection COX-2 expression is increased 50-
fold25. Cell culture studies show a similar trend, COX-2 mRNA expression begins to 
increase within 30 minutes of infection and peaks at 4 hours; however, PGE2 release only 
increases after 8 hours101. 
A further limitation lies within the cell line itself; 5637s do not display the morphological 
characteristics of umbrella cells, lack uroplakin (UP) plaques and do not have a 
glucosaminoglycan (GAG) layer. In a healthy bladder, the GAG layer and UP plaques are 
believed to impede the ability of bacteria to adhere to the urothelium. In a “remodeled” 
bladder, the superficial layer of cells lack umbrella cell differentiation factors, including 
UP plaques. Thus, as a model of RUTI, 5637 are acceptable as they are a better 
representation of the intermediate cell type bacteria will encounter in the bladder. 
Moving forward, our attachment and invasion studies could be repeated with the use of 
microscopy to confirm the increased attachment and characterise potential morphological 
changes that may be driving the phenotype. It would also be worth conducting 
transcriptomics studies to identify new drug targets. Enterococcal invasion of urothelial 
cells is a relatively recent discovery that warrants detailed characterisation. Our data 
suggests antibiotics have the potential to increase uropathogens invasion, if this holds 
true in vivo antibiotic prescribing practices for UTI may need to seriously reconsidered. 
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2.4.1 Conclusions 
These findings highlight the importance of understanding interactions between bacteria 
and antibiotics at a range of concentrations, especially when considering antibiotics that 
are bacteriostatic. Interestingly, the bactericidal properties of nitrofurantoin against 
enterococci begin after 24 hours at 16 × MIC, yet complete killing is still not observed 
after 24 hours at 32 × MIC111. Our data suggest enterococci exhibit increased virulence at 
concentrations of nitrofurantoin that are inhibitory to growth, a finding not previously 
described. This increased attachment correlates with a relative decrease in expression of 
adherence factors, regulatory factors, and fatty acid biosynthesis and an increase in 
expression of nitroreductases, MDR efflux pumps, and a DNA repair exonuclease. We 
also demonstrated inhibitory concentrations of nitrofurantoin increased the rate of 
urothelial cell invasion by Enterococcus. If this holds true in vivo, it may explain the high 
rates of recurrence encountered after antibiotic prophylaxis. 
We also identified three potential new antibiotic targets EF1732, EF1733, and EF0972. 
Expression of these gene products was previously shown to be increased by 
erythromycin53, and an increase in expression has also been described for EF1732 and 
EF1733 in response to chloramphenicol52. Unfortunately, that is the extent of the research 
available on these gene loci. However, our results, in combination with the erythromycin 
and chloramphenicol data suggest target of these proteins in conjunction with antibiotics 
presents a valid therapeutic option. 
On a final note, many researchers have begun to consider IBU a “non-antibiotic,” a 
compound that displays antimicrobial activity although the primary function is not 
infection related106. Research into this field has led to the formation of categories based 
on the antimicrobial mechanism of action. Our research indicates IBU does not have 
direct antimicrobial properties nor potentiate the activity of TMP/SMX or nitrofurantoin 
in vitro against E. faecalis or E. coli. This contradicts clinical reports and murine models. 
Given the lack of research characterising the exact mechanism of action, we believe that 
IBU’s “antimicrobial” properties are a result of its anti-inflammatory effects26. Further 
research into the contribution of PGs to UTI pathogenesis is key to elucidating this 
mechanism. 
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Chapter 3  
3 Longitudinal study of the bacterial communities in urine from 
children with RUTI  
3.1 Introduction 
Urinary tract infections (UTI) are the second most common cause of community and 
hospital-acquired infections in children and adults1-3. Up to 8% of children will 
experience a UTI before the age of 74-7, and risk is increased between the ages of 3 and 
55,8. One of the greatest challenges associated with acute UTI is the development of 
recurrent UTI (RUTI), which is defined as three or more symptomatic UTIs in a 12-
month period, or two or more within six months. Recurrence rates are particularly high in 
children; primary care estimates suggest up to 12% of boys and girls per year will recur5, 
while referral and emergency department data indicates 20-48% will recur within 12 
months9,10. 
Enterococcus faecalis is one of the most commonly isolated pathogens from patients with 
both UTI and asymptomatic bacteriuria (ABU)2,5,11-14. Many reports list E. faecalis as the 
second most common uropathogen15-17, while E. coli is universally recognised as the 
most common, accounting for over 80% of UTIs18. Interestingly, UTIs caused by 
enterococci are significantly less likely to meet the standardised diagnostic criteria 
relative to other uropathogens12. 
Diagnosis of UTI is primarily made based on symptomology and the presence of 
significant bacteriuria, yet the cutoffs for this are widely disputed, have not been formally 
validated in children, and do not provide a measure of disease severity or renal 
involvement4. This traditional definition of UTI, i.e. invasion of a single pathogen beyond 
an artificially defined load threshold, has been further questioned by the recent 
characterisation of the urinary microbiota. Indeed, this definition is based on the 
assumption that the urinary tract is sterile proximal to the urethra in states of health. The 
application of 16S rRNA gene sequencing to the urine of healthy and diseased adults 
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invalidates this assumption and suggests that urinary conditions, including UTI, may be 
states of dysbiosis19,20. 
The urinary microbiota of men was first described in 201021, was quickly followed by the 
female urinary microbiota in 201122, and has since expanded to include over 20 
publications, which correlate altered community profiles with various states of disease 
(Chapter 1, Table 1-1)19,23-26. However, all but two of these studies are cross-
sectional27,28, none have studied a paediatric population, and none of the studies have 
addressed the impact of antibiotics on the urinary microbiota. Given that antibiotic 
therapy is the standard of care for UTI29-31, an understanding of the microbial response to 
this intervention is key. 
Antibiotic prophylaxis, the long-term low-dose use of antibiotics, is often prescribed for 
the treatment and prevention of RUTI4,32. In children, prophylaxis is primarily 
recommended as a strategy to reduce the risk of pyelonephritis, renal scarring, and febrile 
UTI9; yet clinical studies do not demonstrate these benefits4,7,10,33. Infection recurrence is 
quite high following antibiotic prophylaxis34, which may be linked to the development of 
persister cells or bacterial invasion of the urothelium35,36. Of note, recurrence rates are 
higher in children receiving antibiotic therapy for enterococcal UTI in comparison to 
Gram-negative UTIs37. Likewise, antibiotic treatment of enterococcal ABU is associated 
with an increased risk of symptomatic UTI38. 
Relative to other pathogens, enterococcal pathogenesis within the bladder is severely 
understudied. Enterococcal adherence to and biofilm formation on urothelial cells has 
been well documented in vitro and in mouse models of UTI39,40, yet invasion of the 
bladder epithelium was only recently reported41. Furthermore, Chapter 2 has 
demonstrated the in vitro increase of enterococcal attachment and invasion to urothelial 
cells by exposure to nitrofurantoin, an antibiotic commonly used in the management of 
UTI and RUTI. 
In this chapter, we describe a longitudinal study of RUTI in paediatric patients receiving 
antibiotic prophylaxis and those under clinical observation that were not prescribed 
prophylactic antibiotics. We hypothesised that Enterococcus faecalis would be more 
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prevalent in the urine of paediatric patients with a history of RUTI relative to healthy 
controls and that antibiotic prophylaxis would increase the incidence of uropathogens 
within the RUTI population. 
3.2 Materials and methods 
3.2.1 Study design and clinical sample collection 
Paediatric patients with a history of RUTI were recruited through the urology clinic at 
Children’s Hospital at London Health Sciences Centre (London, ON, CAN; 
NCT02357758). Ethical approval for the study was granted by the Health Sciences 
Research Ethics Board at the University of Western Ontario (REB 102817, Appendix B) 
and Lawson Health Research Institute (CRIC R-12-387, Appendix B), both of London, 
Ontario, Canada. The methods were carried out according to the approved guidelines; 
written consent was obtained from the parent/legal guardian at the time of study 
inclusion, and when appropriate, assent was also provided by the participant (Appendix 
C). 
The study proposed to recruit 75 participants over a 6-month recruitment period, 
including 20-30 healthy controls, with participants followed over a 12-month period. 
Inclusion and exclusion criteria for the RUTI group are provided in Table 3-1. All 
patients were required to have an ultrasound to identify urinary tract abnormalities. In the 
event of an abnormal ultrasound or a history of greater than two febrile UTIs, patients 
underwent a voiding cystourethrogram (VCUG), to rule out vesicoureteral reflux (VUR). 
Patients meeting the inclusion criteria were recruited to the study during regularly 
scheduled clinic appointments. 
Upon recruitment, patients were assessed for bladder and bowel dysfunction (BBD) 
through completion of uroflowmetry, and review of a 48-hour bowel bladder diary and 
dysfunctional voiding scoring system questionnaire (DVSS; Appendix C)42. As is 
standard for this clinic, the 48-hour bowel bladder diary was mailed out in the clinic 
information package and reviewed during the initial consultation. 
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Recurrent UTI patients were divided into two groups; 1) patients receiving antibiotic 
prophylaxis, or 2) patients solely undergoing clinical observation, based on the clinical 
experience of the attending urologist and perceived UTI severity. Antibiotic prophylaxis 
patients were prescribed either trimethoprim-sulfamethoxazole (TMP/SMX, Septra; 
trimethoprim at 2 mg/kg) or nitrofurantoin (2 mg/kg) for 6-months, followed by a 6-
month washout period. Patients were provided with prescriptions in the clinic, and the 
antibiotic was acquired in a community pharmacy. Antibiotic compliance was not 
formally assessed; however, participants were asked to report the time during which they 
followed the antibiotic regimen. In the event of a breakthrough UTI (a UTI experienced 
while on antibiotic prophylaxis), the antibiotic was discontinued and the UTI treated with 
an alternative antibiotic; when appropriate, the prophylactic agent was switched. Patients 
under clinical observation received antibiotics if they experienced a UTI during the study; 
these were often treated by the family doctor. Patients under clinical observation and 
those receiving antibiotic prophylaxis were counselled on UTI prevention strategies 
including lifestyle changes, behavioural modifications, and constipation management. 
Participants provided both first-void (FV) and midstream (MS) urine at the initial 
appointment (baseline) and at 3-month intervals, up to 12-months, during scheduled 
appointments. Instructions for urine collection were given to the parent/legal guardian for 
in-clinic collection. First-void included approximately the first 10 mL, and the remainder 
was MS urine. The parent/legal guardian collected FV samples as soon as the child 
started to void, then quickly switched bottles for the MS samples. Urinalysis was 
completed in the clinic by nursing staff using urinalysis strips. Urine samples were only 
collected from patients when they were non-symptomatic and kept on ice until 
processing. 
Age-matched, healthy controls were also recruited; however, they were only asked to 
provide a urine sample at one time-point. Healthy controls had no history of RUTI, no 
presentation of urinary tract abnormalities, and no antibiotic exposure in the last six 
months. 
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3.2.2 Urine sample processing 
Urine samples underwent bacteriological study using both culture-dependent and 
independent (16S rRNA gene sequencing) methods, and quantitation of urinary 
cytokines. In brief, 200 µL of urine was used for bacterial culture, two 1.5 mL aliquots 
saved for cytokine and content analysis, and the remainder stored for 16S rRNA gene 
sequencing. Storage of urine samples was at -80°C. Given the study time-frame, the 
standard procedure for extraction of DNA from urine samples varied throughout the 
study – half of the samples were stored at -80°C as unprocessed urine and half were first 
centrifuged at room temperature for 10 minutes at 5,000 × g and the pellet stored at -
80°C. Samples stored as unprocessed urine were centrifuged under the same conditions 
and the pellet used for DNA extraction; to prevent multiple freeze-thaw effects, these 
samples were pelleted on the day of DNA extraction. Storage conditions were recorded to 
identify confounding factors in 16S rRNA gene sequencing analysis associated with 
storage conditions. 
Uropathogenic bacteria were enumerated and presumptively identified from first-void 
and midstream urine using CHROMagar Orientation (BD, Franklin Lakes, NJ, USA) and 
Columbia Blood Agar (BD) supplemented with 5% defibrinated sheep’s blood (CBA; 
Thermo Fisher Scientific, Waltham, MA, USA). Unprocessed or 10-fold dilutions in 
phosphate buffered saline (PBS) were spread on agar plates and incubated for 48 hours at 
37°C under atmospheric conditions. Pure cultures were added to the Burton-Reid 
uropathogen collection for future study. Heatmaps of bacterial culture data were prepared 
using Superheat v0.1.0 (https://github.com/rlbarter/superheat) in R v3.4.3 
(https://www.R-project.org )43,44.  
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Table 3-1. Inclusion and exclusion criteria for the RUTI group of this study.  
Inclusion criteria Exclusion criteria 
Age: 3-15 years old Age: < 3 or > 15 years old 
Toilet-trained Not toilet-trained 
History of symptomatic, culture-proven 
RUTI, defined as: 
- two or more infections in the last 
year, or 
- more than 3 infections overall. 
No documented history of symptomatic, 
culture-proven RUTI 
Normal renal and bladder ultrasound Renal or bladder ultrasound demonstrate; 
- signs of injury, 
- anatomical abnormalities, 
- blockage or kidney stones, 
- cysts or tumors, 
- diverticula, 
- high volume of post-void residual 
urine. 
Normal VCUG* VCUG indicative of VUR 
Willing and able to receive antibiotic 
prophylaxis as Septra or nitrofurantoin, 
when clinically indicated 
Unwilling or unable to receive antibiotic 
prophylaxis; 
- history of allergic reaction to 
Septra or nitrofurantoin, 
- medical comorbidity preventing 
the use of prophylaxis. 
No clinical evidence of neurogenic 
bladder 
History of neural tube defect, spinal cord 
injury or disease 
*Patients underwent a VCUG if there was a history of greater than two febrile UTIs or 
the ultrasound results were abnormal. 
Abbreviations: RUTI, recurrent urinary tract infection; UTI, urinary tract infection; 
VCUG, voiding cystourethrogram; VUR, vesicoureteral reflux. 
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3.2.3 DNA isolation and 16S rRNA sequencing 
DNA was isolated from urine samples using the DNeasy PowerSoil HTP 96 Kit 
according to the manufacturer’s instructions (Qiagen, Toronto, ON, CAN). In brief, 
pellets were suspended in 200 µL DNAse-, RNase-free water (Qiagen), then transferred 
to individual wells of the PowerSoil-htp Bead Plate containing 750 µL PowerSoil-htp 
Bead Solution and 60 µL Solution C1. Plates were incubated at 65°C for 10 minutes 
followed by shaking for 20 minutes at speed 20 using the MO BIO 96-well plate shaker 
(Qiagen). Plates were centrifuged at room temperature for 12 minutes at 2,250 × g, and 
500 µL of the supernatant from each well transferred to wells of a fresh plate containing 
250 µL Solution C2 and mixed by pipetting. The plates were incubated at 4°C for 10 
minutes followed by centrifugation at room temperature for 12 minutes at 2,250 × g. The 
resulting supernatant was then transferred to individual wells of a fresh plate and the 
centrifugation step repeated. The resulting solution, approximately 600 µL per well, was 
then transferred to a fresh plate containing 200 µL Solution C3 and mixed by pipetting. 
The plate was incubated at 4°C for 10 minutes followed by centrifugation for 12 minutes 
at 2,250 × g. The entire volume, with the exception of the pellet, was again transferred to 
a fresh plate for centrifugation at room temperature for 12 minutes at 2,250 × g. Avoiding 
the residual pellet, 650 µL was transferred from each well to a fresh plate containing 650 
µL Solution C4 followed by an additional 650 µL of Solution C4. Samples were mixed 
by pipetting and 500 µL of solution transferred to a Spin Plate, which was centrifuged at 
room temperature for 7 minutes at 2,250 × g. The flow-through was discarded, and this 
step repeated until the entire sample-Solution C4 mix was processed through the Spin 
Plate. A volume of 500 µL Solution C5-D was then added to the Spin Plate. The plate 
was centrifuged twice at room temperature for 10 minutes at 2,250 × g; the flow-through 
was discarded between spins. Following the second centrifugation, 100 µL Solution C6 
was added to the Spin Plate, incubated at room temperature for 10 minutes and the 
resulting DNA eluted to a Microplate via centrifugation at room temperature for 15 
minutes at 2,250 × g. DNA was stored at -20°C until amplified for sequencing. 
PCR amplification of 1 µL DNA was completed using the Earth Microbiome universal 
primers, 515F and 806R, which are specific for the V4 variable region of the 16S rRNA 
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gene45. Amplification was carried out using Promega GoTaq hot-start colourless master 
mix (Promega, Madison WI, USA) for 25 cycles as 1 minute each of 95°C, 52°C, and 
72°C, preceded by 3 minutes at 95°C to activate the GoTaq. Inline barcodes were 
designed as the left- or right-side Illumina adaptor at the 5’ end followed by 4 random 
nucleotides, the 8-nucleotide barcode and the associated left or right primer at the 3’ 
end46. 
DNA extraction and PCR amplification were completed across a total of four 96-well 
plates. Urine samples were processed in parallel with samples from other experiments. 
DNA extraction and no template PCR controls were also included. 
Sequencing was carried out on the MiSeq System (Illumina Inc., San Diego, CA, USA) at 
the London Regional Genomics Centre (http://www.lrgc.ca; London, ON, CAN) using 
the 600-cycle MiSeq Reagent Kit v3 (Illumina Inc.). Paired-end sequencing was carried 
out as 2 × 220 cycles with the addition of 5% PhiX-174. Data was exported as raw fastq 
files. 
3.2.4 Microbial composition analysis 
Fastq files were de-multiplexed into forward and reverse reads and non-biological 
nucleotides removed using an internal pipeline designed and maintained by members of 
the Gloor lab (https://github.com/ggloor). Sequence files were then processed using 
DADA2 v0.99.7 (https://github.com/benjjneb/dada2)47. In brief, DADA2 was used to 
filter and trim the reads, de-replicate, perform sample inference and error rate estimation, 
merge paired reads, remove chimaeras and assign taxonomy against the SILVA rRNA 
reference database v123 (https://www.arb-silva.de)48. The resulting sequence table was 
used for downstream analyses. 
Compositional data analysis was completed with CoDaSeq v0.99.1 
(https://github.com/ggloor/CoDaSeq) and ALDEx2 v1.10.0 
(https://github.com/ggloor/ALDEx2_dev) in R43,49-53. Use of compositional data tools is 
important, as it takes into account that high-throughput sequencing systems have a fixed 
capacity. Thus, sequencing results provide a random sample of the underlying bacterial 
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ecosystem, which cannot be related to the total number of bacteria in the input sample. 
Other methods of 16S rRNA gene sequencing analysis, such as rarefaction and 
differential abundance, lead to loss of information and unacceptably high false positive 
rates46. Principle component analysis (PCA) plots were prepared using CoDaSeq 
according to the following; each sample had a minimum of 1000 reads, and each 
amplicon sequence variants (ASVs) had to make up a minimum of 0.1% of all reads. 
Samples or ASVs not meeting these criteria were removed from the analysis. 
3.2.5  Quantification of urinary cytokines 
The following human cytokines were quantified in urine samples; interferon gamma 
(IFNγ), interleukin-1beta (IL-1β), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 
(IL-8), interleukin-10 (IL-10), and tumour necrosis factor alpha (TNFα). A subset of 
urine samples were selected to include; 11 control samples, 12 observation samples, as 2 
patients at 3 timepoints and 3 patients at 2 timepoints, and 17 Septra samples, as 5 
patients at 3 timepoints (baseline, during prophylaxis, and after prophylaxis) and one 
patient at baseline. Concentrations of cytokines were measured using multiplexed 
immunoassay kits according to the manufacturer’s instructions (EMD Millipore, 
Burlington, MA, USA). Prior to addition to the kit, urine samples were centrifuged at 
5,000 × g for 5 minutes at room temperature; the supernatant was mixed 1:1 with assay 
buffer and incubated for 20 minutes at room temperature to neutralize sample and reduce 
background. Fluorescence was measured on a Bio-Plex 200 system (Bio-Rad, Hercules, 
CA, USA) using Luminex® xMAP fluorescent bead-based technology (Luminex 
Corporation, Austin, TX, USA). Cytokine concentrations (ρg/mL) were calculated from 
standard curves using Bio-Plex Manager v4.1.1 (Bio-Rad). 
3.2.6 Statistical analysis 
All patient demographic and history, urinalysis and bacterial culture, as well as cytokine 
data, were analysed using GraphPad Prism v7.0a for Mac OS X (GraphPad Software, San 
Diego, CA, USA). To test for significance in the RUTI group, patient demographic and 
history data was analysed using one-way analysis of variance (ANOVA) followed by 
post hoc Tukey’s multiple comparisons tests and unpaired t-tests. Significance of 
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cytokine data was determined using unpaired t-tests to compare control and RUTI 
participants and repeated measures ANOVA for RUTI time-course data. Pearson’s and 
Spearman’s correlation coefficients were used to test for correlation within the dataset. 
3.3 Results 
3.3.1 Patient recruitment and medical history 
Participant recruitment began in October 2012 and ended August 2014 for RUTI patients; 
follow-up continued until August 2015. Recruitment of healthy controls was completed 
in March 2016. A total of 39 patients were approached about study participation, 37 
consented and two declined. In contrast, patient retainment rates were not high; we 
collected 3-month samples from 21 participants (57%), 6-month from 18 (49%), 9-month 
from 16 (43%), and 12-month from 14 (38%). 
All RUTI patients recruited to the study were females between the ages of 3 and 12 (6.8 ± 
2.6). Participants reported experiencing between 3 and 70 (11.3 ± 12.4) symptomatic 
UTIs over a period of 6 months to 10 years (2.8 ± 2.4) prior to study enrollment. 
Participants were split into groups for longitudinal analysis based on antibiotic therapy 
status; antibiotic prophylaxis as Septra (n = 18) or nitrofurantoin (n = 7), or those that 
were not prescribed antibiotic prophylaxis (observation, n = 12). All control patients were 
female. 
Differences in patient-reported history of UTI and voiding habits were generally not 
significant between the three groups (Table 3-2); however, patients receiving 
nitrofurantoin reported more symptomatic UTIs prior to study enrollment than 
observation patients (P = 0.03), voided significantly more often per 24-hour period than 
patients receiving Septra prophylaxis (P = 0.03) and were significantly less likely to 
report symptoms of abdominal pain associated with UTI than those receiving Septra (P = 
0.02). Further, patients receiving antibiotics, Septra or nitrofurantoin, reported 
significantly more UTIs prior to study enrollment than those in the observation group (P 
= 0.01). Almost half of participants (46%) reported constipation. 
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In regards to the DVSS, the reported incidence of nocturnal enuresis was significantly 
worse in the nitrofurantoin group relative to both the Septra (P = 0.0003) and observation 
groups (P = 0.0006). Urgency was also significantly more common in the nitrofurantoin 
(P = 0.04) and antibiotic prophylaxis (Septra and nitrofurantoin; P = 0.02) groups relative 
to observation. Finally, the total DVSS score was significantly higher in the antibiotic 
prophylaxis group (Septra and nitrofurantoin) compared to observation (P = 0.03).  
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Table 3-2. Recurrent UTI patient demographics.  
 Antibiotic Status 
Observation (n = 
12) 
Antibiotic Prophylaxis* 
Septra (n = 18) Nitrofurantoin (n = 7) 
Age 6.8 (± 2.6) 6.9 (± 2.5) 6.3 (± 2.9) 
UTI history 
Symptomatic years 1.9 (± 1.6) 3.0 (± 2.3) 3.9 (± 3.2) 
No. experienced 5.8 (± 3.2)† 11.4 (± 7.9) 20.7 (± 23.8)‡ 
No. febrile 1.8 (± 1.9) 2.3 (± 5.1) 2 (± 3.0) 
Reported UTI symptoms 
Dysuria 10 (83%) 13 (72%) 5 (71%) 
Fevers 10 (83%) 14 (78%) 5 (71%) 
Flank pain 1 (8%) 3 (17%) 0 
Abdominal pain 3 (25%) 10 (56%) 0§ 
Previous UTI Culture§ 
E. coli 9 11 6 
E. faecalis 1 3 3 
Proteus mirabilis 1 4 0 
Klebsiella sp. 0 1 1 
Staphylococcus sp. 0 1 0 
Voiding habits 
24 hr void frequency 6 (± 2.3) 5.8 (± 2.4) 8.9 (± 3.4)|| 
Nocturnal enuresis 5 (42%) 10 (56%) 4 (57%) 
Diurnal enuresis 3 (25%) 7 (39%) 3 (43%) 
OAB Signs 5 (42%) 9 (50%) 5 (71%) 
Straining to void 1 (8%) 5 (28%) 0 
Constipation 4 (33%) 10 (56%) 3 (43%) 
PEG3350 prescribed 3 (25%) 10 (56%) 4 (57%) 
*Prescribed as nitrofurantoin at 2 mg/kg and Septra at a trimethoprim dose of 2 mg/kg. 
†P < 0.05 in comparison to antibiotic prophylaxis (Septra and nitrofurantoin) by unpaired 
t-test with Welch’s correction. 
‡P < 0.05 in comparison to observation by one-way ANOVA with Tukey’s multiple 
comparisons test. 
§Previous culture results were obtained through the consultation request and are not 
available for all patients, thus no percentage is represented. 
||P < 0.05 in comparison to Septra by one-way ANOVA with Tukey’s multiple 
comparisons test. 
Abbreviations: hr, hours; No., number; OAB, overactive bladder; PEG3350, polyethylene 
glycol 3350.  
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3.3.2 Urinalysis 
All samples were negative for glucose, and urine from control participant 6 (C6) was the 
only to test positive for ketones. At baseline, specific gravity was significantly higher in 
healthy controls compared to recurrent UTI patients as both a general group (P = 0.0001) 
and specifically those receiving Septra (P = 0.004). 
3.3.3  Bacterial culture 
Total viable plate counts were not significantly different for FV or MS urine on 
CHROMagar Orientation nor were counts from FV urine on CBA following 48-hour 
incubation. However, total viable counts from the MS urine of children with RUTI were 
significantly higher on CBA in comparison to the urine of healthy children (P = 0.04). 
Presumptive identification was completed using CHROMagar Orientation, a 
chromogenic culture medium optimised for the enumeration and differentiation of 
uropathogens (Tables 3-3 and 3-4). Based on these presumptive identifications, we 
identified Citrobacter in urine samples from patients 8, 12, and C17 at baseline, always 
below the limit of quantitation (LOQ). Further, we only isolated Proteus mirabilis from 
one patient following Septra antibiotic prophylaxis. E. coli and E. faecalis were the two 
most commonly isolated uropathogens. Notably, 19% of MS urine samples met the 
diagnostic cutoff for UTI (Table 3-3; Figures 3-1 and 3-2;), 105 bacteria of one species, 
yet patients remained symptom-free suggesting this was a state of ABU. 
E. faecalis viable counts were not significantly different between RUTI and control 
urines, yet enterococci were significantly more likely to be isolated in RUTI samples (P = 
0.04; Figures 3-1 and 3-3). In comparison, E. coli viable counts were significantly higher 
in RUTI relative to control urine (P < 0.0001), yet there was no difference in incidence. 
Further, there was a positive correlation between the CFU of E. faecalis and non-E. coli 
uropathogens in both healthy and RUTI urines (Figure 3-5), the correlation coefficient 
was 0.52 from FV urine (P = 0.0003, 95% CI 0.27-0.71) and 0.4 from MS urine (P = 
0.01, 95% CI 0.10-0.63). 
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Over the course of the study, E. faecalis was detected in the FV urine of 22 RUTI 
patients (n = 35, 63%) and in the MS urine of 15 (n = 33, 45%; Tables 3-3 and 3-4). 
Additionally, antibiotic prophylaxis mediated a slight decrease in uropathogen load; 
however, bacterial counts returned to pre-antibiotic levels following cessation of therapy 
(Figures 3-2 and 3-4). The majority of cultures were polymicrobial, and multiple colony 
morphologies were noted; only uropathogens were presumptively identified. 
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Figure 3-1. Uropathogen isolation from midstream urine of healthy and RUTI 
patients. 
The enumeration and presumptive identification of E. faecalis, E. coli, 
Klebsiella/Enterobacteri, Staphylococcus saprophyticus, and Pseudomonas/S. aureus 
was completed with CHROMagar orientation from the midstream urine of healthy 
controls and patients with a history of RUTI at baseline. Data is presented as log10 
CFU/mL; gray boxes denote species that were not detected in that sample.   
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Figure 3-2. Uropathogen isolation from midstream urine of RUTI patients over 
time. 
The enumeration and presumptive identification of E. faecalis, E. coli, 
Klebsiella/Enterobacter, S. saprophyticus, and Pseudomonas/S. aureus was completed 
with CHROMagar orientation from the midstream urine of patients with a history of 
RUTI over a 12-month period. Patients were observed clinically (Observation), or 
received nitrofurantoin (Nitro.) or TMP/SMX (Septra) prophylaxis. Antibiotic status is 
indicated to the left of the heatmap (Abx.); no antibiotic (light gray), on at antibiotic at 
sample collection (medium gray), or off antibiotic (dark gray). Data is presented as log10 
CFU/mL; gray boxes denote species that were not detected in that sample.  
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Figure 3-3. Uropathogen isolation from first-void urine of healthy and RUTI 
patients.  
The enumeration and presumptive identification of E. faecalis, E. coli, 
Klebsiella/Enterobacteri, Staphylococcus saprophyticus, and Pseudomonas/S. aureus 
was completed with CHROMagar orientation from the first-void urine of healthy controls 
and patients with a history of RUTI at baseline. Data is presented as log10 CFU/mL; gray 
boxes denote species that were not detected in that sample.   
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Figure 3-4. Uropathogen isolation from first-void urine of RUTI patients over time. 
The enumeration and presumptive identification of E. faecalis, E. coli, 
Klebsiella/Enterobacter, S. saprophyticus, and Pseudomonas/S. aureus was completed 
with CHROMagar orientation from the first-void urine of patients with a history of RUTI 
over a 12-month period. Patients were observed clinically (Observation), or received 
nitrofurantoin (Nitro.) or TMP/SMX (Septra) prophylaxis. Antibiotic status is indicated 
to the left of the heatmap (Abx.); no antibiotic (light gray), on at antibiotic at sample 
collection (medium gray), or off antibiotic (dark gray). Data is presented as log10 
CFU/mL; gray boxes denote species that were not detected in that sample. 
  
171 
 
 
Figure 3-5. Correlation between Enterococcus and non-E. coli bacterial load in 
urine. 
Enumeration and presumptive identification of uropathogens from urine was completed 
using CHROMagar orientation. Of the uropathogens identified, the bacterial load of 
Enterococcus and the non-E. coli bacteria were positively correlated in both midstream 
(A; r = 0.40, P = 0.01) and first-void (B; r = 0.52, P = 0.0003) urine. Data is presented as 
CFU/mL. Correlation was determined using Pearson’s correlation coefficient.  
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3.3.4 16S rRNA sequencing 
Our initial data exploration indicated there were no differences in the microbial 
communities of FV or MS urine from any of the study participants. Additionally, the 
DNA extraction and no template controls grouped with the urine samples in our principle 
component analysis (PCA) plot (Figure 3-6, A). To overcome this, we attempted to 
remove amplicon sequence variants (ASVs) that were of significantly higher relative 
abundance in the experimental blanks compared to urine samples; however, this did not 
improve data separation. 
Given that the urine samples were processed alongside chemostat samples, we combined 
the individual datasets to assess for differences between urine, blanks, and chemostat 
samples. The resulting PCA plot demonstrated a separation between urine and chemostat 
samples along principle component 1 (PC1); however, PC1 accounted for only 12.5% of 
the variance (Figure 3-6, B). We were able to determine that over 90% of the variance 
was attributed to a single ASV, which corresponded to Escherichia/Shigella (data not 
shown). This ASV was removed, and the dataset reanalysed. 
The resulting PCA (Figure 3-6, C) continued to demonstrate grouping of the 
experimental blanks with the urine samples, and the separation of urine and chemostat 
samples along PC1 could be explained by less than 13% of the variance. Given that the 
PCA takes into account all the samples analysed, we removed the chemostat samples and 
repeated the CoDaSeq analysis and PCA plot (Figure 3-6, D). Similar to the initial PCA, 
no separation was noted between FV or MS urine, regardless of disease status, and 
experimental blanks continued to group with the samples. A subsequent scree plot of the 
data indicated that no single factor accounts for the lack of variance (Figure 3-7).  
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Figure 3-6. Principle component analyses of 16S rRNA gene sequencing data. 
Variance in the 16S rRNA gene sequencing data was visualised as a series of principle 
component analyses (PCA). A | Experimental blanks (black) did not group separately 
from the first-void (FV; red) or midstream urine (MS; blue). B | Urinary and chemostat 
datasets were combined to assess for contamination. Most chemostat samples (green) 
grouped separately of the urine and blanks (FV, red; MS, blue; blanks, black) along 
principle component 1 (PC1; 0.125). C | Amplicon sequencing variant 1 (ASV1) was 
removed from the urine-chemostat dataset; most chemostat samples continued to group 
separately from the urine and blanks along PC1 (0.128). D | Variance of urine samples 
and blanks was visualised following the removal of ASV1 from the data set. Healthy FV 
(blue), healthy MS (green), recurrent urinary tract infection (RUTI) FV (red), RUTI MS 
(orange), and experimental blank (black) samples were inseparable by PCA. 
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Figure 3-7. Scree plot of 16S rRNA gene sequencing data from urine and 
experimental blanks. 
A plot of the fraction of total variance associated with each principle component (PC) is 
presented for the urinary dataset following the removal of amplicon sequencing variant 1 
(ASV1). The y-axis of the graph demonstrates that no single PC is associated with the 
datasets variation.   
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3.3.5 Urinary cytokines 
Cytokine levels were below the LOQ in most of the samples assayed (Figure 3-8, 3-9, 
and 3-10). There were no significant differences in the concentration of IL-1β, IL-2, IL-8, 
IL-10, IFNγ, or TNFα (Figure 3-8 and 3-9); however, IL-6 was significantly higher in the 
healthy group compared to RUTI at baseline (P = 0.03). Control 8 (C8), was the only 
sample we were able to determine the concentration of IL-2 in (6.8 ρg/mL), and had the 
highest concentration of IL-1β (226.0 ρg/mL), IFNγ (20.35 ρg/mL), and IL-10 (17.38 
ρg/mL). There was also no significant difference in cytokine concentrations across the 
longitudinal samples (Figure 3-8 and 3-10, B).   
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Figure 3-8. Baseline urinary pro-inflammatory cytokines.  
Cytokine concentrations are presented in ρg/mL from the urine of healthy and RUTI 
participants at baseline. The dashed line represents the lower limit of quantitation, and 
corresponds to 3.1 for IL-1β (A), 2.9 for IL-2 (B), 3.0 for IL-6 (C), 3.6 for IL-8 (D), 4.0 
for IFNγ (E), and 4.5 ρg/mL for TNFα (F). Urinary cytokine concentrations were 
determined for each patient in duplicate using Luminex® xMAP fluorescent bead-based 
technology. Significance was determined using unpaired t-tests (*, P < 0.05).  
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Figure 3-9. Urinary pro-inflammatory cytokines over the course of Septra 
prophylaxis. 
Urinary cytokine concentrations of five patients over the course of Septra prophylaxis are 
presented in ρg/mL. Samples were collected at baseline (before), 3-months into 
prophylaxis (during), and during the antibiotic wash-out period (after). The dashed line 
represents the lower limit of quantitation, and corresponds to 3.1 for IL-1β (A), 3.0 for 
IL-6 (B), 3.6 for IL-8 (C), and 4.5 ρg/mL for TNFα (F). Urinary cytokine concentrations 
were determined for each patient in duplicate using Luminex® xMAP fluorescent bead-
based technology. Significance was determined using repeated-measures one-way 
ANOVA.   
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Figure 3-10. Urinary anti-inflammatory cytokines.  
Urinary IL-10 concentrations are presented for healthy patients and RUTI patients at 
recruitment (A), and over the course of Septra prophylaxis (B). Longitudinal samples 
were collected at baseline (before), 3-months into prophylaxis (during), and during the 
antibiotic wash-out period (after). The dashed line corresponds to the lower limit of 
quantitation, 4.6 ρg/mL. Urinary cytokine concentrations were determined for each 
patient in duplicate using Luminex® xMAP fluorescent bead-based technology. 
Significance was determined between healthy and RUTI participants using an unpaired t-
test and over-time using repeated-measures one-way ANOVA.   
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3.4 Discussion 
In this pilot study, we followed paediatric patients with RUTI over the course of 12-
months, during which patients either received antibiotic prophylaxis as TMP/SMX or 
nitrofurantoin, or were clinically observed. We demonstrated the presence of 
uropathogens, including E. coli and E. faecalis, in the urine of both healthy and RUTI 
participants. Additionally, we demonstrated prophylaxis may not be having its desired 
effect, as bacterial loads increase following cessation of therapy and have no measurable 
effect on urinary cytokine levels. 
Participant recruitment began in October 2012 and ended August 2014 for RUTI patients; 
follow-up continued until August 2015. Recruitment of healthy controls was completed 
in March 2016. We had initially projected a 6-month recruitment period; however, it was 
almost two years before we successfully recruited 37 patients. This was a direct reflection 
of the available population, as we had a recruitment rate of over 95%. In total, 39 patients 
were approached and 37 agreed to participate, those who declined cited costs associated 
with the increased frequency of clinic visits and a lack of interest. 
In contrast, our participant retainment rates were quite low, dropping from 56% at 3-
months to below 40% by the 12-month mark. One participant officially dropped out of 
the study after three months, while the rest ceased to attend appointments. In comparison, 
the PRIVENT, RIVUR, and IRIS prophylaxis trials lost less than 8% of patients to 
follow-up10,33,54. As our study was designed as a pilot and was initially unfunded, we 
were unable to offer incentives; participants and their families were responsible for all 
travel and parking costs, and prescriptions were at personal cost or covered by family 
drug plans. Procedures, such as uroflowmetry, ultrasound, and/or VCUG were within the 
standard of care and thus covered by the Ontario Health Insurance Plan (OHIP). In an 
effort to increase retainment, administrative staff reached out to participants prior to 
appointments to provide a reminder. Further, all study associated appointments were 
scheduled at recruitment and the family mailed a letter with the prospective dates 
(Appendix C). While the loss of patients to follow-up was detrimental to the study 
outcome, it was not out of character for this clinic, which regularly sees 10-20% of 
patients fail to attend appointments. 
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Given that the decision to begin antibiotic prophylaxis or clinical observation was based 
on the clinical experience of the attending urologist, we expected significant differences 
in patient histories between the observation and prophylaxis groups. Unsurprisingly, 
patients in the prophylaxis group reported significantly more UTIs prior to study 
enrollment than those in the observation group (Table 3-2). This is likely an indicator of 
perceived RUTI severity; however, there were no significant differences in the number of 
febrile UTIs or UTI-associated symptoms.  
Similarly, patients receiving nitrofurantoin reported more severe nocturnal enuresis and 
urgency in the DVSS. The total DVSS score was also significantly higher in the 
prophylaxis group relative to observation; this was expected given clinician bias in the 
use of antibiotic prophylaxis when BBD is a suspected contributor to RUTI. Indeed, BBD 
is a well-characterised risk factor for the development of RUTI in children4; however, to 
the best of our knowledge, no research has linked BBD to success rates in antibiotic 
prophylaxis. 
In contrast, the relationship between UTI-associated abdominal pain and choice of 
prophylactic agent was unexpected, as was the relationship between voiding frequency 
and prophylactic choice. Neither of these participant characteristics were significantly 
different between the observation and prophylaxis groups; thus, this observation is not 
likely to be clinically relevant. Further, clinical guidelines recommend Septra as the first 
choice for antibiotic prophylaxis, unless local antibiograms indicate TMP/SMX 
resistance is high in uropathogens or previous urine culture results have isolated 
TMP/SMX resistant strains13. 
In regards to the urinalysis results, all samples were negative for glucose, indicating none 
of our patients had mismanaged or undiagnosed diabetes, which is a risk factor for RUTI 
given the increased nutrient availability. Specific gravity was significantly lower, yet still 
within the normal range, in RUTI patients relative to healthy controls; however, this is 
likely a reflection of the collection conditions. Patients with a history of RUTI provided 
urine in the clinic, thus urinalysis tests were conducted on the sample immediately, while 
healthy patients often collected the urine at home and brought the sample to the study 
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site. The time between urine collection and urinalysis was significantly longer for healthy 
urine samples, which is associated with loss of test accuracy55,56. Alternatively, specific 
gravity is generally considered a measure of hydration57, RUTI patients were asked to 
arrive at the clinic with a full bladder, it is likely that parents increased fluid intake prior 
to the appointment for this purpose. 
Bacterial enumeration and presumptive identification was completed with CHROMagar 
Orientation, a chromogenic culture medium optimized for uropathogens. Notably, E. 
faecalis grows as teal colonies, E. coli as dark pink, Staphylococcus saprophyticus as 
light pink, Klebsiella/Enterobacter as metallic blue, Citrobacter as dark blue with a red 
halo, Proteus mirabilis is notable for its brown halo, and both Staphylococcus aureus and 
Pseudomonas grow as white/cream colonies on these agar plates. Thus, enumeration and 
presumptive identification of these common uropathogens can be made within 24 hours 
of urine collection. CHROMagar Orientation has been extensively validated and is used 
by many diagnostic laboratories58-60. Using this strategy, E. coli and E. faecalis were the 
most commonly isolated uropathogens from our samples (Figure 3-1, 3-2, 3-3, and 3-4), 
which corresponds with E. coli and E. faecalis being the most commonly reported agents 
of pre-study culture-proven UTI (Table 3-2). Notably, 19% of MS urine samples met the 
diagnostic cutoff for UTI, >105 CFU/mL of one bacterial species, yet patients remained 
symptom free, suggesting this was a state of ABU. 
Asymptomatic bacteriuria is generally considered a protective state and eradication of the 
ABU-associated bacteria, particularly enterococci, is associated with increased risk of 
symptomatic UTI15,61-64. Our culture results suggest that antibiotic prophylaxis does not 
completely eradicate uropathogens, and that cessation of prophylaxis may be associated 
with an increase in bacterial load (Figures 3-2 and 3-4). These results support research 
indicating ABU should not be treated15,61-64, and implies the diagnostic threshold for 
ABU, in patients with a history of RUTI, may be too high. 
Interestingly, total viable counts were not significantly different between the healthy and 
RUTI group at baseline on CHROMagar Orientation for either FV or MS urine; yet 
counts from MS urine on CBA plates were significantly higher in the RUTI population. 
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Likewise, E. faecalis counts were not significantly different between RUTI and control 
urines; however, E. faecalis was more likely to be isolated from RUTI urine. In 
comparison, E. coli CFUs were significantly higher in RUTI urine, yet there was no 
difference in incidence. These findings raise questions in regards to what constitutes a 
“healthy” urinary microbiota in the paediatric population. 
Study of the urinary microbiota in adult women has described E. faecalis in the urine of 
patients with interstitial cystitis/bladder pain syndrome (IC/BPS), neurogenic bladder, 
and in the majority of non-symptomatic patients with a history of UTI, yet none have 
identified E. faecalis in the urine of healthy women15,65-68. Thus, E. faecalis presence in 
the urinary tract may be an indicator of ill-health. A clinical study of the urinary 
microbiota in renal transplant patients found E. faecalis to be significantly abundant in 
the urine of patients prior to development of symptomatic UTI28. 
The data also indicates a positive correlation between the bacterial load of E. faecalis and 
non-E. coli uropathogens (Figure 3-5), which is notable given the prevalence of 
enterococci in polymicrobial UTI69. Of note, Enterococcus sp. were found in low 
abundance within almost one-third of E. coli-dominated acute UTI samples24, suggesting 
enterococci may be a significant contributor to both mono- and polymicrobial UTI. 
Indeed, the majority of our urine cultures were polymicrobial, with multiple colony 
morphologies noted per urine sample; however, only uropathogens were presumptively 
identified. We documented a variety of pinpoint colonies on our plates (CHROMagar and 
CBA), yet were unable to subculture most of these bacteria. These colonies may 
represent small colony variants, or, more likely, are dependent on the byproducts of other 
bacteria for in vitro growth as their colony counts were discontinuous with increasing 
dilutions. 
Unfortunately, we were unable to assess the polymicrobial nature of our urine samples 
using the 16S rRNA gene sequencing data. Our initial exploratory analysis indicated no 
significant differences in variance between the urine and experimental blanks (Figure 3-6, 
A), thus we attempted to remove contaminating ASVs; however, this did not improve 
data separation. Given that DNA extraction, PCR amplification, and ultimately 
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sequencing were completed in parallel with chemostat samples, we made the assumption 
that the higher abundance chemostat samples were the source of the contamination. To 
test this, we combined the individual datasets and completed a second PCA (Figure 3-6, 
B). The urine and chemostat groups did separate along PC1; however, this only 
accounted for 12.5% of the variance and we should expect a much larger difference 
between urine and chemostat samples. We were able to attribute a large portion of this 
variance to ASV1, which we subsequently removed from the analysis. Notably, when 
data is analysed as proportions, removal of a single attribute disrupts the proportions of 
the remaining data; however, as our data was analysed as compositions49,50,52,53, we were 
able to remove ASV1 without interfering with the interpretation of the remaining ASVs. 
Following the removal of ASV1, we noted no significant changes in the urine-chemostat 
dataset (Figure 3-6, C), nor was there separation of the urine and experimental blanks 
subsequent to removal of the chemostat samples (Figure 3-6, D). Given the low 
abundance of the urine samples we would have expected the experimental blanks to 
group separately, thus we concluded the urinary data was contaminated by the higher-
abundance chemostat samples and would not convey meaningful results. 
Finally, we measured urinary cytokine levels as an indication of bladder inflammation 
and bacterial interactions with the urothelium. Given that bacterial attachment to 
urothelial cells is one of the first steps in bacterial colonization, the urothelium acts as the 
one body’s early infection defence systems. In vitro experiments have demonstrated the 
production and release of cytokines by the urothelium in response to whole bacteria and 
purified bacterial toxins, such as pyocyanin or lipopolysaccharide (LPS)70-72. Of interest 
to our group, E. faecalis infection was associated with increased expression of IL-6, IL-
12, G-CSF, IL-1β, IL-1α, and IL-17 in a murine model of catheter-associated UTI73,74, 
and in humans bacterial cystitis correlates with increased urinary IL-1α, IL-1β, TNFα, IL-
6, and IL-872,75. Furthermore, urinary IL-6 and IL-8 have shown prognostic value for 
paediatric UTI76, and been identified as markers of disease severity75. 
Contradictory to these reports, our data demonstrates significantly higher concentrations 
of IL-6 in the urine of healthy children. While statistically significant, the biological 
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relevance of our cytokine results is debatable, as both the n-value and concentration 
differential were relatively small. There are however, a number of potential explanations 
for the decrease in urinary IL-6; first of all, RUTI patients may not be able to mount an 
effective immune response to uropathogens and/or low-level inflammation may be 
beneficial to the maintenance of homeostasis, which aligns with the genetic aspects of 
RUTI14,77. Alternatively, uropathogens may be interfering with the bladder’s immune 
response through a dampening of cytokine levels and/or interruption of urothelial 
signaling; this may help explain the increase in cytokine levels associated with 
symptomatic UTI relative to ABU75. Interestingly, most cytokines were either undetected 
in the urine samples or detected below the LOQ (Figure 3-8, 3-9, and 3-10), regardless of 
the uropathogen load within the sample. Cytokines levels were also not significantly 
altered over the course of prophylaxis, indicating antibiotic prophylaxis may not be 
having its desired effects.  
3.4.1 Conclusions 
Originally designed as a pilot, the goal of this clinical study was to explore the urinary 
prevalence of enterococci in paediatric patients with RUTI and determine if antibiotic 
prophylaxis would induce alterations in the microbial communities of this population. 
Our culture results demonstrated the presence of uropathogens in the urine of healthy 
children and children with a history of RUTI, although none of our participants were 
experiencing symptomatic-UTI. Further, antibiotic prophylaxis appears to temporarily 
decrease urine CFUs, yet following cessation of therapy the bacterial load drastically 
increases, similar to what is noted with the treatment of ABU. It is possible that these 
low-levels of bacteria noted in our RUTI samples behave similarly to ABU strains. This 
warrants future study, especially considering the high rates of prophylaxis-associated 
recurrent infections. The positive correlation of E. faecalis with non-E. coli uropathogens 
is also of interest and highlights the contribution of E. faecalis to polymicrobial UTI. 
Indeed, most polymicrobial urine samples are considered contamination, yet data exists 
suggesting enterococci contribute to the pathogenesis of other bacteria and symptom 
onset may be a result of a disruption in homeostasis28. Finally, the decreased urinary IL-6 
noted in our RUTI population may be indicative of bacterial interference with the bladder 
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immune response. Given the link between paediatric UTI history and subsequent disease 
development, such as overactive bladder, IC/BPS, and adult RUTI incidence78,79, study of 
this population and prevention of infection in paediatric patients is likely to decrease 
lifetime incidence of other urinary diseases. 
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Chapter 4  
4 Enterococcal production of neuroactive substances 
4.1 Introduction 
Microbial endocrinology, the study of host-microbe interactions through neuroendocrine 
hormones1, is a relatively old field, dating back over 100 years2, yet the concept of 
bacteria acting as an exogenous source of neuroactive compounds is relatively recent3, 
particularly with regard to disease pathogenesis and pharmacology. Indeed, the study of 
psychobiotics, probiotics capable of producing neuroactive compounds4, as a 
pharmacological delivery vehicle is a rapidly developing research field.  
Many researchers have suggested the gut microbiota functions as an endocrine organ in 
its own right that is capable of regulating host homeostasis both locally within the 
gastrointestinal tract and also at more distally located sites4-8. Notable studies include 
those assessing the microbiota content in lean and obese humans and mice, dysbiosis 
associated with the onset of diabetes, metabolic syndrome, and irritable bowel syndrome 
secondary to acute gastritis9-14. Yet while the role of the gut microbiota in homeostasis is 
on the way to being thoroughly characterised, no steps have yet been taken with respect 
to the urinary microbiota. Our research thus focuses on the ability of Enterococcus 
faecalis, a member of this bacterial community, to influence bladder homeostasis. 
Enterococci are one of the most common causes of urinary tract infection (UTI) and 
asymptomatic bacteriuria (ABU)15-17, yet the virulence properties between UTI and ABU 
strains are similar18-20. Further, patients with recurrent UTI (RUTI) often have ABU 
between symptomatic episodes16, suggesting uropathogens may be capable of mediating 
the host response or sensation perception. Additionally, enterococcal UTI symptoms are 
often characterised as less severe than those of a “classical” E. coli UTI17,21,22. Given the 
role of lipopolysaccharide (LPS) in pain mediation of uropathogenic E. coli (UPEC) 
infection23, study of the Gram-positive E. faecalis bypasses this confounding factor. 
Further, presence of enterococci has been associated with urinary disease states, 
including interstitial cystitis/bladder pain syndrome (IC/BPS), neurogenic bladder and in 
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the majority of non-symptomatic patients with a history of RUTI, while absence is 
associated with health16,24-27. 
There is a precedent for lactic acid bacteria to interact with the nervous system through 
production or utilisation of neuroactive substances, such as γ-aminobutyric acid 
(GABA)3,28,29. Production of GABA has been demonstrated for a variety of bacteria 
including, Bifidobacterium sp., Enterococcus sp., Lactobacillus sp., Leuconostoc sp, 
Streptococcus sp., Listeria monocytogenes, and Pseudomonas aeruginosa30-35. In 
bacteria, the functional role of GABA varies; for example, L. monocytogenes and 
Lactobacillus brevis produce GABA in response to acid stress36,37, while GABA is a 
quorum sensing molecule for P. aeruginosa38. In humans, GABA functions as the 
primary inhibitory neurotransmitter, is involved in antinociception, and has been 
documented to inhibit nerve-mediated detrusor contraction of isolated detrusor strips39-42. 
In this chapter, through a targeted metabolomics approach using solid-phase 
microextraction coupled with liquid chromatography-tandem mass spectrometry (SPME-
LC-MS/MS) we assessed the production of neuroactive compounds by E. faecalis in 
vitro. We hypothesised that E. faecalis can produce neuroactive compounds that block 
the host’s perception of pain or reduce the frequency of bladder contractions, thereby 
allowing the organism to persist undetected. Our approach targeted compounds that had 
previously been detected in urine, produced by other bacterial species and others with 
known neuroactive abilities (Table 4-1).  
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Table 4-1. Neuroactive metabolites for targeted metabolomics. 
Common Name LogP* Molecular Weight 
2-arachidonylglycerol (2-AG) 5.65/5.41 P 378.5454 
3-Methoxytyramine (3-MT)† -0.08 E 167.205 
Acetylcholine (ACh)† -2.9/-4.2 E 146.2074 
Agmatine† -1/-1.2 P 130.1915 
Androsterone 3.69 E 290.4403 
Angiotensin-II (Ang-II) -0.8/-5.3 P 1046.1786 
Dopamine (DA)† -0.98 P 153.1784 
Epinephrine (EPI)† -1.37 E 183.2044 
Glycine -3.21 E 75.0666 
Histamine -0.70 E 111.1451 
L-aspartic acid (aspartate) -3.89 E 133.1027 
L-glutamic acid (glutamate) -3.69 E 147.1293 
L-lysine -3.05 E 146.1876 
L-phenylalanine -1.38 E 165.1891 
L-proline -2.54 E 115.1305 
L-serine -3.07 E 105.0926 
Melatonin 1.42/1.15 P 232.2783 
N-arachidonoyl dopamine (NADA) -2.9/-4.1 P 160.1711 
Norepinephrine (NE)† -1.24 E 169.1778 
Progesterone 3.87 E 314.4617 
Resveratrol 2.57/3.4 P 228.247 
Serotonin (5-HT)†‡ 0.21 E 176.2151 
Synephrine -0.45 E 167.205 
Taurine† -2.2/-2.6 P 125.147 
Testosterone 3.32 E 288.4244 
Thiamine -2.1/-3.1 P 265.355 
Tryptamine† 1.55 E 160.2157 
Tyramine† -0.14/0.68 P 137.179 
β- phenethylamine (β-PEA) 1.41/1.39 E 121.1796 
γ-aminobutyric acid (GABA) † -3.17 E 103.1198 
γ-hydroxybutyric acid (GHB) -0.6/-0.51 P 103.0966 
*LogP values are differentiated as either predicted (P) or experimental (E) according to 
the Human Metabolome Database43-45. 
†Metabolites were included in quantitative experiments. 
‡Serotonin was not included in the exploratory metabolomics experiments. 
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4.2 Materials and methods 
4.2.1 Bacterial strains and urothelial cell lines 
Bacterial strains used throughout these experiments are listed in Table 4-2. Strains were 
routinely cultured without aeration at 37°C, in brain-heart infusion broth (BHI; Difco 
Laboratories Inc., Franklin Lakes, NJ, USA) for E. faecalis and Luria-Bertani (LB) broth 
for E. coli. Experiments were conducted with LB, BHI, BHI supplemented with 0.25% 
yeast extract (Difco; BHYE), and Mclean’s Artificial Urine (AU)46. 
Urinary bladder epithelial cell lines were acquired from the American Type Culture 
Collection (ATCC); 5637’s (ATCC HTB-9) were initially isolated from a 68-year-old 
male with grade II carcinoma, and T24’s (ATCC HTB-4) were isolated from an 81-year-
old female with transitional cell carcinoma. Urothelial cells were maintained in T75 
flasks, in a 5% CO2 tissue culture incubator at 37°C in Roswell Park Memorial Institute 
medium 1640 (RPMI; Gibco, Burlington, ON, CAN) supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Gibco), 2 mM glutamine (Gibco) and penicillin-
streptomycin (Gibco) at 100 U/mL and 100 µg/mL respectively. Supplemented-RPMI 
without the addition of antibiotics will herein be referred to as infection media. 
Cells were routinely passed when confluency reached greater than 80%. To pass cells, the 
monolayer was gently washed with warm phosphate buffered saline (PBS) followed by 
trypsinisation for 5 (T24s) or 10 (5637s) minutes at 37°C and 5% CO2 by addition of 
0.25% trypsin-ethylenediaminetetraacetic acid (EDTA; Gibco). Cells were dislodged 
with gentle tapping and trypsin inactivated by the addition of cell culture media. For cell 
maintenance, cell suspensions were reconstituted 10-fold in a new T75 flask with fresh 
supplemented-RPMI. For experiments, an aliquot of the cell suspension was mixed 1:1 
(v/v) with 0.4% trypan blue (Invitrogen, Carlsbad, CA, USA) and 10 µL of sample 
mixture added to the chamber port of a Countess Cell Counting Chamber Slide 
(Invitrogen) for use with a Countess Automated Cell Counter (Invitrogen). Only viable 
cell counts were considered. Cell suspensions then underwent centrifugation at 3,000 rpm 
for 6 minutes, were reconstituted in infection media, and subsequently seeded to 24-well 
tissue-culture treated plates (Sarstedt, Nümbrecht, Germany) at 1 x 105 cells/mL. Plates 
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were incubated as above until the monolayer reached confluency, at approximately 48 
hours. 
For SPME-LC-MS/MS, HPLC grade acetonitrile, methanol and N,N-dimethylformamide 
(DMF) were purchased from Caledon Labs (Halton Hills, ON, CAN). Non-sterile 
polypropylene 96-well deep well plates and polystyrene-divinylbenzene weak anion 
exchange (PS-DVB-WAX) 80 µm particles were purchased from VWR International 
(Missisauga, ON, CAN); while the Oasis hydrophilic-lipophilic balanced (HLB) 30 µm 
polymeric reversed-phase particles were supplied by Waters (Mississauga, ON, CAN). 
All metabolites were purchased from Sigma-Aldrich (St. Louis, MO, USA). Stock 
solutions of metabolites were prepared at a concentration of 1 mg/mL in methanol or 
water, depending on solubility properties, and stored at -20°C according to the 
manufacturer’s instructions.  
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Table 4-2. Strains used in this study. 
Strain Initial Isolation Source 
E. faecalis 
A256 Urine of patient with RUTI and urosepsis47 Our laboratory 
1131 Uropathogen48 Our laboratory 
1396 Female with UTI49 Our laboratory 
23241 Urine of patient with pyelonephritis50 ATCCa 
29212b Urine51 ATCCa 
OG1X Derivative of oral isolate 2SaR52 Our laboratory 
19433b,c Documentation not available ATCCa 
E. faecium 
19434c Documentation not available ATCCa 
aAmerican Type Culture Collection. 
bStrain often used in quality control testing. 
cType strain53.  
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4.2.2 Bacterial and urothelial co-culture 
Bacteria were prepared for co-infections as follows; overnight broth cultures (stationary 
phase) were reconstituted 100-fold to infection media and incubated to mid-exponential 
phase (4-hours) at 37°C and 5% CO2. Exponential phase cultures were then diluted to a 
final concentration equivalent to a multiplicity of infection (MOI) of 10:1, 50:1, or 100:1 
bacteria per host cell in appropriately supplemented infection media (co-culture). The 
MOI was calculated based on the urothelial cell count from a representative well. Cell 
counts were determined as described above. 
Confluent monolayers were washed three times with warm PBS, followed by the addition 
of 500 µL of the prepared bacterial suspension. Co-cultures were incubated at 37°C and 
5% CO2. 
4.2.3 GABase Assay 
A commercial preparation of GABA transaminase (GABA-T) and succinate 
semialdehyde dehydrogenase (SSDH) from Pseudomonas florescens (GABase; Sigma-
Aldrich) was prepared at a concentration of 2 mg/mL in 75 mM potassium phosphate 
buffer with 25% (v/v) glycerol (pH 7.2); stocks were stored at -20°C. Initial assays were 
completed according to the optimized method of Tsukatani et al.54; 80 mM Tris-HCl 
buffer (pH 9.0) with 750 mM sodium sulfate, 10mM dithiothreitol (DTT), 1.4 mM 
nicotinamide adenine dinucleotide phosphate (NADP+) and 2.0 mM α-ketoglutarate. 
GABase was added to the reactions at a final concentration of 0.3 µg/µL. Reactions were 
kept on ice until optical density (OD) readings; the OD was read every 60 seconds at 340 
nm for 60 minutes at 37°C using an Eon microplate spectrophotometer (BioTek, 
Winooski, VT, USA). The assay was modified by the addition of ethanolamine-O-
sulphate (EOS), a GABA-T inhibitor, allowing for the distinction between GABA and 
succinate semialdehyde55. Stock solutions of assay components and GABA were stored at 
-20°C, except for DTT, which was made fresh for each experiment. 
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4.2.4 SPME-LC-MS/MS 
4.2.4.1 SPME blade preparation 
Stainless steel blades (length, 50 mm; width 2.5 mm; depth, 0.7 mm) were prepared for 
the SPME coating as follows; sonicated with concentrated HCl for 60 minutes, washed 
with nanopure water, and subsequently dried at 180°C for 30 minutes. The final 20 mm 
of the blades was coated in a 50:50 (w/w) mixture of PS-DVB-WAX and HLB in 
polyacetonitrile (PAN) solution using a flask-type sprayer with nitrogen gas source. This 
coating was selected based on the metabolite target list (Table 4-1). The PAN solution 
was prepared by dissolving 10% (w/w) PAN in DMF and heating at 90°C for 60 minutes. 
Coatings were thermally cured at 150°C for 5 minutes, and the coating procedure 
repeated to a final thickness of 80 µm56,57. 
4.2.4.2 Exploratory metabolomics sample preparation 
To determine the bacterial production of neuroactive substances in vitro, stationary phase 
Enterococcus sp. were diluted 1:100 in BHI, BHYE, or LB, and cultures were incubated 
without aeration at 37°C for 3 or 24 hours. At the appropriate time, aliquots were 
centrifuged at 12,000 × g for two minutes at room temperature, and the supernatant stored 
at -80°C. To determine if enterococci could induce neuroactive substance production by 
urothelial cells, T24s were exposed to E. faecalis 1131 or 29212 at an MOI of 10, 50, or 
100. Following a 60-minute incubation, the supernatant from three replicates was pooled, 
centrifuged and stored as above. This preliminary experiment was conducted with 
duplicates of the pooled co-culture samples and the 24- and 3-hour bacterial cultures. 
4.2.4.3 Quantitative metabolomics sample preparation 
For quantitation of metabolites, stationary cultures of E. faecalis 1131, 1396, 23241, and 
A256 were diluted 1/100 to LB or AU in triplicate. Cultures were incubated at 37°C, 
without aeration to exponential phase, 3 hours for LB and 6 hours for AU. At the 
appropriate time, 1.8 mL of culture was transferred to an eppendorf, centrifuged at 
12,000 × g for two minutes at room temperature, and 1.5 mL of the supernatant 
transferred to a fresh eppendorf. The supernatant was stored at -80°C until extraction. 
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Prior to centrifugation, an aliquot of each culture was plated on BHI agar to confirm 
culture purity. Media controls were handled under the same conditions as samples. 
Co-culture experiments were completed using 6-well tissue culture treated plates with 
T24s and 5637s seeded at 1 × 105 cells/mL. Exponential phase enterococci were added to 
washed urothelial cells at an MOI of 10 and the co-culture incubated for 1 or 4 hours. 
Urothelial cells that were washed and exposed to fresh media were included as controls. 
Further, all samples and controls, including the calibration curve, were prepared using the 
same batch of media to reduce experimental variance. 
4.2.4.4 High-throughput SPME 
The manual Concept 96-blade SPME device was provided by Professional Analytical 
System (PAS) Technology (Magdala, Germany). The system consists of eight rows of 
blades, which are each composed of 12 thin film pins. The rows are held together by nine 
inter-blade holders, generating a 96-blade SPME system that functions as part of an 
autosampler56. 
Prior to extraction, blades were preconditioned in ethanol and water at a ratio of 7:3 (v/v) 
for 60 minutes with 1000 rpm of agitation. The extraction step then consisted of 1 ml of 
room temperature sample at 1000 rpm for 60 minutes. All target metabolites had 
previously been shown to reach equilibrium with the coating by 60 minutes. The 
extraction was followed by a 20-second wash in 0.1% formic acid at 1000 rpm, which 
functions to remove the particulates and macromolecules from the coating surface. 
Desorption was then performed for 60 minutes in acetonitrile and water at a ratio of 1:1 
(v/v) with agitation. The resulting solution was stored at -80°C until LC-MS/MS analysis. 
A second desorption was performed to clean the blades. 
4.2.4.5 LC-MS/MS conditions 
Chromatographic separation was performed using a Discovery HS F5, 5cm x 4.6mm ID, 
3µm particle size (Supelco, Bellfont, PA, USA) column (Courtesy of the University of 
Waterloo). Mobile phase A consisted of water/acetic acid at 99:1 (v/v) and mobile phase 
B consisted of acetonitrile/acetic acid at 99:1 (v/v); the flow rate was 200 µL/minute. The 
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gradient conditions were as follows; 100% of phase A from 0 to 3.0 minutes, increasing 
the linear gradient to 0% phase A from 3.0 to 25.0 minutes, and an isocratic hold at 10% 
phase A until 34.0 minutes. The column was then re-equilibrated to the starting phase 
over 6 minutes, with a 5-minute hold at 100% phase A. Thus, total run time was 45 
minutes per sample. 
Sample analysis was performed using an API 4000 triple quadrupole mass spectrometer 
(Applied Biosystems, Foster City, CA, USA) equipped with a TurboIonSpray source. A 
CTC PAL autosampler (LEAP Technologies, Carrboro NC, USA) injected 20 µL of 
sample to the LC-MS/MS system. The MS/MS analysis was performed in positive mode 
under multiple reaction monitoring conditions. Analyst software (AB Sciex LP, Concord, 
ON, CAN) was used for data acquisition and processing. 
4.2.5 Urothelial gene expression 
4.2.5.1 RNA extraction and cDNA conversion 
Following either a 1-hour or 4-hour incubation of 5637s with E. faecalis or E. coli, the 
supernatant was removed, and 500 µL TRIzol reagent (Invitrogen) was added to the co-
culture. Following a 5-minute incubation at room temperature, the lysate was 
homogenised by pipetting and transferred to an RNase-free 1.5 mL eppendorf. Cell 
lysates were stored at -20°C until processed using the PureLink RNA MiniKit 
(Invitrogen) as per the manufacturer’s instructions. 
In brief, 200 µL of chloroform (Sigma-Aldrich) was added to the microcentrifuge tube 
and shaken vigorously, followed by an additional 500 µL TRIzol reagent. The solution 
was incubated at room temperature for 3 minutes followed by centrifugation at 4°C and 
12,000 × g for 15 minutes. The upper phase was transferred to a fresh microcentrifuge 
tube, followed by the addition of 100% ethanol (Sigma-Aldrich) at a 1:1 ratio. This 
mixture was then vortexed and transferred to a Spin Cartridge, which was centrifuged at 
room temperature and 12,000 × g for 15 seconds. The column was washed with Wash 
Buffer I. The product was washed twice with Wash Buffer II and eluted in 30 µL RNase-
free water. The resulting RNA was converted to complementary DNA (cDNA) using the 
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High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Unused RNA 
was flash frozen and stored at -80°C. 
4.2.5.2 Quantitative PCR 
Pre-validated quantitative PCR (qPCR) primers were purchased from Sigma-Aldrich 
against a selection of adherens junction proteins and TRPV4 (Table 4-3). Quantitative 
PCR experiments were completed using Power SYBR Green PCR Master Mix (Applied 
Biosystems) on the QuantStudio 5 Real-Time PCR System (Applied Biosystems). Initial 
data analysis and quality control assessment was completed using the QuantStudio 
Design and Analysis Software v1.4.1 (Applied Biosystems). Data is presented as relative 
quantification according to the ΔΔCT method, wherein vehicle treated 5637s were used as 
the comparator with GAPDH, ACTB, and B2M as endogenous controls. 
4.2.6 Statistical analysis 
All experiments were completed in biological and technical triplicates, except the 
exploratory metabolomics experiment, which was completed in duplicate. Results in the 
figures are presented as mean per group ± standard deviation. To test for significance in 
the quantitative metabolite experiments, we analysed the data using one-way analysis of 
variance (ANOVA) followed by Dunnett’s multiple comparisons post hoc tests. 
Urothelial relative gene expression analyses were completed using two-way ANOVA 
followed by Dunnett’s multiple comparisons post hoc tests. Data analysis was completed 
using GraphPad Prism v7.0a for Mac OS X (GraphPad Software, San Diego, CA, USA). 
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4.3 Results 
4.3.1 GABase assay 
To measure GABA production by enterococci, we first needed to optimise an enzyme-
based microtiter plate assay with GABA standards in LB. We were able to increase the 
final absorbance at 340 nm with various adaptations, including the addition of EOS to 
control for succinic semialdehyde in the sample, decrease in reaction temperature, and 
increase in reactants (Figure 4-1). Despite this improvement in absorbance, we were 
unable to achieve the sensitivity levels equivalent to urinary GABA concentrations, 
which ranges between 0.543 µg/mL (5.27 µM) and 67-179 ng/mL (0.65-1.7 µM)58,59. 
4.3.2 Exploratory SPME-LC-MS/MS 
Given our issues with the lack of sensitivity of the GABase assay for our requirements, 
we altered our methodology to utilise a mass spectrometry approach which gave us the 
opportunity to target a variety of metabolites, rather than just one per assay (Table 4-2). 
In a preliminary screening analysis of our bacterial supernatants using the high-
throughput LC-MS/MS, we elected not to include standard curve of various metabolites, 
nor did we include internal standards to maximum the number of samples that could be 
screened. Our aim was to narrow our metabolite target list, strains, and conditions for 
future experiments. Data was therefore analysed as the average change in analyte peak 
area relative to the media control. The results were not quantitative; however, we based 
our preliminary analysis on the assumption that a higher analyte peak area in the samples 
relative to controls correlated with bacterial and/or urothelial production of the metabolite 
of interest. 
Bacterial production of tyramine was demonstrated in the supernatant of all E. faecalis 
strains cultured in LB, BHI, or BHYE at both 3 and 24 hours (Figure 4-2). Enterococcus 
faecium 19434 did not produce tyramine at 3 hours in BHYE and produced less tyramine 
than the E. faecalis strains at 3 hours in BHI and LB. Other biogenic amines, including, 
dopamine (DA), norepinephrine (NE), epinephrine (EPI), 3-methoxytyramine (3-MT), 
tryptamine, and histamine (HIS) were also detected at higher concentrations in samples 
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than media controls. Production of the amino acids proline, aspartate, glutamate, 
phenylalanine, and lysine was demonstrated under most conditions. Interestingly, a 
subset of samples appeared to be producing angiotensin-II (Ang-II), resveratrol, 
synephine, γ-hydroxybutyric acid (GHB), β-phenethylamine (β-PEA), and GABA. 
Further, culture in LB was associated with production of a wider variety of metabolites 
than BHI or BHYE and profiles were generally quite similar between the 3 and 24-hour 
time points. 
Co-culture of E. faecalis 29212 or 1131 with T24s was associated with production of 
proline, tyramine, glutamine, GHB, agmatine, tryptamine and acetylcholine (ACh) when 
compared to the supernatant of T24s that were not exposed to bacteria (Figure 4-3). 
Analyte peaks were generally lower in the co-cultures than pure cultures. Resveratrol, 
synephrine, DA, phenylalanine, and lysine were not produced by enterococcal-urothelial 
cell co-culture. Similarly, signals were detected from standards but not samples for; 2-
arachidonoylglycerol (2-AG), N-arachidonoyl dopamine (NADA), testosterone, 
androsterone, progesterone, and melatonin. 
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Figure 4-3. Exploratory metabolite production by enterococcal-urothelial co-
culture. 
Metabolites were measured via SPME-LC-MS/MS of the supernatant from a T24 
monoloayer exposed to E. faecalis 29212 or 1131 for 1-hour. Enterococci were added at a 
multiplicity of infection (MOI) of 10, 50, or 100 enterococci per T24 cell. Data is 
presented as the log10 transformation of the change in analyte peak area relative to 
untreated T24s of two experiments. Only positive data is presented, relative decreases in 
analyte peak were considered to be 0 for this analysis. 
Abbreviations: 3-MT, 3-methoxytyramine; ACh, acetylcholine; Ang-II, angiotensin-II; 
EPI, epinephrine; GABA, γ-aminobutyric acid; GHB, γ-hydroxybutyric acid; MOI, 
multiplicity of infection; NE, norepinephrine; β-PEA, β-phenethylamine. 
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4.3.3 Quantitative SPME-LC-MS/MS 
Based on the results obtained through our exploratory SPME-LC-MS/MS run we opted to 
focus our efforts on enterococcal production of tyramine, tryptamine, taurine, agmatine, 
NE, EPI, 3-MT, GABA, DA, and ACh, as well as serotonin (5-HT). We restricted our 
enterococcal culture conditions to 3 hours in LB or AU and expanded the co-culture to 
include two cell lines at two time points. We defined the limit of detection (LOD) as 3 
times the signal-to-noise (s/n) ratio and the limit of quantitation (LOQ) as 10 times the 
noise. 
As such, we detected tyramine production by enterococci in AU up to 940 µM (Table 4-
4), and this was significantly higher in supernatant from E. faecalis 1396, 23241, and 
A256 (P = 0.001) relative to the experimental control. We were unable to quantitate 
tyramine in LB cultures; however, tyramine was produced by E. faecalis 1396, 23241, 
and A256 and was not detected in the experimental LB controls or E. faecalis 1131 
supernatant. In our co-culture experiments, the tyramine concentration was not 
significantly higher in supernatant from T24 or 5637 cells exposed to enterococci (Table 
4-5), nor was there production of tyramine when Enterococcus was incubated in infection 
media alone. The data was also suggestive of enterococcal production of tryptamine; 
however, this trend was not statistically significant. Agmatine, EPI, GABA, NE, and 
taurine were not detected in any of the samples above the LOD. Similarly, ACh was only 
detected in AU and the supernatant from 5637 exposed to E. faecalis A256 for 1 hour, 
while DA was only detected in AU samples. Finally, 5-HT was detected in AU and co-
culture supernatants, but not LB. Enterococcal culture in infection media, without 
urothelial cells, was included in the experiment to differentiate between enterococcal 
production of metabolites in response to urothelial cells or culture media; however, 
concentrations of metabolites were not significantly increased in samples realative to 
experimental blanks. 
4.3.4 Urothelial response to bacteria 
Given that the host response to bladder infection involves shedding of umbrella cells and 
transient receptor potential cation channel subfamily V member 4 (TRPV4) have been 
212 
 
linked with adherens junctions (AJs)60, we assessed the effect of enterococcal and E. coli 
infection on expression of AJ proteins and TRPV4. Expression of TRPV4, α-catenin 
(CTNNA1), β-catenin (CTNNB1), γ-catenin (junction plakoglobin, JUP), and E-cadherin 
(CDH1) was unchanged following both the 1 and 4 hour incubations (Figure 4-4). 
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Figure 4-4. Urothelial gene expression of adherens junction proteins in response to 
bacterial infection. 
Urothelial gene expression of adherens junction proteins was assessed by qPCR 
following either a 1-hour (black bars) or 4-hour (grey bars) exposure to E. faecalis (1131 
or A256) or E. coli (CFT073 or UTI89). Expression of TRPV4 (A), CTNNA1 (B), 
CTNNB1 (C), JUP (D), and CDH1 (E) is presented relative to vehicle controls. 
Experiments and qPCR reactions were completed in triplicate. Means from at least three 
different experiments are shown with significance. Significance was determined against 
the vehicle control using two-way ANOVA with Dunnett’s multiple comparisons test.  
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4.4 Discussion 
Given the recent studies demonstrating the links between oral administration of GABA-
producing lactic acid bacteria with resultant decreases in anxiety and depression-like 
symptoms in mice3,4,61; we postulated that enterococci produce neuroactive substances in 
the bladder. These metabolites, in turn, would decrease bladder contractions, which are 
associated with urgency and frequency, and host perception of pelvic pain and/or dysuria. 
Initial experiments targeted only GABA; however, we transitioned to mass spectrometry 
methods to increase sensitivity, which also corresponded with expansion of the target list. 
The application of SPME-LC-MS/MS to enterococcal cultures indicated a variety of 
metabolites were being produced. Using a refined list of target metabolites, we then 
quantified the enterococcal production of tyramine at concentrations up to 940 µM in 
AU.  
Approximately 5% of patients meeting the laboratory diagnostic criteria for UTI are 
symptom-free - by definition, these patients have ABU62. The molecular mechanisms 
responsible for the differences in these two states are not understood, although it is well 
documented that ABU isolates demonstrate similar virulence properties to UTI isolates18-
20. The traditional assumption is that UTI-associated pain is a consequence of bladder 
inflammation; however, a murine model of UPEC UTI indicates this is not the case23. 
Using this model, researchers were unable to correlate bacterial load or inflammation 
with pain. Rather, LPS-activation of toll-like receptor 4 induced pain independent of 
neutrophil-induced inflammation. Patients with ABU, who by definition are not 
symptomatic, often have pyuria62,63, indicating that inflammation alone is not sufficient to 
mediate pain. This change in our understanding of pain modulation in UTI raises 
interesting avenues of exploration. Indeed, if UPEC-associated pain is not correlated with 
bacterial load or inflammation, but is induced by LPS, how do Gram-positive bacteria, 
such as E. faecalis, induce bladder pain and how do they mitigate the symptoms of UTI? 
Contrary to popular belief, many classical neurotransmitters and neuromodulation 
systems are found outside of the nervous system in eukaryotes. Indeed, communication 
between the nervous and immune system is dependent on many such factors. For 
example, Substance P is the primary pain signal in the nervous system, yet also 
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modulates inflammation within the immune system64. This highlights a key interplay 
between these two systems in infectious states; signalling to the brain that there is 
something wrong (pain) and initiating the immune response to foreign invasion through 
recruitment of neutrophils65. While neuroactive substances are primarily active within the 
central, peripheral, and enteric nervous systems, there is plenty of research suggesting 
such molecules are active in other tissues as well. Many receptors involved in neural 
transmission are present, and active, within non-neuronal tissues of the bladder66-70. 
The initial experimental design involved the application of an enzyme-based microtiter 
plate assay for the measurement of GABA produced by enterococci. This method is 
dependent on the “in series” enzymatic reactions of GABA-T and SSDH (GABase), of 
which the final products are succinate, NADPH, and H+ (Figure 4-1, D). Absorbance is 
measured at 340 nm, and the NADPH-mediated increase in absorbance is assumed to 
directly correlate with the concentration of GABA in the sample54; however, this does not 
account for any succinic semialdehyde present in the sample and could lead to inaccurate 
results (data not shown). To overcome this, we repeated our experiments, using GABA 
standards in LB with EOS, an inhibitor of GABA-T (Figure 4-1, A)55. As expected, the 
addition of EOS to the GABase reaction decreased absorbance and provided a method to 
measure the contribution of succinic semialdehyde to the reaction. We then moved 
forward with reaction optimisation as the change in absorbance between negative 
controls, such as water, and 10 mM GABA was less than 0.4 in our standard runs. 
Reaction optimisation included; decreasing the temperature to 30°C, replacing the 
reducing agent (DTT) with β-mercaptoethanol, incorporation of 0.1 M EDTA to stabilise 
DTT, and increases in the reactants, α-ketoglutarate and NADP+ from 2 and 1.4 mM, 
respectively, to 4 and 3 mM. Given that optimal growth conditions for P. fluorescens, 
which is the source of the GABase, are between 25°C and 30°C, the inverse relationship 
between absorbance and temperature was expected (Figure 4-1, B). Increases in α-
ketoglutarate and NADP+ were also associated with increased absorbance (Figure 4-1, 
C). For measurement of GABA, it is key that other reactants, such as α-ketoglutarate and 
NADP+ are present in the reactions in excess and that GABA is the limiting factor. 
Unfortunately, despite numerous attempts and experimental permutations, we were 
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unable to achieve assay sensitivity equivalent to urinary GABA concentrations. Indeed, 
we were unable to detect GABA below 100 µM and urinary GABA has been measured in 
the range of 0.543 µg/mL (5.27 µM) and 67-179 ng/mL (0.65-1.7 µM)58,59. 
Given our desire for a more sensitive method, we transitioned to LC-MS/MS and 
increased our target list (Table 4-1). The target list was developed based on a thorough 
review of the literature for neuroactive substances that had previously been documented 
as produced by bacteria, were known to have effects on the bladder or urothelium, or had 
been detected in human urine. Notably, Table 4-1 does not include all of the molecules 
identified through this search, but rather a subset of the list based on compound 
availability, extraction using SPME blades coated with PS-DVB-PAN:HLB (50:50), and 
identification by LC-MS/MS. Given its high-throughput nature, requirements for small 
sample volume and high sensitivity71, we selected SPME as the extraction method. 
Further, our collaborators had recently demonstrated quantitation of DA, GABA, 5-HT, 
and glutamate by SPME in the range of 20-35 pg/mL from rat brain tissue and synthetic 
cerebral spinal fluid, as well as successfully applied SPME to E. coli metabolomics57,72,73. 
The initial SPME-LC-MS/MS experiments were conducted primarily to narrow our 
research focus. Thus we completed these experiments without an extraction standard 
curve or internal standards. While this meant we sacrificed quantitative capabilities, we 
were able to analyse more conditions, which was key to identifying Enterococcus strains 
for further experimentation. This significantly limited the conclusions we could take from 
the data; however, we assumed that a higher analyte peak area in samples relative to 
controls correlated with production of the metabolite of interest and used this as a 
baseline for later studies. 
Based on these assumptions, the data is indicative of E. faecalis production of tyramine 
under most of the conditions assayed. This was expected as tyramine production, through 
the decarboxylation of tyrosine, is a defining characteristic of E. faecalis74-84. Enterococci 
also appeared to be producing DA, NE, EPI, 3-MT, histamine (HIS), and tryptamine 
under most conditions, and resveratrol, synephrine, GHB, Ang-II, β-PEA, and GABA in 
a subset of samples. In addition to tyramine, E. faecalis production of agmatine, DA, β-
219 
 
PEA 5-HT, tryptamine, and HIS has previously been documented77-86. Interestingly, 
culture in LB was associated with the production of a wider variety of metabolites than 
BHI or BHYE, which may be a reflection of nutrient availability, as LB is the least 
nutrient-rich of the three media. Enterococcal co-culture with T24s suggested enterococci 
produced, or induced host-production of, proline, glutamine, GHB, ACh, tyramine, 
tryptamine, and agmatine. Interestingly, the analyte peaks were generally lower in the co-
cultures than pure cultures, which may be a result of a shorter incubation time (1 vs 3 or 6 
hours), a measure of the enterococcal response to FBS, or linked to the increased nutrient 
value. That this decreased signal is indicative of the urothelial response to abnormal 
metabolite concentrations is unlikely, as E. faecalis growth in infection media was 
assessed in the quantitative experiments and demonstrated a similar trend. 
In contrast, 2-AG, NADA, testosterone, androsterone, progesterone, or melatonin were 
not detected; however, we cannot rule out bacterial production of these analytes as we did 
not include extraction controls, and the method had not been assessed for extraction from 
infection media at this time. Method validation in infection media and AU was completed 
at the time of quantitative metabolomics. Further, lack of signal may indicate that 
enterococci do not produce these compounds under these culture conditions, that they 
were produced below the limit of detection, or that they failed to bind the extraction 
interface in the complex media. 
Accordingly, we narrowed our metabolite list for further study to; DA, NE, EPI, 3-MT, 
5-HT, ACh, tyramine, taurine, tryptamine, and agmatine (Table 4-1). Based on the higher 
occurrence of neuroactive molecules in the LB samples, we opted to repeat the 
experiments using LB and AU, which are significantly less nutrient-rich than BHI and 
BHYE. Interestingly, the quantitative metabolomics experiments demonstrated 
significant enterococcal production of tyramine. For example, E. faecalis 23241 produced 
940 µM in AU, which correlates to between approximately 190 and 3000 times the 
average concentration of tyramine in human urine87-89. Due to issues with the standard 
curve, we were unable to quantitate tyramine in LB. 
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Tyramine production by E. faecalis is an acid resistance mechanism and has been 
suggested to contribute to supplemental energy acquisition90-92. This may explain why we 
were able to measure tyramine production in AU, but not infection media, as the 
expression of tyrosine decarboxylase, which catalyses the formation of tyramine, is 10-
fold upregulated at pH 5 relative to pH 791. For perspective, the pH of AU is 5.846, while 
the pH of infection media is 8.2. 
Given that most studies on enterococcal production of tyramine are completed from a 
food science perspective, little information is available about the implications of 
microbial tyramine production in humans or how this contributes to endogenous tyramine 
concentrations. Interestingly, in vitro study of Enterococcus durans has demonstrated 
enterococcal production of tyramine under conditions stimulating gastrointestinal transit 
and linked both immunomodulation of, and increased attachment to, enterocytes via 
tyramine production93. This mechanism of tyramine-induced attachment to the 
gastrointestinal luminal surface has been shown for multiple bacterial species94-97. The 
concentrations of tyramine assessed in these studies (10 - 1000 µM) correlates with the 
concentrations we determined in AU, suggesting this may be a mechanism by which 
enterococci promote polymicrobial UTI.  
In humans, tyramine is recognised as a neuromodulator and has been shown to modulate 
GABA, ACh, DA, 5-HT, and NE signalling through activation of trace amine-associated 
receptor (TAAR) 1 and 298-101. To the best of our knowledge, no studies have assessed 
the impact of intravesical instillation of tyramine or TAAR1/2 agonists, yet TAAR1 is 
highly expressed in the urothelium102,103. Study of TAARs is compounded by a number of 
factors, including low basal expression levels, lack of sensitive and specific human 
TAAR antibodies, lack of a single consensus ligand, and high inter-species variability 
and ligand promiscuity100,101,104-106. No data is available on TAAR2 expression in the 
bladder. 
Although most tyramine research has focused on its neuromodulatory functions, the study 
of tyramine-induced detrusor strip contraction suggests the contractile action may be 
nonadrenergic in guinea-pigs and rabbits107,108. With regard to human health, levels of 
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tyramine in cheese have been extensively studied as ingestion of high concentrations can 
trigger hypertensive crises in people taking monoamine oxidase (MAO)-inhibitors, an 
effect that is mediated through the increased release and inhibited reuptake of NE, DA, 
and 5-HT90,109. Further, urinary tyramine is increased in IC/BPS patients relative to 
healthy controls, and increased tyramine concentrations have also been correlated with 
diseases characterised by pain, such as migraine110,111. 
Co-culture samples were not associated with increased production of tyramine, or any of 
the metabolites analysed. Further, while the data was suggestive of tryptamine 
production, this was not significantly higher in samples relative to media controls. 
Indeed, our quantitative results present an interesting contrariety; the noise was 
determined as the average analyte peak area of matrix blanks and the LOD of detection as 
three times the s/n ratio, yet experimental blanks, which were handled alongside samples, 
gave signals significantly higher than the LOD, some of which were above the LOQ. All 
experimental blanks were confirmed as sterile prior to storage at -80°C, thus, explaining 
this discrepancy as contamination is unlikely. Further, all matrix blanks and samples were 
from the same media batch. Thus variance due to media preparation can also be ruled out. 
It is possible that the storage conditions induced breakdown of the metabolites in the 
matrix blanks, thus artificially reducing the s/n ratio. Alternatively, the metabolites may 
be present at such low concentrations, that noise and signal are indistinguishable by this 
methodology. 
Prior to the exploratory metabolomics experiments, the SPME-LC-MS/MS method was 
validated in terms of linearity, sensitivity, LOD and LOQ, in PBS and LB, wherein the 
LOD and LOQ were in the range of 0.1-3 and 0.4-9 ng/mL, respectively. However, the 
method was not validated for BHI, BHYE, or infection media, which may explain some 
of the discrepancies between the exploratory and quantitative experiments. Further, the 
exploratory experiments were assessed as the relative increase in analyte peak area 
relative to the appropriate control, not as a factor of the s/n ratio. 
To measure the bladder’s response to tyramine, and the other metabolites, we obtained a 
human bladder smooth muscle cell line (T4091; Applied Biological Materials Inc., 
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Richmond, BC, CAN), which had previously been reported to contract in response to the 
muscarinic agonist bethanechol112. The authors of the original report, and the company, 
stated that these cells maintained contractile and smooth muscle cell properties beyond 50 
passages. However, this was not the case, as the cells did not contract in response to 
bethanechol (data not shown) and this was later confirmed by the supplier. Thus, we 
transitioned to the measurement of the urothelial response to bacterial metabolites, using 
a commercial fluorescent calcium assay, originally been acquired to measure calcium 
influx of the contracting the smooth muscle cells. Unfortunately, downstream effects for 
most, if not all, of our metabolite targets involved calcium influx (data not shown), 
indicating this assay lacked specificity for our purposes without the inclusion of specific 
agonists or antagonists. 
Finally, we assessed the potential for enterococci to differentially regulate the expression 
of TRPV4 and adherens junction (AJ) proteins in vitro. Urothelial expression of the 
transient receptor potential (TRP) superfamily of ion channels has been well 
characterised113,114, and activation of TRPV4 by mechanical, chemical, and osmotic 
stimuli, such as cell swelling, shear stress, and anandamide, increases intracellular 
Ca2+115,116. Urothelial co-localisation experiments demonstrate that TRPV4 interacts with 
AJs through α-catenin and that this complex is located between umbrella cells in human 
and murine bladders60. In brief, the C-terminus of TRPV4 is coupled to α-catenin, which 
interacts directly with the actin cytoskeleton and indirectly with E-cadherin through β- or 
γ-catenin (Figure 4-5). It has been proposed that this is a mechanism by which TRPV4 
responds to bladder stretch60. 
Interestingly, cyclophosphamide-induced cystitis in rats is associated with decreased 
TRPV4 expression within the urothelium and detrusor 4 hours post-treatment, yet in a 
chronic model, TRPV4 expression was increased113. To determine if bacteria could elicit 
a similar response, we exposed 5637s to E. faecalis or E. coli for 1 or 4 hours and 
measured relative gene expression. However, we did not note changes in relative 
expression for any of the genes assayed. Unlike our quantitative metabolomics 
experiments, which used both T24 and 5637s, these experiments were only completed 
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with 5637s. T24s do not express E-cadherin, α-, β-, or γ-catenin, while 5637s express all 
four AJ proteins117. 
4.4.1 Conclusions 
In conclusion, tyramine is produced by enterococci cultured in AU at concentrations 
significantly higher than encountered in the urine of healthy individuals. Further, TAAR1 
is expressed within the urothelium, indicating that the bladder is capable of responding to 
bacterial production of this metabolite. We attempted to measure the urothelial response 
to tyramine, and the other target metabolites, through a number of avenues, including 
metabolite-induced or inhibited contraction of a human bladder smooth muscle cell line 
in vitro and visualisation of calcium influx in urothelial cells. However, the commercially 
available smooth muscle cells had lost their contractile properties, and calcium influx as 
an assay of urothelial cells lacks specificity without the inclusion of specific agonists or 
antagonists. Thus, the urothelial response to enterococcal tyramine remains to be 
demonstrated. Further, while, chemically induced cystitis disrupts TRPV4 expression 
within the urothelium in a rat model, the same cannot be said for bacterial interactions 
with urothelial cells in vitro. 
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Figure 4-5. Hypothetical model of TRPV4 interactions with adherens junctions. 
The TRPV4 response to bladder stretch is believed to be mediated through interactions 
with adherens junctions (AJs), leading to Ca2+ influx. The C-terminus of TRPV4 is 
coupled to α-catenin, which interacts directly with the actin skeleton and indirectly with 
E-cadherin via either β- or γ-catenin. This figure has been modified from Janssen et al.60. 
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Chapter 5  
5 General discussion 
Urinary tract infection (UTI) pathogenesis has been extensively characterised with regard 
to Escherichia coli; however, non-E. coli UTI receives much less attention. This is 
understandable given that E. coli is the aetiological agent in the vast majority of UTIs. In 
contrast, Enterococcus faecalis is the least likely uropathogen to meet standardised 
diagnostic criteria1. In addition to monomicrobial UTI, E. faecalis is a major player in 
polymicrobial UTI2-5, wherein enterococci increase the virulence and reduce host 
clearance of other bacterial species6-9. However, polymicrobial UTI is likely under-
diagnosed, as most polymicrobial urine samples are considered contaminated. This fact, 
in combination with the decreased likelihood of enterococcal infections meeting 
diagnostic criteria, suggests enteorococcal UTI may often be missed. 
The purpose of this thesis was to increase understanding of enterococcal UTI, in 
particular the response of Enterococcus to antibiotic prophylaxis in vitro and in vivo and 
enterococcal communication with the bladder. Within this thesis we demonstrated 
increased enterococcal virulence in response to growth inhibitory concentrations of 
nitrofurantoin in vitro, but not trimethoprim-sulfamethoxazole (TMP/SMX). This 
increased virulence did not correlate with increased expression of virulence factors, but 
was correlated with increased expression of three putative genes. We then explored 
whether this corresponded to alterations in bacterial communities throughout antibiotic 
prophylaxis for paediatric patients with recurrent UTI (RUTI). Our bacterial culture 
results indicated uropathogens were present in the urine of children with and without a 
history of RUTI and that antibiotic prophylaxis induced a transient decrease in 
uropathogen load. Interestingly, none of our patients were experiencing symptomatic UTI 
at the time of urine sample collection, yet a significant proportion of midstream (MS) 
urine samples met the clinical threshold for UTI, indicating these patients had 
asymptomatic bacteriuria (ABU). Further, E. faecalis bacterial load was positively 
correlated with non-E. coli uropathogens, suggesting some patients may be pre-disposed 
to polymicrobial UTI. In an effort to elucidate mechanisms by which enterococci can 
236 
 
mask the host’s perception of UTI, we completed targeted metabolomics of neuroactive 
molecules in vitro under conditions mimicking the bladder environment. Our results 
suggest Enterococcus may produce tyramine in the bladder at concentrations that are 
likely to have a physiological effect on both urothelial cells and cohabiting bacteria, 
potentially leading to the development of asymptomatic infections, and prevalence of 
polymicrobial UTI commonly observed with E. faecalis infection. 
 A main tenet of this thesis was to assess whether antibiotic prophylaxis is an appropriate 
and effective therapeutic strategy for the treatment and prevention of RUTI. The increase 
in antimicrobial resistance trends, especially among Enterococcus sp., is concerning and 
indicates unnecessary antibiotic use should be restricted. Therefore, we assessed the 
effect of nitrofurantoin and TMP/SMX on bacterial attachment to urothelial cells in 
Chapter 2. Attachment is the first step to successful bacterial colonization of the bladder, 
and prevention or downregulation of this virulence trait will presumably decrease 
bacterial colonization rates and subsequent development of UTI. Coincidentally we 
identified a significant increase in the attachment of both E. faecalis and E. coli to 
urothelial cells at the minimal inhibitory concentration (MIC) of nitrofurantoin, but not 
TMP/SMX. To understand this phenotype better, we assessed the gene expression of 
classical E. faecalis adhesion and colonization factors, along with other genes that had 
been previously documented as differentially regulated under antibiotic stress or by 
growth in pooled human urine relative to laboratory growth medium10-13. 
Contrary to the expected results, nitrofurantoin exposure decreased the expression of 
adhesion and colonization factors. Notably, we also documented an increase in the 
relative expression of two putative MDR efflux pumps, EF1732 and EF1733, as well as a 
putative DNA repair exonuclease, EF0972. Given that increased relative gene expression 
has been previously demonstrated for these loci in response to erythromycin and 
chloramphenicol11,12, two antimicrobials with different mechanisms of action compared 
to nitrofurantoin, we can assume that these gene products may be involved in either 
antibiotic-associated stress, or more general stress responses. Therefore, we believe 
EF1732, EF1733, and EF0972 may represent potential new antibiotic targets, particularly 
for use in tandem with the aforementioned antimicrobials. Application of such a 
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therapeutic strategy may decrease the rate of antibiotic resistance development, 
prolonging the clinical lifespan of these drugs. 
The observation of increased enterococcal attachment in the presence of MIC 
nitrofurantoin is concerning and was a driving force behind the clinical study described in 
Chapter 3. The pilot study we conducted recruited less children receiving nitrofurantoin 
(n = 7) than we had hoped; the remainder received TMP/SMX or were clinically 
observed. However, we were able to demonstrate the presence of bacteria in urine 
regardless of antibiotic status and in the urine of both healthy and RUTI patients. Despite 
the fact that none of the patients were symptomatic at the time of urine collection, 29% of 
MS urine samples from RUTI patients were indicative of ABU, supporting research that 
suggests patients experience periods of ABU between symptomatic episodes14. 
We collected both first-void (FV) and MS urine from our study population. Clinically, 
MS urine is used to assess bacterial load in the bladder, while FV urine gives an 
indication of urethritis and is used for testing of some sexually transmitted infections, 
such as Chlamydia trachomatis15. As our interest lay within profiling the bacterial 
communities of the urinary tract we included both of these samples in our analysis. 
Additionally, we did not require patients to clean the labia or urethral opening prior to 
urine collection. By not mandating this step we obtained a more accurate representation 
of the bacterial community associated with all aspects of the lower urinary tract. Bacteria 
in this environment were considered sources of UTI, given that UTIs are initiated by 
fecal ascension up the urethra16. Further, transient exposure of E. coli intracellular 
bacterial communities (IBCs) to vaginal Gardnerella vaginalis induces E. coli egress and 
subsequent UTI17, which highlights the importance of profiling the urethra and labial 
surfaces as UTI reservoirs. 
With regards to antibiotic efficacy, prophylaxis appeared to be associated with a transient 
decrease in bacterial load that returned to pre-prophylaxis levels following cessation of 
therapy. Other studies suggest 50% of women will develop symptomatic UTI within 3 
months of discontinuing prophylaxis18, indicating the long-term effects of prophylaxis are 
ineffective for these patients.  
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Surprisingly, we noted a significant decrease in the levels of urinary interleukin-6 (IL-6) 
in RUTI patients relative to healthy controls. The suggestion that IL-6 is depressed in 
patients raises two possibilities, the first being a genetic basis for the lack of response, 
and the second that bacteria are producing molecules that inhibit the immune response. A 
recent study supports this, whereby E. faecalis suppressed NF-κB-driven responses in 
macrophages and promoted polymicrobial catheter-associated UTI9. Of note, the secreted 
molecule(s) responsible for this effect has yet to be identified. 
Moving forward, we explored the potential for E. faecalis to mask the host’s perception 
of UTI in Chapter 4, which may contribute to its ability to influence the development of 
polymicrobial UTI, through the use of mass spectrometry. Our target list included a 
selection of classic neurotransmitters, biogenic amines, amino acids, and a variety of 
neuromodulators. In doing so, we identified the production of tyramine by E. faecalis 
under conditions simulating human urine. Given high levels of trace amine-associated 
receptor 1 (TAAR1) within the urothelium19,20, we theorise that this activity is 
biologically relevant, and that the bladder is able to respond to this bacterial production 
of tyramine. 
Throughout this thesis we have referenced human studies, where possible; however, 
when human studies were not available, or were in contrast with animal studies, we have 
attempted to highlight that information. This is because of the extent of species variation 
within the systems activated by neuroactive substances. For example, the β-adrenoceptor 
(β-AR) subtype involved in detrusor relaxation varies between species; humans and pigs 
rely on β3-AR for mediation of detrusor relaxation, rabbits on β2-AR, and rats on all three 
subtypes21. Similarly, in a rat model of bladder obstruction, expression of α1-AR subtypes 
differed between control and obstructed animals; α1A-AR was the predominant subtype in 
healthy rats and α1D-AR predominant in obstructed rats22. Yet in humans with bladder 
obstruction there is no change in α1-AR subtype expression relative to healthy controls23. 
Given that α1-AR subtypes are characterised by agonist affinity24, such changes have the 
ability to significantly alter the host response. Species variation is also noted for trace 
amine-associated receptors (TAARs); human TAAR1 is responsive to tyramine, β -PEA, 
and DA, yet unresponsive to NE, EPI, or 5-HT25-27. In contrast, TAAR1 from the rhesus 
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monkey responds to tyramine, β –PEA, and DA in a similar manner to the human 
TAAR1, yet also responds to NE and 5-HT28. Anatomically, muscularis mucosae is 
present in the human and guinea pig bladder, yet is not morphologically evident in the 
rat, rabbit, cat, or dog29-31. Although, these differences may seem small, their impact is 
potentially huge when considering that urine contains over 3000 metabolites32, many of 
which modulate the expression and effects of others. 
In principle, the ideal animal model for bacteria-bladder interactions is a “unicorn”; the 
immense complexity associated with urinary bladder signaling, suggests this is unlikely 
to exist. Animal models are useful, and indeed have been referenced throughout this 
thesis; yet the application of these models to the study of microbiota and/or bacterial-host 
interactions within the urinary tract should be considered carefully. 
5.1 Future directions 
Alternatively, we suggest the use of human bladder tissue in Ussing chamber systems. In 
brief, Ussing systems consist of a chamber and perfusion system, the chamber is filled 
with a physiologically relevant solution and separated by an epithelial or tissue layer. 
Each hemichamber is distinct and corresponds to either the luminal or serosal surface of 
the epithelium or tissue layer. The epithelial response to electrical, chemical or 
mechanical stimuli can then be measured as diffusion between the chambers, basolateral 
or apical release of chemicals, and alterations in electrophysiology, including 
transmembrane voltage, transepithelial electrical resistance (TER), and short circuit 
current. Ussing chambers have been effectively applied to study of the urothelium, 
providing measurements of ATP release, membrane capacitance, and alterations in 
barrier function induced by multiple stimuli, such as distension and osmotic stress33-36. 
Ussing systems have also been used to study bacterial attachment to the gut mucosa 
following addition of chemicals to the luminal or contraluminal hemichambers.  
Notably, addition of tyramine to the luminal surface, at concentrations ranging from 10 to 
1000 µM, dose-dependently increased E. coli attachment to the mucosa by 4- to 16-fold, 
an effect that was mediated through its sympathomimetic properties37-39. Further, this 
effect is not species specific; the same has been demonstrated for Salmonella enterica 
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serovar cholerasuis using ex vivo Peyer’s patches isolated from the porcine jejunum40. 
Interestingly, our targeted metabolomics data (Chapter 4) indicates enterococci produce 
similar concentrations of tyramine in artificial urine, which raises questions about 
whether this relationship exists in the bladder. This mechanism may explain the positive 
correlation between urinary enterococcal load and non-E. coli uropathogens noted in 
Chapter 3. Thus, similar experiments should be completed using human bladder tissue 
and these should include pre-treatment of the luminal aspect with enterococci followed 
by the addition of other uropathogens. Indeed, the mechanisms and pathogenesis of 
polymicrobial UTI are poorly understood; study of the role enterococci play in this 
condition would fill this void. 
Acquisition of human bladder tissue is understandably difficult; however, these 
experiments do not require large tissue segments, and could be sourced through 
urologists completing various surgeries or organ donation upon death. The disclaimer 
being that surgical intervention is not required in those with healthy urinary tracts, thus 
results would need to take into consideration the reason for surgical intervention. For 
instance, expression of cadherin-catenin complexes is highly variable in urothelial cell 
lines isolated from urinary cancers. Given that these complexes are involved in adherens 
junction (AJ) formation41, their dysregulation may be a sign of bladder mucosal 
remodeling. As discussed in the introduction, bladder mucosa remodelling occurs in 
response to chronic UTI, and is characterised by loss of terminal UC differentiation and 
impaired barrier function42-46. Clearly, responses elicited from such tissues may not 
correspond with the response of a healthy bladder. 
Within Chapter 2, we explored the antimicrobial properties of ibuprofen (IBU) and one 
of its major metabolites, carboxyibuprofen (CIBU); however, we were unable to link IBU 
with direct antimicrobial properties in vitro. Neither IBU nor CIBU altered growth of E. 
coli or E. faecalis at biologically relevant concentrations, nor did these molecules effect 
bacterial attachment to urothelial cells. Therefore, we support the conclusions by other 
groups that IBU’s in vivo anti-UTI effects are likely mediated through its anti-
inflammatory properties42,47-49. The contribution of prostaglandins (PGs) to UTI is poorly 
understood, yet the increase in clinical cure rate associated with inhibition of 
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cyclooxygenases (COX)47,49-51, and decrease in intracellular colonisation following COX-
2 inhibition42, indicates PGs play a key role in UTI pathogenesis. Indeed, PGE2 release is 
increased following urothelial exposure to pyocyanin, lipopolyasaccharide (LPS), and 
type-1 fimbriae52,53. Furthermore, urinary concentrations are increased in patients with 
UTI54,55; however, PG concentrations have not been assessed in the urine of patients with 
RUTI between symptomatic episodes. As we have stored aliquots of urine from the 
clinical study described in Chapter 3, future studies have the capability to measure 
urinary PG, and can correlate the bacteriological data with urinary PG concentrations. 
Identification of increased urinary PGs in paediatric patients with RUTI relative to 
healthy controls may provide the impetus for clinical study of IBU for prevention of 
RUTI, rather than just symptomatic therapy. 
The assessment of urinary tyramine in the samples from Chapter 3 is also of interest, 
particularly in samples E. faecalis was isolated from. Such a correlation, in combination 
with our in vitro metabolomics data from Chapter 4, would support our proposed theory 
of tyramine-mediated enterococcal contribution to polymicrobial UTI.  Assessment of the 
host response to tyramine is also of interest, and members of the Burton lab are already 
looking into the expression of monoamine oxidases in response to bacterial exposure. 
Together with experiments using the Ussing system, future studies may be able to 
elucidate mechanisms of enterococcal-influence in polymicrobial infections in UTI. This 
understanding will provide groundwork to expand to other sites of common enterococcal 
infection, and will expand the understanding of enterococcal-host interactions as a whole. 
5.2 Concluding remarks 
Although the focus of this thesis was not polymicrobial UTI, our results suggest E. 
faecalis may contribute more to this state than previously thought. We identified 
enterococci in a large proportion of our clinical samples and further a positive correlation 
between E. faecalis and non-E. coli uropathogens, which our in vitro data suggests may 
be mediated through enterococcal production of tyramine. We also identified 
nitrofurantoin-induced increases in enterococcal attachment to the urothelium. Taken 
together, these data raise interesting questions about the application of nitrofurantoin 
treatment of enterococcal UTI and the efficacy of antibiotic prophylaxis for RUTI. 
242 
 
5.3 References 
1 Armbruster, C. E., Prenovost, K., Mobley, H. L. T. & Mody, L. How often do 
clinically diagnosed catheter-associated urinary tract infections in nursing homes 
meet standardized criteria? J Am Geriatr Soc 63, 395-401 (2017). 
2 Croxall, G. et al. Increased human pathogenic potential of E. coli from 
polymicrobial urinary tract infections in comparison to isolates from 
monomicrobial culture samples. J Med Microbiol 60, 102-109 (2011). 
3 Flores-Mireles, A. L., Walker, J. M., Caparon, M. & Hultgren, S. J. Urinary tract 
infections: epidemiology, mechanisms of infection and treatment optios. Nat Rev 
Microbiol 13, 269-284 (2015). 
4 Stickler, D. J. Bacterial biofilms in patients with indwelling urinary catheters. Nat 
Clin Pract Urol 5, 598-608 (2008). 
5 Tambayh, P. A., Halvorson, K. T. & Maki, D. G. A prospective study of 
pathogenesis of catheter-associated urinary tract infections. Mayo Clin Proc 74, 
131-136 (1999). 
6 Armbruster, C. E. et al. The pathogenic potential of Proteus mirabilis is enhanced 
by other uropathogens during polymicrobial urinary tract infection. Infect Immun 
85, e00808-e00816 (2017). 
7 Tsuchimori, N., Hayashi, R., Shino, A., Yamazaki, T. & Okonogi, K. 
Enterococcus faecalis aggravates pyelonephritis caused by Pseudomonas 
aeruginosa in experimental ascending mixed urinary tract infection in mice. Infect 
Immun 62, 4534-4541 (1994). 
8 Rani, A. et al. Urinary microbiome of kidney transplant patients reveals dysbiosis 
with potential for antibiotic resistance. Transl Res 181, 59-70 (2017). 
9 Tien, B. Y. Q. et al. Enterococcus faecalis promotes innate immune suppression 
and polymicrobial catheter-associated urinary tract infection. Infect Immun, 
doi:10.1128/IAI.00378-17 (2017). 
10 Vebo, H. C., Solheim, M., Snipen, L., Nes, I. & Brede, D. A. Comparative 
genomic analysis of pathogenic and probiotic Enterococcus faecalis isolates, and 
their transcriptional responses to growth in human urine. PLoS One 5, e12489 
(2010). 
11 Aakra, Å. et al. The response of Enterococcus faecalis V583 to chloramphenicol 
treatment. Int J Microbiol 2010, 483048 (2010). 
12 Aakra, Å. et al. Transcriptional response of Enterococcus faecalis V583 to 
erythromycin. Antimicrob Agents Chemother 49, 2246-2259 (2005). 
243 
 
13 Shepard, B. D. & Gilmore, M. S. Differential expression of virulence-related 
genes in Enterococcus faecalis in response to biological cues in serum and urine. 
Infect Immun 70, 4344-4352 (2002). 
14 Cai, T. et al. The role of asymptomatic bacteriuria in young women with recurrent 
urinary tract infections: to treat or not to treat? Clin Infect Dis 55, 771-777 (2012). 
15 Nelson, D. E. et al. Characteristic male urine microbiomes associate with 
asymptomatic sexually transmitted infection. PLoS One 5, e14116 (2010). 
16 Foxman, B. The epidemiology of urinary tract infection. Nat Rev Urol 7, 653-660 
(2010). 
17 Gilbert, N. M., O'Brien, V. P. & Lewis, A. L. Transient microbiota exposures 
activate dormant Escherichia coli infection in the bladder and drive severe 
outcomes of recurrent disease. PLoS Pathog 13, e1006238 (2017). 
18 Mazzulli, T. Diagnosis and management of simple and complicated urinary tract 
infections (UTIs). Can J Urol 19, 42-48 (2012). 
19 Uhlén, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 
(2015). 
20 Human Protein Atlas, < http://www.proteinatlas.org> (2017). 
21 Propping, S. et al. Mucosa of human detrusor impairs contraction and β-
adrenoceptor-mediated relaxation. BJU Int 112, 1215-1222 (2013). 
22 Hampel, C. et al. Modulation of bladder α1-adrenergic receptor subtype 
expression by bladder outlet obstruction. J Urol 167, 1513-1521 (2002). 
23 Nomiya, M. & Yamaguchi, O. A quantitative analyis of mRNA expression of α1 
and β-adrenoceptor subtypes and their functional roles in human normal and 
obstructed bladders. J Urol 170, 649-653 (2003). 
24 Schwinn, D. A. et al. Cloning and pharmacological characterization of human α-1 
adrenergic receptors: sequence corrections and direct comparison with other 
species homologues. J Pharmacol Exp Ther 272, 134-142 (1995). 
25 Lindemann, L. et al. Trace amine-associated receptors form structurally and 
functionally distinct subfamiles of novel G protein-coupled receptors. Genomics 
85, 372-385 (2005). 
26 Borowsky, B. et al. Trace amines: identification of a family of mammalian G 
protein-coupled receptors. PNAS 98, 8966-8971 (2001). 
27 Bunzow, J. R. et al. Amphetamine, 3,4-methylenedioxymethamphetamine, 
lysergic acid aiethylamide, and metabolites of the catecholamine 
244 
 
neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60, 
1181-1188 (2001). 
28 Maguire, J. J. et al. International Union of Pharmacology. LXXII. 
Recommendations for trace amine receptor nomenclature. Pharmacol Rev 61, 1-8 
(2009). 
29 Dixon, J. S. & Gosling, J. A. Histology and fine structure of the muscularis 
mucosae of the human urinary bladder. J Anat 136, 265-271 (1983). 
30 Heppner, T. J., Layne, J. J., Pearson, J. M., Sarkissian, H. & Nelson, M. T. 
Unique properties of muscularis mucosae smooth muscle in guinea pig urinary 
bladder. Am J Physiol Regul Comp Physiol 301, R351-R362 (2011). 
31 Ro, J. Y., Ayala, A. G. & El-Naggar, A. Muscularis mucosa of urinary bladder: 
importance for staging and treatment. Am J Surg Pathol 11, 668-673 (1987). 
32 Bouatra, S. et al. The human urine metabolome. PLoS One 8, e73076 (2013). 
33 Shina, K., Hayashida, K.-I., Ishikawa, K. & Kawatani, M. ATP release from 
bladder urothelium and serosa in a rat model of partial bladder outlet obstruction. 
Biomed Res 37, 299-304 (2016). 
34 Balestreire, E. & Apodaca, G. Apical epidermal growth factor receptor signaling: 
regulation of stretch-dependent exocytosis in bladder umbrella cells. Mol Biol 
Cell 18, 1312-1323 (2007). 
35 Apodaca, G. et al. Disruption of bladder epithelium barrier function after spinal 
cord injury. AM J Physiol Renal Physiol 284, F966-F976 (2003). 
36 Smith, C. P., Vemulakonda, V., Kiss, S., Boones, T. B. & Somogyi, G. T. 
Enhanced ATP release from rat bladder urothelium during chronic bladder 
inflammation: effect of botulinum toxin A. Neurochem Int 47, 291-297 (2005). 
37 Lyte, M. The biogenic amine tyramine modulates the adherence of Escherichia 
coli O157:H7 to intestinal mucosa. J Food Prot 67, 878-883 (2004). 
38 Chen, C., Brown, D. R., Xie, Y., Green, B. T. & Lyte, M. Catecholamines 
modulate Escherichia coli O157:H7 adherence to murine cecal mucosa. Shock 20, 
183-188 (2003). 
39 Green, B. T. et al. Adrenergic modulation of Escherichia coli O157:H7 adherence 
to the colonic mucosa. Am J Physiol Gasterointest Liver Physiol 287, G1238-
G1246 (2004). 
40 Green, B. T., Lyte, M., Kulkarni-Narla, A. & Brown, D. R. Neuromodulation of 
enteropathogen internalization in Peyer's patches from porcine jejunum. J 
Neuroimmun 141, 74-82 (2003). 
245 
 
41 Giroldi, L. A., Bringuier, P.-P., Shimazui, T., Jansen, K. & Schalken, J. A. 
Changes in cadherin-catenin complexes in the progression of human bladder 
carcinoma. Int J Cancer 82, 70-76 (1999). 
42 O’Brien, V. P. et al. A mucosal imprint left by prior Escherichia coli bladder 
infection sensitizes to recurrent disease. Nat Microbiol 2, 16196 (2016). 
43 Mathai, J. C. et al. Hypercompliant apical membranes of bladder umbrella cells. 
Biophys J 107, 1273-1279 (2014). 
44 Hu, P. et al. Ablation of uroplakin III gene results in small urothelial plaques, 
urothelial leakage, and vesicoureteral reflux. J Cell Biol 151, 961-971 (2000). 
45 Hu, P. et al. Role of membrane proteins in permeability barrier function: 
uroplakin ablation elevates urothelial permeability. AM J Physiol Renal Physiol 
283, F1200-F1207 (2002). 
46 Kong, X.-T. et al. Roles of uroplakins in plaque formation, umbrella cell 
enlargement, and urinary tract diseases. J Cell Biol 167, 1195-1204 (2004). 
47 Bleidorn, J., Gagyor, I., Kochen, M. M., Wegscheider, K. & Hummers-Pradier, E. 
Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for 
uncomplicated urinary tract infection? - Results of a randomized controlled pilot 
trial. BMC Med 8, 30-38 (2010). 
48 Vik, I. et al. Ibuprofen versus mecillinam for uncomplicated cystitis - a 
randomized controlled trial study protocol. BMC Infect Dis 14, 693 (2014). 
49 Gágyor, I. et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract 
infection in women: randomised controlled trial. BMJ 351, h6544 (2015). 
50 Bleidorn, J., Hummers-Pradier, E., Schiemann, G., Wiese, B. & Gágyor, I. 
Recurrent urinary tract infections and complications after symptomatic versus 
antibiotic treatment: follow-up of a randomised controlled trial. Ger Med Sci 14, 
Doc01, doi:10.3205/000228 (2016). 
51 Hannan, T. J. et al. Inhibition of cyclooxygenase-2 prevents chronic and recurrent 
cystitis. EBioMedicine 1, 46-57 (2014). 
52 McDermott, C. et al. Alterations in acetylcholine, PGE2 and IL6 release from 
urothelial cells following treatment with pyocyanin and lipopolysaccharide. Tox 
in vitro 27, 1693-1698 (2013). 
53 Chen, T.-C. et al. Regulation of cyclooxygenase-2 expression in human bladder 
epithelial cells infected with type I fimbriated uropathogenic E. coli. Cell 
Microbiol 13, 1703-1713 (2011). 
246 
 
54 Farkas, A., Alajem, D., Dekel, S. & Binderman, I. Urinary prostaglandin E2 in 
acute bacterial cystitis. J Urol 124, 455-457 (1980). 
55 Wheeler, M. A., Hausladen, D. A., Yoon, J. H. & Weiss, R. M. Prostaglandin E2 
production and cylooxygenase-2 induction in human urinary tract infections and 
bladder cancer. J Urol 168, 1568-1573 (2002). 
 
  
247 
 
Appendix A: Content license from Nature Reviews Urology 
  
Title: The microbiome of the urinary
tract[mdash]a role beyond
infection
Author: Samantha A. Whiteside, Hassan
Razvi, Sumit Dave, Gregor Reid,
Jeremy P. Burton
Publication: Nature Reviews Urology
Publisher: Nature Publishing Group
Date: Jan 20, 2015
Copyright © 2015, Rights Managed by Nature
Publishing Group
If you're a copyright.com
user, you can login to
RightsLink using your
copyright.com credentials.
Already a RightsLink user or
want to learn more?
Author Request
If you are the author of this content (or his/her designated agent) please read the following. If you
are not the author of this content, please click the Back button and select an alternative Requestor
Type to obtain a quick price or to place an order. 
Ownership of copyright in the article remains with the Authors, and provided that, when reproducing
the Contribution or extracts from it, the Authors acknowledge first and reference publication in the
Journal, the Authors retain the following non-exclusive rights: 
a) To reproduce the Contribution in whole or in part in any printed volume (book or thesis) of which
they are the author(s). 
b) They and any academic institution where they work at the time may reproduce the Contribution for
the purpose of course teaching. 
c) To reuse figures or tables created by them and contained in the Contribution in other works created
by them. 
d) To post a copy of the Contribution as accepted for publication after peer review (in Word or Text
format) on the Author's own web site, or the Author's institutional repository, or the Author's funding
body's archive, six months after publication of the printed or online edition of the Journal, provided
that they also link to the Journal article on NPG's web site (eg through the DOI). 
NPG encourages the self-archiving of the accepted version of your manuscript in your funding
agency's or institution's repository, six months after publication. This policy complements the recently
announced policies of the US National Institutes of Health, Wellcome Trust and other research funding
bodies around the world. NPG recognises the efforts of funding bodies to increase access to the
research they fund, and we strongly encourage authors to participate in such efforts. 
Authors wishing to use the published version of their article for promotional use or on a web site must
request in the normal way. 
If you require further assistance please read NPG's online author reuse guidelines. 
For full paper portion: Authors of original research papers published by NPG are encouraged to submit
the author's version of the accepted, peer-reviewed manuscript to their relevant funding body's
archive, for release six months after publication. In addition, authors are encouraged to archive their
version of the manuscript in their institution's repositories (as well as their personal Web sites), also
six months after original publication. 
v2.0
248 
 
Appendix B: Ethical approval for clinical study 
 
249 
 
 
  
250 
 
Appendix C: Clinical study documentation 
Letter of Intent 
 
Version Date:  June 6, 2014 Page 1 of 5 Initials: ________ 
 
 
 
Western                             
 
Recurrent urinary tract infections in children: Bacterial 
identification, antibiotic susceptibility profiling and cytokine 
levels associated with antibiotic prophylaxis 
 
Investigator: Dr. Sumit Dave  
 
 
The pronouns ‘you’ and ‘your’ should be read as referring to the participant rather than 
the parent/guardian/next of kin who is signing the consent form for the participant. 
 
Purpose of Study 
The purpose of the study is to identify the changes in bacterial profiles and antibiotic 
susceptibilities and disease severity in children receiving antibiotic prophylaxis as a 
treatment for recurrent urinary tract infection. Drs. Sumit Dave and Gregor Reid will 
administer the study at the Children’s Hospital, University of Western Ontario and 
Lawson Health Research Institute. 
 
Procedures 
Pediatric patients between the ages of 3 and 15 years are invited to participate in this 
study if they have been diagnosed with a recurrent urinary tract infection and prescribed 
antibioticsParticipants will have either received antibiotics before, or be receiving 
antibiotics for the first time.  The study is also going to include approximately 20-30 
participants who do not experience urinary tract infections.  This research study will only 
involve those who choose to take part. This letter of information and consent form 
describe the study so you can make an informed decision on participating. Please take 
time to make a decision and if necessary, discuss this proposal with your doctor, family 
members and friends.  Please feel free to ask questions if anything is unclear or there 
are words or phrases you do not understand. You have been asked to participate 
because you have been diagnosed with recurrent urinary tract infection and prescribed 
antibiotics. 
 
If you agree to participate, you will be asked to come for a visit. On the day of the first 
visit (baseline appointment) you will be asked for a urine sample, undergo uroflowmetry 
and to fill in the dysfunctional voiding scoring system (DVSS) questionnaire, possibly 
with the assistance of a parent or guardian. 
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You will be provided with a prescription for antibiotics and instructions on taking them.  If 
you are in the group of the study that does not experience urinary tract infections you 
won’t have to take antibiotics, but you will be asked to participate in other study-related 
procedures (such as giving a urine sample and filling out a questionnaire). There will be 
follow up visits at months 3, 6, 9, and 12; as well as any additional times that you 
experience a urinary tract infection.  Each visit will involve similar examinations as the 
baseline appointment. 
 
Number of Participants 
This study hopes to enroll 75  participants; 25 patients new to antibiotics,25 patients 
receiving antibiotics for a second time, and 25 participants who do not experience 
urinary tract infections. 
 
Participant Inclusion and Exclusion Criteria 
Participants will be included if they have been diagnosed with recurrent urinary tract 
infection and require antibiotics. 
 
Participants will be excluded if they are unable to make an informed decision, are 
severely immune compromised, have an abnormal urinary tract or any other condition 
that may influence an outcome. 
 
Description of Research 
As a participant in this study you will be asked to provide the following; 
1) Urine sample 
2) Fill in the DVSS questionnaire 
 
Time Requirements 
The collection of urine samples takes 5-10 minutes and will be completed during a 
regularly scheduled appointment with Dr. Dave.  
 
Risks 
There are no known risks associated with participating in this study.   
 
Benefits 
There are no known direct benefits for participating in this study, however it is hoped 
that the information gathered will benefit future patients who also suffer from recurrent 
urinary tract infections. 
 
Voluntary Participation 
Your participation in this study is voluntary. You may refuse to participate, refuse to 
answer any questions or you may withdraw from the study at any time with no effect on 
your future healthcare. Samples and information collected before the date of withdrawal 
will not be excluded from the study. 
  
Participation in concurrent or future studies 
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While the likelihood of this study interfering with other studies is minimal, please inform 
Dr. Dave immediately if you are participating in or plan to be involved in another study. 
He will then determine if it is appropriate for you to continue participation in this study. 
Use of Data 
The urine samples will become the property of the researchers and once you have 
provided them you will not have further access to them. They will be used and retained 
by Dr. Reid for research purposes; however, specimens retained by Dr. Reid will not be 
linked to personal information. Data will be kept for 7 years and will then be destroyed. 
New Findings 
If, during the course of this study, new information becomes available that may relate to 
your willingness to continue to participate, this information will be provided to you by the 
investigator. 
Confidentiality 
Your privacy will be respected. All medical records and research materials in which you 
are identified will be kept confidential and will not be made publicly available, unless 
required by applicable laws or regulations. No personal identifiers will be sent off site. If 
the results of this study are published, your name will not be used and no information 
that discloses your identity will be released. 
Representatives of The University of Western Ontario Health Sciences Research Ethics 
Board may contact you or require access to your study-related records to monitor the 
conduct of the research.  All electronic data collected for this study will be stored on the 
hospital drive which is a secure network and access will only be granted to authorized 
personnel.  All hard copies will be stored in a locked office.   
All participants will be given a study number. Only that number and your initials will be 
used on any study related documents. The master list will be held separate from the 
data in a secure research office at Children’s Hospital on a confidential computer 
server. Your family doctor will be notified of your participation in this research project 
unless you do not give permission. 
We cannot guarantee that the results of this study will be made accessible to you, but if 
you would like to be informed of the outcome of the study you are asked to provide 
current contact information.  
Contacts 
If you have any questions about your rights as a research participant or the conduct of 
the study you may contact Dr. David Hill, Scientific Director, Lawson Health Research 
Institute at 
If you have any questions during the study, experience a side effect from sample 
collection or wish to withdraw from the study at any time, you may contact Dr. Sumit 
Dave, Principal Investigator at 
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Western                            
 
Recurrent urinary tract infections in children: Bacterial identification, antibiotic 
susceptibility profiling and cytokine levels associated with antibiotic prophylaxis 
 
 
Consent Form 
I have read the Letter of Information, have had the nature of the study explained to me and I 
agree/I agree for my child to participate.  All questions have been answered to my satisfaction 
and I understand that once this form is signed I will receive a photocopy to keep. 
 
 
 
 
    
Printed Name of Participant     Signature of Participant     Date (DD-MON-YYYY ) 
 
 
 
 
     
Printed Name of Legally 
Authorized Representative  
 Signature of Legally 
Authorized Representative 
     Date (DD-MON-YYYY ) 
 
 
 
     
Printed Name of Person 
Obtaining Consent  
 Signature of Person 
Obtaining Consent  
      Date (DD-MON-YYYY ) 
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Western                            
 
Recurrent urinary tract infections in children: Bacterial identification, antibiotic 
susceptibility profiling and cytokine levels associated with antibiotic prophylaxis 
 
 
Interest in Study Outcome 
 
Please indicate whether you would like to be informed of the outcomes of this study: 
* Yes (provide contact information below)   * No 
 
Address:   _____________________________________________________ 
      
                 _____________________________________________________ 
 
 _____________________________________________________ 
 
 _____________________________________________________ 
 
 
Please indicate whether your family doctor may be notified of your participation in this research  
* Yes                                                   * No 
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Letter of Assent 
 
Version Date:  June 6, 2014 Page 1 of 3 Initials: ________ 
 
 
 
Western                           
Recurrent urinary tract infections in toilet trained children: Alterations to 
bacterial profile and antibiotic susceptibilities associated with the use of 
prophylactic antibiotics 
 
Investigator: Dr. Sumit Dave 
 
Why are you here? 
Dr. Sumit Dave wants to discuss a study with you about children with recurrent urinary tract 
infections. Dr. Dave is wondering if you would like to participate in this study because you have 
a recurrent urinary tract infection and are going to be taking antibiotics to treat your infection. 
 
Why are we doing this study? 
Dr. Dave, along with researchers at the Lawson Health Research Institute, want to know if your 
antibiotic treatment is changing the bacteria that are in your urine. They also hope to determine 
if your treatment is working.  
 
What will you have to do? 
If you agree to participate in the study, this is what will happen: 
1. You and your parent/guardian will answer some questions. 
2. You will start taking antibiotics according to the directions Dr. Dave has given you. 
These are the same antibiotics you will be getting even if you decide not to be involved 
in the study.  If you are going to be in the study group that does not have recurrent 
urinary tract infections you will not be taking antibiotics but you will be asked to 
participate in other parts of the study, like giving a urine sample and filling out a 
questionnaire.   
3. Every 3 months you will give a urine sample, the doctors will then study your urine. The 
urine sample will be collected during an appointment with Dr. Dave and will involve you 
peeing in a cup. 
4. If you and your parent/guardian are willing, you will also give a urine sample when you 
are experiencing urinary tract infection symptoms during the study. 
No part of this study should cause you pain or make you physically uncomfortable.  
 
How does this study benefit you? 
The study may not directly benefit you, however, the results of this study may help other 
children like you with recurrent urinary tract infections in the future.  
 
What about questions? 
You can ask questions anytime, now or later. You can talk to your doctors, family, or friends, it 
is up to you. Feel free to ask questions if anything is unclear or there are words or phrases you 
do not understand. 
 
Do you have to participate in the study? 
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Your participation in this study is voluntary. You may choose not to participate or refuse to 
answer any questions; there will be no negative consequences.  If you change your mind and 
decide you no longer want to participate, you may withdraw from the study at any time.  
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Western   
 
 
 
Assent 
 
I have read the assent form, have had the study explained to me and agree to 
participate. All my questions have been answered and I understand that once this form 
is signed I will receive a copy to keep. 
 
 
 
 
     
Print Name of Child       
      
Signature of Child  Age  Date 
 
 
 
 
 
    
Signature of Person Obtaining Assent    Date 
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Clinic Intake form 
 
Page 1 of 2 
  PLEASE NOTE:  IF THESE FORMS ARE NOT FILLED 
OUT IN FULL AND BROUGHT TO YOUR CONSULTATION 
APPOINTMENT, YOUR CHILD WILL NOT BE SEEN!  
 
DAYTIME WETTING 
Does your child wet his/her clothes during the day?.....................................Yes____ No____ 
Has your child ever been dry during the day?...............................................Yes____ No____ 
If yes, for how long ______________ (weeks/months/years) 
And at what age ______________ (years) 
On how many days a week does your child wet during the day  _____ (days per week) 
How many times a day does your child wet ___________ (times per day) 
Is the clothing usually damp? ………………………………………………Yes____ No____ 
Is the clothing usually wet?............................................................................Yes____ No____ 
Does urine dribble constantly?.......................................................................Yes____ No____ 
Does your child wet his/her clothes immediately after  
going to the toilet?..........................................................................................Yes____ No____ 
Does your child notice when he/she wets?.....................................................Yes____ No____ 
 
NIGHTTIME WETTING 
Does your child wet the bed (or diapers) during the night?...........................Yes____ No____ 
Has your child ever been dry at night?..........................................................Yes____ No____ 
If yes, for how long ______________ (weeks/months/years) 
And at what age ______________ (years) 
On how many nights a week does your child wet? ___________(nights per week) 
Is the bed usually damp?................................................................................Yes____ No____ 
Is the bed usually wet?...................................................................................Yes____ No____ 
Does your child wake up to go to the toilet?..................................................Yes____ No____ 
Does your child wake up after wetting the bed?............................................Yes____ No____ 
Is your child a deep sleeper ie. Difficult to wake up? ………………………Yes____ No____ 
Has other members of your family wetted? (Day/night)……………………Yes____ No____ 
 
TOILET HABITS 
How many times a day does your child void (on average) __________ (times/day) 
How long can your child manage without going to the toilet (shopping, car trips etc) _______(hours) 
Does your child go to the toilet by themselves when needed ………………Yes____ No____ 
Do you have to send your child to the toilet? ………………………………Yes____ No____ 
If your child wants to pee, do they have to strain at the  
beginning or during voiding? ………………………………………………Yes____ No____ 
When your child voids, is the stream interrupted?.........................................Yes____ No____ 
Does your child hurry and not take enough time to void?..............................Yes____ No____ 
 
OBSERVABLE REACTIONS 
Does your child feel a sudden urge to go to the toilet?..................................Yes____ No____ 
When your child has to void, do they have to rush to  
the toilet immediately?....................................................................................Yes____ No____ 
Does your child cross their legs, squat, sit on their  
heels to prevent wetting?................................................................................Yes____ No____ 
Does your child postpone going to the toilet for as long as possible………. Yes____ No____ 
If yes, in which situations? (school/play/TV etc) 
 
Please specify:_______________________________________________ 
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URINARY TRACT INFECTIONS 
Has your child ever had a urinary tract infection?.........................................Yes____ No____ 
If yes, how many times? ___________________________ 
Has your child had urinary tract infections with fever?.................................Yes____ No____ 
Has your child been treated for any illness of the urinary tract?....................Yes____ No____ 
If yes, please specify: _________________________________________ 
 
STOOL HABITS 
Does your child have regular bowel movements?..........................................Yes____ No____ 
If not, how many times/week: _______________ 
Is your child regularly constipated?...............................................................Yes____ No____ 
Does your child soil their underwear (during the day)?.................................Yes____ No____ 
Does your child soil during sleep?..................................................................Yes____ No____ 
If yes, small amounts? (smear)……………………………………………....Yes____ No____ 
Or:  large amounts? (stool)…………………………………………….…….Yes____ No____ 
How often does your child soil?  __________x/week___________x/month 
Has your child previously had a complete bowel control?.............................Yes____ No____ 
If yes, for how long ______________ (weeks/months/years) 
And at what age ______________ (years) 
Does the soiling occur in special situations?...................................................Yes____ No____ 
If yes, please specify: _________________________________________ 
 
BEHAVIOR: WETTING 
Is your child distressed by their wetting?.......................................................Yes____ No____ 
Are you distressed because of your child’s wetting?.....................................Yes____ No____ 
Has your child been teased because of the wetting?......................................Yes____ No____ 
Are there any things your child did not do (school outings/sleepovers) 
because of the wetting?..................................................................................Yes____ No____ 
Does your child wet more often in stressful times?.......................................Yes____ No____ 
Is your child cooperative and motivated for treatment?................................Yes____ No____ 
If your child was previously dry, do you see any event that might be 
associated with the relapse?............................................................................Yes____ No____ 
If yes, please specify: ________________________________________ 
What, in your opinion is the reason for wetting? Please specify: 
____________________________________________________________________________________ 
 
BEHAVIOR: GENERAL 
Does your child have difficulties in accepting rules? ………………………Yes____ No____ 
Is your child restless, on the go, easily distracted?........................................Yes____ No____ 
Does your child have difficulty concentrating?.............................................Yes____ No____ 
Is your child sometimes anxious?..................................................................Yes____ No____ 
Is your child sometimes sad, unhappy, withdrawn?......................................Yes____ No____ 
Does your child have problems at school?.....................................................Yes____ No____ 
If yes, please specify: ________________________________________ 
Does your child have problems in other areas?.............................................Yes____ No____ 
If yes, please specify: ________________________________________ 
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48-hour bowel bladder diary 
  
 
 
 
48 HOUR FREQUENCY/VOLUME CHART   *PATIENT NAME:__________________________________ 
THIS MUST BE FILLED OUT IN FULL OR YOU WILL NOT BE SEEN.   
 
FILL OUT AND BRING TO YOUR CONSULTATION APPOINTMENT 
Instructions:  Please fill out this chart on a day without school, or on a weekend/holiday, every time your child goes to the 
toilet, or wets.  This should start one morning and continue for 48 hours.  Please discuss with your child prior.  You should 
not “send” your child to the toilet, instead they should tell you when they need to go. Have them empty into a measuring 
cup.  Please measure the amount of urine, record it with the time of day.  You do not need to “save” the urine, it may be 
flushed once recorded.  Please note the following on the chart:  Does your child strain getting started or if the stream is 
interrupted, if your child wets their clothes, please note the time and if they were damp or wet.  If your child feels a 
sudden urge to go to the toilet, not this in the next column.  If your child crosses their legs, squats or tries to hold back 
the urine, please note this with the time in the next column.  Finally:  please record the amount of fluid your child drinks 
during the day, along with the time.  Thank you for your assistance!   
 
TIME 
OF DAY 
URINE 
VOLUME 
(ML) 
STRAINING/ 
INTERRUPTED 
STREAM? 
WETTING: 
DAMP/WET 
URGE? COMMENTS/ 
OBSERVATIONS 
DRINKING 
FLUIDS  
(ML) 
 
 
      
 
 
      
 
 
      
 
 
      
 
 
      
 
 
      
 
 
      
 
 
      
 
 
      
 
 
      
 
 
      
 
 
      
 
 
      
 
 
      
 
 
      
       
261 
 
Dysfunction voiding scoring system questionnaire 
  
This	Section	For	Office	Use	Only:	
Patient	Identifier:	 	
Date:	 	
Appointment:	 	
	
	 	 Adapted	from	Farhat	et	al.,	2000,	J	Urol.	
Voiding	Habits	Questionnaire	
	
Over	the	last	month	
Almost	
Never	
Less	
than	half	
the	time	
About	
half	the	
time	
Almost	
every	
time	
Not	
available	
1	–	I	have	had	wet	clothes	or	wet	
underwear	during	the	day	
0	 1	 2	 3	 NA	
2	–	When	I	wet	myself,	my	
underwear	is	soaked.	
0	 1	 2	 3	 NA	
3	–	I	miss	having	a	bowel	
movement	everyday.	
0	 1	 2	 3	 NA	
4	–	I	have	to	push	for	my	bowel	
movements	to	come	out.	
0	 1	 2	 3	 NA	
5	–	I	have	to	go	to	the	bathroom	
one	or	two	times	a	day.	
0	 1	 2	 3	 NA	
6	–	I	can	hold	onto	my	pee	by	
crossing	my	legs,	squatting	or	
doing	the	“pee	dance.”	
0	 1	 2	 3	 NA	
7	–	When	I	have	to	pee,	I	cannot	
wait.	
0	 1	 2	 3	 NA	
8	–	I	have	to	push	to	pee.	 0	 1	 2	 3	 NA	
9	–	When	I	pee	it	hurts.	 0	 1	 2	 3	 NA	
10	–	Parents	to	answer:	
Has	your	child	ever	experienced	
something	stressful	like	the	
examples	below?	
NO	(0)	 YES	(3)	
TOTAL	 	
	
- New	baby.	
- New	home.	
- New	school.	
- School	problems.	
- Abuse	(sexual/physical).	
- Home	problems	(divorce/death).	
- Special	events	(birthday).	
- Accident/injury.	
- Others	
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